Document:

Teradata Savings Plan

 Exhibit 4.1 
 TERADATA SAVINGS PLAN 

 TABLE OF CONTENTS 
  

					
	 ARTICLE 1. DEFINITIONS
	  	2
			
	 1.1.
	    	 Account
	  	2
	 1.2.
	    	 Administrator
	  	2
	 1.3.
	    	 Affiliated Companies
	  	2
	 1.4.
	    	 After-Tax Contributions
	  	2
	 1.5.
	    	 After-Tax Contribution Account
	  	2
	 1.6.
	    	 Beneficiary
	  	3
	 1.7.
	    	 Board of Directors
	  	3
	 1.8.
	    	 Break-in-Service
	  	3
	 1.9.
	    	 Business Day
	  	3
	 1.10.
	    	 Code
	  	3
	 1.11.
	    	 Compensation
	  	3
	 1.12.
	    	 Disabled
	  	4
	 1.13.
	    	 Effective Date
	  	4
	 1.14.
	    	 Eligible Employee
	  	4
	 1.15.
	    	 Employee
	  	5
	 1.16.
	    	 Employee Contributions
	  	5
	 1.17.
	    	 Employer
	  	5
	 1.18.
	    	 Employer Matching Contributions
	  	6
	 1.19.
	    	 Employer Matching Contribution Account
	  	6
	 1.20.
	    	 Employment Commencement Date
	  	6
	 1.21.
	    	 ERISA
	  	6
	 1.22.
	    	 Highly Compensated Employee
	  	6
	 1.23.
	    	 Hour of Service
	  	6
	 1.24.
	    	 Normal Retirement Date
	  	8
	 1.25.
	    	 Participant
	  	8
	 1.26.
	    	 Plan
	  	9
	 1.27.
	    	 Plan Year
	  	9
	 1.28.
	    	 Pre-Tax Contributions
	  	9
	 1.29.
	    	 Pre-Tax Contribution Account
	  	9
	 1.30.
	    	 Recordkeeper
	  	9
	 1.31.
	    	 Rollover Account
	  	9
	 1.32.
	    	 Rollover Contributions
	  	9
	 1.33.
	    	 Severance From Service Date
	  	9
	 1.34.
	    	 Spouse
	  	10
	 1.35.
	    	 Teradata Common Stock
	  	10
	 1.36.
	    	 Trust or Trust Fund
	  	10
	 1.37.
	    	 Trustee
	  	10
	 1.38.
	    	 Valuation Date
	  	10
	 1.39.
	    	 Value
	  	10
	 1.40.
	    	 Year of Service
	  	10
	 1.41.
	    	 Additional Definitions in Plan
	  	11

  

 i 

					
		
	 ARTICLE 2. PARTICIPATION
	  	12
			
	 2.1.
	    	 Participation
	  	12
	 2.2.
	    	 Reemployment After Termination
	  	12
	 2.3.
	    	 Employees in a Bargaining Unit
	  	12
	 2.4.
	    	 Inactive Participation
	  	12
		
	 ARTICLE 3. PLAN CONTRIBUTIONS
	  	13
			
	 3.1.
	    	 Employee Contributions
	  	13
	 3.2.
	    	 Employer Matching Contributions
	  	15
	 3.3.
	    	 Participant Rollover Contributions
	  	15
	 3.4.
	    	 Time of Contribution
	  	15
	 3.5.
	    	 Profits Not Required
	  	16
	 3.6.
	    	 Make-Up Contributions for Participants on Military Leave
	  	16
		
	 ARTICLE 4. NONDISCRIMINATION TESTS
	  	17
			
	 4.1.
	    	 Non-Discrimination Test for Deferrals (ADP Test)
	  	17
	 4.2.
	    	 Non-Discrimination Test for Employer Matching Contributions and After-Tax Contributions (ACP Test)
	  	17
	 4.3.
	    	 Corrective Procedures to Satisfy Discrimination Tests
	  	18
	 4.4.
	    	 Return of Contributions
	  	18
		
	 ARTICLE 5. ACCOUNT ADMINISTRATION
	  	21
			
	 5.1.
	    	 Types of Accounts
	  	21
	 5.2.
	    	 Investment Options
	  	21
	 5.3.
	    	 Participant Direction of Investments
	  	21
	 5.4.
	    	 Allocation of Trust Fund Earnings and Losses to Participant Accounts
	  	22
	 5.5.
	    	 Account Statements
	  	22
		
	 ARTICLE 6. BENEFITS AND FORMS OF PAYMENT
	  	23
			
	 6.1.
	    	 Eligibility for Benefits
	  	23
	 6.2.
	    	 Time of Benefit Commencement
	  	23
	 6.3.
	    	 Form of Payment
	  	24
	 6.4.
	    	 Benefits for Terminated Participants
	  	25
	 6.5.
	    	 Commencement of Payment
	  	25
		
	 ARTICLE 7. WITHDRAWALS AND LOANS
	  	26
			
	 7.1.
	    	 After-Tax and Rollover Withdrawals
	  	26
	 7.2.
	    	 Hardship Withdrawal
	  	26
	 7.3.
	    	 Loans
	  	28
	 7.4.
	    	 Withdrawals After Age 59-1/2
	  	30

  

 ii 

					
		
	 ARTICLE 8. VESTING
	  	31
			
	 8.1.
	    	 Vesting
	  	31
	 8.2.
	    	 Changes in Vesting Schedule
	  	31
	 8.3.
	    	 Forfeitures
	  	32
	 8.4.
	    	 Reemployment
	  	32
		
	 ARTICLE 9. LIMITATION ON CONTRIBUTIONS
	  	34
			
	 9.1.
	    	 Maximum Annual Contribution to the Plan
	  	34
		
	 ARTICLE 10. TOP HEAVY PROVISIONS
	  	36
			
	 10.1.
	    	 Scope
	  	36
	 10.2.
	    	 Top Heavy Status
	  	36
	 10.3.
	    	 Minimum Contribution
	  	38
	 10.4.
	    	 Limitation to Annual Additions in Top Heavy Plan
	  	39
	 10.5.
	    	 Vesting
	  	39
		
	 ARTICLE 11. ADMINISTRATION OF THE PLAN
	  	40
			
	 11.1.
	    	 Responsibility for Plan Administration
	  	40
	 11.2.
	    	 Asset Management Authority of the Employer
	  	40
	 11.3.
	    	 Duties and Authority of the Administrator
	  	40
	 11.4.
	    	 Plan Expenses
	  	41
	 11.5.
	    	 Bonding and Insurance
	  	42
	 11.6.
	    	 Maintenance of Written Records
	  	42
	 11.7.
	    	 Scope of Authority
	  	42
	 11.8.
	    	 Appeal Procedure
	  	43
		
	 ARTICLE 12. TRUST FUND
	  	44
			
	 12.1.
	    	 Contributions to the Trust Fund
	  	44
	 12.2.
	    	 Trust Fund for Exclusive Benefit of Participants
	  	44
	 12.3.
	    	 Trustee
	  	44
	 12.4.
	    	 Investment Manager
	  	44
	 12.5.
	    	 Voting of Proxies
	  	45
	 12.6.
	    	 Voting Shares of Teradata Common Stock: Options and Other Rights
	  	45
		
	 ARTICLE 13. AMENDMENT AND TERMINATION
	  	49
			
	 13.1.
	    	 Amendment - General
	  	49
	 13.2.
	    	 Amendment - Consolidation or Merger
	  	49
	 13.3.
	    	 Termination of the Plan
	  	49
	 13.4.
	    	 Allocation of the Trust Fund on Termination of Plan
	  	49

  

 iii 

					
		
	 ARTICLE 14. FIDUCIARIES
	  	50
			
	 14.1.
	    	 Limitation of Liability of the Employer and Others
	  	50
	 14.2.
	    	 Indemnification of Fiduciaries
	  	50
	 14.3.
	    	 Scope of Indemnification
	  	50
		
	 ARTICLE 15. ADOPTION BY AFFILIATED COMPANIES
	  	51
			
	 15.1.
	    	 Adoption by Affiliated Companies
	  	51
	 15.2.
	    	 Spin-Off of a Division
	  	51
	 15.3.
	    	 Merger of an Employer
	  	51
	 15.4.
	    	 Termination of Participation by an Employer
	  	51
	 15.5.
	    	 Adoption by Non-Affiliated Companies
	  	51
		
	 ARTICLE 16. MISCELLANEOUS PROVISIONS
	  	52
			
	 16.1.
	    	 Facility of Payment
	  	52
	 16.2.
	    	 Correction of Errors
	  	52
	 16.3.
	    	 Missing Persons
	  	52
	 16.4.
	    	 Domestic Relations Orders
	  	52
	 16.5.
	    	 Plan Qualification
	  	54
	 16.6.
	    	 Deductible Contribution
	  	54
	 16.7.
	    	 Plan Administration - Miscellaneous
	  	54
		
	 APPENDIX A
	  	57
		
	 Participating Affiliated Companies
	  	57

  

 iv 

 PREAMBLE 
 THIS TERADATA SAVINGS PLAN (hereinafter referred to as the “Plan”) is adopted effective October 1, 2007 by Teradata Corporation (hereinafter “Employer” or “Teradata”). 
 The Plan is a qualified profit sharing plan containing qualified cash or deferred arrangement and the Employer established this Plan effective
October 1, 2007 to attract and retain Eligible Employees by providing them with an opportunity to save for their retirement. 
 The Plan
shall be maintained for the exclusive benefit of covered employees, and is intended to comply with the Internal Revenue Code of 1986, as amended, the Employee Retirement Income Security Act of 1974, as amended, and other applicable law. 

Effective as of October 1, 2007, the accounts, and the related assets of the trust fund for the NCR Savings Plan, of all participants under the
NCR Savings Plan who are employees or former employees of the Employer immediately after the spin-off of Teradata by NCR Corporation (the “Spin-Off”) (or who are on an approved leave of absence at the time of the Spin-Off and become
employees of the Employer upon return to active employment). 

 ARTICLE 1. 
 DEFINITIONS 
 The following terms when used herein shall have the following meaning, unless a different meaning is plainly
required by the context. Capitalized terms are used throughout the Plan text for terms defined by this and other sections. 
  

	1.1.	Account 

 “Account” means a
Participant’s Pre-Tax Contribution Account, Employer Matching Contribution Account, After-Tax Contribution Account and Rollover Account. 
  

	1.2.	Administrator 

 “Administrator” means the
person, persons or entity with the responsibility to administer the Plan, as provided in Article 11. 
  

	1.3.	Affiliated Companies 

 “Affiliated
Companies” means 
  

	 	(a)	the Employer, 

  

	 	(b)	any other corporation which is a member of a controlled group of corporations which includes the Employer (as defined in Section 414(b) of the Code), 

 

	 	(c)	any other trade or business under common control with the Employer (as defined in Section 414(c) of the Code), or 

  

	 	(d)	an affiliated service group which includes the Employer (as defined in Section 414(m) of the Code). 

 For purposes of the limitation on benefits in Article 9, the determination of whether a corporation is an Affiliated Company will be made by modifying
Sections 414(b) and (c) of the Code as specified in Section 415(h). 
  

	1.4.	After-Tax Contributions 

 “After-Tax
Contributions” means that portion of a Participant’s Compensation which he or she elects to defer and authorizes to be contributed to the Plan by the Employer, and which shall be included in the Participant’s gross income. 

 

	1.5.	After-Tax Contribution Account 

 “After-Tax
Contribution Account” means an account established and maintained by the Recordkeeper to hold a Participant’s After-Tax Contributions to the Plan. 
  

 2 

	1.6.	Beneficiary 

 “Beneficiary” means the
person or persons designated to be the Beneficiary by the Participant in writing. Unless designated otherwise, the Beneficiary of a married Participant shall be his or her Spouse. In the event a married Participant designates someone other than his
or her Spouse as Beneficiary, such initial designation or subsequent change shall be invalid unless the Spouse consents in a writing, which names the designated Beneficiary, acknowledges the effect of the designation, and is notarized, or witnessed
by a Plan representative. If an unmarried Participant fails to designate a Beneficiary, or if the designated Beneficiary does not survive the Participant, the benefit will be paid in equal amounts to the first eligible category in the following
order: (i) the Participant’s children, (ii) the Participant’s parents, (iii) the Participant’s brothers and sisters, (iv) the Participant’s estate or personal administrator. If a Participant designates his or
her Spouse as beneficiary and subsequently is divorced or legally separated from such Spouse, the Spouse shall not be the Beneficiary if (i) the domestic relations order awarding the divorce or legal separation divests the Spouse of beneficiary
rights to the Participant’s accounts under the Plan, or (ii) the state law of the state in which the divorce or legal separation is awarded divests former Spouses of beneficiary rights under beneficiary designations executed prior to the
divorce or legal separation, as applicable. 
  

	1.7.	Board of Directors 

 “Board of Directors”
shall mean the Board of Directors of Teradata Corporation. 
  

	1.8.	Break-in-Service 

 “Break-in-Service”
means the period of time commencing at the Severance From Service Date and ending on the date the Employee again performs an Hour of Service for the Company; provided, however, such period shall commence one year later if a male or female Employee
is absent due to pregnancy, birth or adoption of a child, or caring for a child immediately following birth or adoption. 
  

	1.9.	Business Day 

 “Business Day” means a day
on which the New York Stock Exchange is open for trading. 
  

	1.10. 	Code 

 “Code” means the Internal Revenue
Code of 1986, as amended and including all regulations promulgated pursuant thereto. 
  

	1.11. 	Compensation 

 “Compensation” for purposes
of Articles 3 and 4 means amounts received during a Plan Year by an Employee from the Company through the U.S. payroll while actively employed that are currently includible in gross income for Federal income tax purposes, and sick pay and any salary
deferral contributions made by the Company on behalf of the Employee for the Plan Year, including employee contributions to the Company’s Code 

  

 3 

 
Section 125 cafeteria plan; but excluding expense reimbursements, retention and work completion bonuses, sign-on bonuses, fringe benefits, moving
expense, deferred compensation, welfare benefits and severance pay. “Compensation” does not include amounts received after termination of employment, except that for participants who transfer employment directly from the Employer to an
Affiliated Company, “Compensation” includes bonuses received from the Employer while employed by the Affiliated Company. 
 Notwithstanding the foregoing, a Participant’s Compensation for a Plan Year in excess of the amount prescribed for such Plan Year under Section 401(a)(17) of the Code (as adjusted for increases in the cost of living pursuant to
Section 401(a)(17) of the Code and the regulations thereunder) shall not be taken into account for any purposes under the Plan. For 2007, the amount prescribed under Section 401(a)(17) of the Code is $225,000. 
 For purposes of the Section 415 limits of Article 9, for purposes of determining who is a Highly Compensated Employee and for purposes of Article 10
(Top Heavy Provisions), “Compensation” has the meaning set forth in Section 415(e)(3) of the Code, which also includes Participant Pre-Tax Contributions to this Plan and elective Employee contributions to a cafeteria plan described in
Section 125 of the Code. 
 For Participants on foreign assignment, “Compensation” includes “notional pay,” which is
the U.S. base salary of the Participant in effect when the Participant commences the foreign assignment, adjusted at any time the Participant’s salary is adjusted, to reflect the corresponding U.S. base salary which would be in effect for the
Participant if the Participant were employed within the United States. 
  

	1.12. 	Disabled 

 “Disabled” with respect to a
Participant means that due to sickness, pregnancy, or accidental injury, established by objective medical evidence provided by the Participant, the Participant is receiving appropriate care and treatment from a doctor on a continuing basis, and that
the Participant is unable to earn more than 80% of the Participant’s pre-disability earnings at the Participant’s own occupation for any employer in the Participant’s local economy. 
  

	1.13. 	Effective Date 

 ‘“Effective Date”
means October 1, 2007. 
  

	1.14. 	Eligible Employee 

 “Eligible Employee”
means any Employee who is on the U.S. payroll of the Employer, but excluding: 
  

	 	(a)	an Employee in a collective bargaining unit represented by a labor union unless there is in existence an agreement making the Plan available to eligible employees in such unit.

  

 4 

	 	(b)	a Leased Employee. 

  

	 	(c)	“payroll service or agency employees” as defined in the following sentence. “Payroll service or agency employee” means an individual (i) for whom the direct
payor of compensation with respect to the performance of services for the Employer or any Subsidiary or Affiliate is any outside entity, including but not limited to a payroll service or temporary employment agency, rather than by the Teradata
internal corporate payroll system or such other entity providing payroll services for Teradata, or (ii) who is paid directly by the Employer or any Subsidiary or Affiliate, but not through an internal corporate payroll system (e.g., through
purchase order accounts). The determination whether an individual is a “payroll service or agency employee” shall be made solely according to the method of paying the individual for services, without regard to whether the individual is
considered a common law employee of the Employer for any other purpose, and such determination will be within the discretionary authority of the plan administrator. 

  

	 	(d)	an employee classified as part-time (including intern, co-op or seasonal) unless the Employee completes an Eligibility Year in which more than 1,000 Hours of Service are worked. For
this purpose, “Eligibility Year” initially means the first 12 months of employment, and then Plan Years, including the Plan Year commencing in the first 12 months of employment. 

 “Eligible Employee” also means any other employee of the Employer or an affiliated Employer who is listed in Appendix A to this Plan, which
appendix may be amended at any time by the Senior Vice President, Human Resources. 
  

	1.15. 	Employee 

 “Employee” means any person
(other than a nonresident alien who receives no U.S. source income from the Employer) who is employed by the Employer as a common law employee and any leased employee within the meaning of Code Section 414(n)(2); provided, however, if leased
employees constitute twenty percent or less of the Employer’s non-highly compensated work force, the term “Employee” shall not include a leased employee who is covered by a plan maintained by the leasing organization which meets the
requirements of Code Section 414(n)(5). 
  

	1.16. 	Employee Contributions 

 “Employee
Contributions” means a Participant’s Pre-Tax Contributions and After-Tax Contributions. 
  

	1.17. 	Employer 

 “Employer” means Teradata
Corporation, a Delaware corporation. For purposes other than Articles 11, 12 and 13, the term “Employer” shall also include other employers as provided in Section 15.1 and 15.5. 
  

 5 

	1.18. 	Employer Matching Contributions 

 “Employer
Matching Contributions” means the contributions made to the Plan by the Employer as provided in Section 3.2. 
  

	1.19. 	Employer Matching Contribution Account 

 “Employer Matching Contribution Account” means an account established and maintained by the Recordkeeper to receive a Participant’s share of Employer Matching Contributions to the Plan. 
  

	1.20. 	Employment Commencement Date 

 “Employment
Commencement Date” means the date on which an Employee first completes an Hour of Service for the Employer or an Affiliated Company during the current period of employment. For Employees of the Employer immediately after the Spin-Off (or who
are on an approved leave of absence at the time of the Spin-Off and become employees of the Employer upon return to active employment, “Employment Commencement Date” means the date on which the Employee first completed an Hour of Service
for NCR Corporation. 
  

	1.21. 	ERISA 

 “ERISA” means the Employee
Retirement Income Security Act of 1974, as amended, and including all regulations promulgated pursuant thereto. 
  

	1.22. 	Highly Compensated Employee 

 “Highly
Compensated Employee” means an Employee who is included in one of the following categories within the meaning of Section 414(q) of the Code: 
  

	 	(a)	an Employee who was a 5% owner of the Employer during the Plan Year or the preceding Plan Year; or 

  

	 	(b)	an Employee who received aggregate Compensation from all the Affiliated Companies in excess of $100,000 (or such other amount as may be in effect for such Plan Year under Code
Section 414(q)(6)) in the preceding Plan Year. 

 A former Employee shall be considered a Highly Compensated Employee if he
or she was a Highly Compensated Employee when he or she separated from service or at any time after attaining age 55. 
  

	1.23. 	Hour of Service 

 “Hour of Service” means
each hour for which an Employee is paid or entitled to payment for the performance of duties for the Employer or any Affiliated Company. 
  

 6 

 For purposes of determining whether an Employee classified as part-time (including intern, co-op, and
seasonal) is an Eligible Employee, “Hour of Service” means: 
  

	 	(a)	An Eligible Employee shall receive credit under the Plan for each hour for which he is paid or entitled to payment by the Company for which no duties are performed due to the
following periods of absence: vacation, holiday, illness, incapacity (including disability), layoff, jury duty, military duty, or leave of absence. 

 No hour shall be credited under this Subsection (a), however, with respect to any such period of absence for which payment is made solely to comply with any applicable workers’ compensation, or unemployment
compensation or disability insurance laws or for payments which solely reimburse an Employee for medical or medically-related expenses incurred by the Employee. 
 An Hour of Service credited under this Subsection (a) shall be subject to the following rules: 
  

	 	(1)	With respect to any such hours that are computed with specific reference to the length of time of the period of absence, the number of hours credited shall be the number of
regularly scheduled working hours consistently determined with respect to all employees of the Company within the same job classification for the specific duration of the holiday, illness, etc. for which hours are to be credited. The hours shall be
credited to the Year(s) of Service during which the absence occurred. 

  

	 	(2)	With respect to any such hours that are computed without regard to the length of time of the period of absence, the number of hours credited shall be equal to the amount of the
payment made with respect to such period of absence divided by the Eligible Employee’s most recent hourly rate of compensation, or its equivalent. The hours shall be credited to the Year of Service during which the absence occurs; provided,
however, that the Plan Administrator, following uniform rules, may pro rate such hours between the first two of any Years of Service which may be overlapped by such period of absence. 

  

	 	(3)	No Hours of Service shall be credited which exceed the number of hours regularly scheduled for the performance of duties during any period of absence as determined in accord with
procedures consistently applied by the Plan Administrator with respect to all Eligible Employees within any one job classification. 

  

	 	(4)	In no event shall more than 501 Hours of Service be credited under this Subsection (a) unless otherwise specifically provided in Subsection (b) below.

  

	 	(b)	In addition, an Eligible Employee shall be credited with Hours of Service for the following absences which are authorized by the Company whether paid or unpaid:

  

 7 

	 	(1)	Periods of absence for sickness or disability shall be counted at the rate of the number of hours in his regularly scheduled work day with a weekly maximum equal to the number of
hours in his regularly scheduled work week with an overall maximum of 52 weeks per period of such absence. 

  

	 	(2)	Periods of absence due to any other authorized leave of absence determined in accordance with uniform rules applicable to all employees of the Company similarly situated shall be
counted at the rate of the number of hours in his regularly scheduled work day with a weekly maximum equal to the number of hours in his regularly scheduled work week. 

  

	 	(3)	Periods of absence for service in the Armed Forces of the United States if the Employee returns to employment with the Company within 90 days of the first opportunity to do so,
shall be counted at the rate of the hours in his regularly scheduled work day with a weekly maximum equal to the hours in his regularly scheduled work week. 

  

	 	(c)	For purposes of computing compensated hours, hours of pay at premium rates shall count only as straight time hours. 

  

	 	(d)	The term “Hour of Service” shall include each hour for which back pay, irrespective of mitigation of damages, has been awarded or agreed to by the Company or an Affiliated
Company. No credit shall be given for such Hours of Service for hours which may be credited under any other provision of this Section 1.23. No more than 501 Hours of Service shall be credited for any period of time during which back pay has
been awarded, if during such period an Eligible Employee did not or would not have performed duties for the Company. Back pay shall be awarded with respect to the Year of Service to which the award or agreement for back pay pertains.

  

	 	(e)	Hours of Service shall be calculated in accordance with regulations under 29 CFR 2530-200b-2 which are incorporated herein by reference. 

  

	1.24. 	Normal Retirement Date 

 “Normal Retirement
Date” means the Participant’s sixty-fifth (65th) birthday. 
  

	1.25. 	Participant 

 “Participant” means any
Eligible Employee who qualifies for participation pursuant to Article 2. A non-vested Participant shall cease to be a Participant on the date he or she incurs a one-year Break-in-Service. A vested Participant shall cease to be a Participant when his
or her benefit payments are completed. 
  

 8 

	1.26. 	Plan 

 “Plan” means the Teradata Savings
Plan either in its present form or as amended from time to time. 
  

	1.27. 	Plan Year 

 The first Plan Year shall be a short
Plan Year commencing on the Effective Date and ending on December 31, 2007; thereafter the Plan Year shall be the 12-month period beginning on each January 1 and ending on the next December 31. 
  

	1.28. 	Pre-Tax Contributions 

 “Pre-Tax
Contributions” means that portion of a Participant’s Compensation which he or she elects and authorizes, or is deemed to elect to defer and authorize, to be contributed to the Plan by the Employer, and which shall not be included in the
Participant’s gross income. 
  

	1.29. 	Pre-Tax Contribution Account 

 “Pre-Tax
Contribution Account” means an account established and maintained by the Recordkeeper to receive a Participant’s Pre-Tax Contributions to the Plan. 
  

	1.30. 	Recordkeeper 

 “Recordkeeper” means the
entity appointed by the Administrator to maintain records of Participant Accounts and perform administrative functions related to such recordkeeping. 
  

	1.31. 	Rollover Account 

 “Rollover Account”
means an account established and maintained by the Recordkeeper to hold a Participant’s Rollover Contribution to the Plan. 
  

	1.32. 	Rollover Contributions 

 “Rollover
Contributions” means a Participant’s account balances under a similar plan sponsored by a former employer which are deposited in this Plan. 
  

	1.33. 	Severance From Service Date 

 “Severance From
Service Date” means the earlier of the date on which an Employee quits, is discharged, or dies, or the first anniversary of absence from work for any other reason, except that a Participant on a military leave of absence from the Employer or
any Affiliated Company for qualified military service, within the meaning of Chapter 43 of Title 38, United States Code, who is reemployed by the Employer or any Affiliated Company as provided in that chapter following such service, with not incur a
Severance From Service Date during the military leave of absence. 
  

 9 

	1.34. 	Spouse 

 “Spouse” means a person of the
opposite sex who is a husband or a wife. 
  

	1.35. 	Teradata Common Stock 

 “Teradata Common
Stock” means the shares of the $0.01 par value common stock of Teradata Corporation as may be authorized from time to time, or issued upon a change of shares of such common stock or any other shares, whether in subdivision or combination
thereof and whether as a part of a classification or reclassification thereof, or otherwise, and which may or may not be duly registered with the Securities and Exchange commission or listed on the New York Stock Exchange. 
  

	1.36. 	Trust or Trust Fund 

 “Trust or Trust
Fund” means the trust fund into which shall be paid all contributions and from which all benefits shall be paid under this Plan. 
  

	1.37. 	Trustee 

 “Trustee” means the trustee or
trustees who receive, hold, invest, and disburse the assets of the Trust in accordance with the terms and provisions set forth in a trust agreement. 
  

	1.38. 	Valuation Date 

 “Valuation Date” means
each Business Day and any other day which the Plan Administrator may designate from time to time. 
  

	1.39. 	Value 

 “Value” means (a) as used
generally, the fair market value, and (b) as used with respect to a share of Teradata Common Stock on any date, the closing sale price of a share of Teradata Common Stock on the New York Stock Exchange on such date, or if there is no sale of
Teradata Common Stock on such exchange on such date, the average of the bid and asked prices at the closing of trading on such date. 
  

	1.40. 	Year of Service 

 “Year of Service” means
each 12 month increment of a Participant’s Period of Service. “Period of Service” means the period of time commencing with the date on which an Employee first completes an Hour of Service for the Employer or an Affiliated Company and
ending on the Severance from Service Date. Non-successive periods are aggregated to determine an Employee’s total Period of Service. 
 A
Participant’s Period of Service shall include periods not in service due to a “Temporary Termination.” A Temporary Termination occurs if a Participant is rehired and actively employed within one year after a Severance From Service
Date. 
  

 10 

 For vesting and participation purposes, an Employee’s Period of Service shall also include Periods
of Service with an Affiliated Company, and where the Company maintains the plan of a predecessor employer, service for such predecessor employer shall be treated as service for the Company as required by the Code. 
 For Employees of the Employer immediately after the Spin-Off (or who are on an approved leave of absence at the time of the Spin-Off and become employees
of the Employer upon return to active employment, all years of service recognized under the NCR Savings Plan covering the Employee at the time of transfer, hire or rehire will be recognized under this Plan. 
  

	1.41. 	Additional Definitions in Plan 

  

				
	  	  	Section	 
	 ACP Test
	  	4.2	 
	 ADP Test
	  	4.1	 
	 Aggregate Account
	  	10.2	(e)
	 Aggregation Group
	  	10.2	(h)
	 Annual Additions
	  	9.1	 
	 Claimant
	  	11.8	(b)
	 Determination Date
	  	10.2	(c)
	 Investment Manager
	  	12.4	 
	 Key Employee
	  	10.2	(g)
	 Lump Sum
	  	6.3	(a)
	 Present Value of Accrued Benefits
	  	10.2	 
	 Qualified Domestic Relations Order
	  	16.4	 
	 Super Top Heavy
	  	10.2	(b)
	 Teradata Unitized Stock Fund
	  	5.2	 
	 Top Heavy
	  	10.2	(a)
	 Valuation Date (for Top Heavy)
	  	10.2	(d)

  

 11 

 ARTICLE 2. 
 PARTICIPATION 
  

	2.1.	Participation 

 Except as set forth below, an
Eligible Employee shall become a Participant in accordance with enrollment procedures established by the Plan Administrator. Each Eligible Employee may become a Participant in this Plan on the first payday following the commencement of employment
with the Employer, or, if later, the date on which he or she becomes an Eligible Employee. An Eligible Employee classified as part-time (including intern, co-op and seasonal) may become a Participant on the next January 1 or July 1 after
completing an Eligibility Year in which 1,000 hours of Service are worked. 
 Notwithstanding the foregoing, participants in the NCR Savings
Plan prior to the Spin-Off who become Employees or former employees of the Employer pursuant to the Spin-Off, shall become Participants in the Plan as of the Effective Date, or such later date when such Employees become Employees of the Employer
following a return to work from an approved leave of absence that commenced prior to the Spin-Off. 
  

	2.2	Reemployment After Termination 

 Upon the
reemployment of a terminated former Participant as an Eligible Employee, he or she may immediately become a Participant by following enrollment procedures established by the Plan Administrator. 
 An Employee who terminates prior to becoming a Participant and is later reemployed may become a Participant after satisfying the requirements of
Section 2.1. 
  

	2.3.	Employees in a Bargaining Unit 

 An Employee
belonging to a collective bargaining unit, which has entered an agreement with the Employer that does not provide for retirement benefits under this Plan, shall not qualify for participation. If such an Employee is a Participant when such an
agreement is entered, the Employee shall cease active participation on the effective date of the bargaining agreement. If such an agreement provides for Plan participation, a covered Employee may continue or resume participation. 
  

	2.4.	Inactive Participation 

 If a Participant transfers
to a position with the Employer or an Affiliated Company in which he or she is not an Eligible Employee, the Participant shall not make Employee Contributions to the Plan, but his or her Account Balances will not be distributed until termination of
employment with the Company or Affiliated Company. If such a Participant transfers back to a position in which he or she is again an Eligible Employee, he or she may resume making Employee Contributions to the Plan as of the first of any month
following re-enrollment in the Plan. 
  

 12 

 ARTICLE 3. 
 PLAN CONTRIBUTIONS 
  

	3.1.	Employee Contributions 

  

	 	(a)	Authorization of Payroll Deductions 

 A Participant
who desires to make payroll deduction contributions pursuant to this Section 3.1(a) shall authorize the Employer to make payroll deductions equal to a whole percentage of Compensation between 1% and the applicable maximum total contribution
shown in the chart below, and shall specify the percentage which shall be contributed as a Pre-Tax Contribution (not in excess of the applicable maximum Pre-Tax Contribution shown in the chart below), and the percentage which shall be contributed as
an After-Tax Contribution, which shall not exceed the difference between the amount of the Pre-Tax Contributions and the applicable maximum total contribution. Payroll deductions shall be based on Compensation for each payroll period, and shall
become effective as soon as administratively possible. Payroll deductions shall be deducted from Participant Compensation each payroll period, except for any period in which the authorized amount exceeds the amount remaining after other payroll
deductions. 
  

										
	 Maximum Prior Year Compensation
	  	Maximum
Pre-Tax
Contribution	 	 	Maximum
After-Tax
Contribution	 	 	Total
Contribution	 
	 Less than $100,000
	  	50	%	 	50	%	 	50	%
	 $100,000 and over
	  	16	%	 	4	%	 	20	%

 For purposes of the above chart, a Participant’s maximum Pre-Tax Contribution shall be
determined according to the prior year’s total Compensation received from the Employer. For a newly hired Participant, the base salary in effect on the date of hire shall be used instead of prior year Compensation. For those Employees who were
participants in the NCR Savings Plan prior to the Spin-Off who become Participants in the Plan as of the Effective Date, or such later date when such Employees become Employees of the Employer following a return to work from an approved leave of
absence that commenced prior to the Spin-Off, their maximum Pre-Tax Contribution for 2007 shall be determined according to their prior year’s total compensation received from NCR. 
  

	 	(b)	Deemed Authorization of Payroll Deductions 

 An
Eligible Employee who satisfies the participation requirements of Section 2.1 shall be deemed to have elected to have Pre-Tax Contributions made on his or her behalf at a rate equal to 3% of Compensation, effective as soon as 

  

 13 

 
administratively practicable coincident with or next following satisfaction of the participation requirements of Section 2.1, unless the Eligible
Employee elects otherwise prior to satisfaction of such requirements in the time and manner prescribed by the Administrator. Notwithstanding the foregoing, any Eligible Employee who satisfies the participation requirements of Section 2.1 on the
Effective Date, or such later date when such Eligible Employee becomes an Employee of the Employer following a return to work from an approved leave of absence that commenced prior to the Spin-Off, or such later date on which such Eligible Employee
becomes an Employee of Teradata, shall be deemed to have elected to have Pre-Tax Contributions made on his or her behalf at a rate equal to the Pre-Tax Contribution rate in effect under the NCR Savings Plan on the last date on which such Eligible
Employee was an active participant in the NCR Savings Plan, unless the Eligible Employee elects otherwise in the time and manner prescribed by the Administrator. 
  

	 	(c)	Maximum Dollar Contribution 

 Notwithstanding the
foregoing, Pre-Tax Contributions to this Plan (and any other plans of Affiliated Companies subject to Section 402(g) of the Code) for any calendar year shall not exceed the maximum dollar limitation on elective deferrals under
Section 402(g) of the Code in effect for such calendar year (as adjusted for increases in the cost of living pursuant to Code Section 402(g) and the regulations thereunder) For 2007, the maximum dollar limitation on elective deferrals
under Section 402(g) of the Code is $15,500. 
  

	 	(d)	Participant Modification of Deduction Percentage 

 The payroll deduction percentages authorized by a Participant shall continue in effect regardless of changes in Compensation until the Participant elects to change the percentage. A Participant may change the percentages, discontinue
contributions or resume contributions by following procedures established by the Plan Administrator. Any such change will become effective as soon as administratively practical thereafter. 
  

	 	(e)	Employer Deposit of Employee Contributions 

 The
Employer shall contribute to the Plan on behalf of each active Participant an amount equal to 100% of the payroll deduction amount pursuant to the Participant’s payroll deduction authorization for each payroll period. Participant contributions
shall be credited to the Participant’s Pre-Tax Contribution Account or After Tax Contribution account, as applicable. 
 The Employer
shall pay the Employee Contributions for each payroll period in cash to the Trustee within a reasonable time after the payroll period. 
  

	 	(f)	Employee Catch-Up Contributions 

  

 14 

 All Employees who are eligible to make elective contributions under this Plan and who have attained age
50 before the close of the Plan Year shall be eligible to make catch-up contributions in accordance with, and subject to the limitations of, Section 414(v) of the Code. Such catch-up contributions shall not be taken into account for purposes of
the required limitations in Section 3.1(b), Maximum Dollar Contribution, and ARTICLE 9, Limitation on Contributions. The Plan shall not be treated as failing to satisfy the requirements in Section 4.1, Non-Discrimination
Test for Deferrals (ADP Test), ARTICLE 10, Top-Heavy Provisions, or Section 410(b) of the Code, by reason of the making of such catch-up contributions. 
 Such catch-up contributions, including any amounts that are recharacterized as Pre-Tax Contributions subject to the limitations in Section 3.1(b), Maximum Dollar Contribution, shall not be eligible for an
Employer Matching Contribution. Catch-up contributions shall be limited to 60% of an eligible Participant’s Compensation. 
  

	3.2.	Employer Matching Contributions 

 The Employer shall
make an Employer Matching Contribution for each payroll cycle in an amount equal to 100% of the first 4% and 50% of the next 2% (5%-6%) of each Participant’s Compensation contributed as Employee Contributions during such payroll cycle not in
excess of the limits contained in Sections 3.1(b) (Maximum Dollar Contributions) and 4.1 (ADP Test). This Employer Matching Contribution shall be credited to the Participant’s Employer Matching Contribution Account. 
 The Employer shall pay the Employer Matching Contributions for each payroll cycle to the Trustee within a reasonable time after such payroll cycle.

  

	3.3.	Participant Rollover Contributions 

 A Participant
may request in writing acceptance of a rollover amount from another qualified plan or conduit Individual Retirement Account (IRA), or a Section 403(b) plan or a Section 457(b) plan maintained by a governmental employer. The amount must be
directly transferred from another qualified plan or rolled over by the Participant within 60 days of receiving the distribution from the other plan or conduit IRA, or such other time period as may be permitted by the IRS due to hardship. The
Administrator has total discretion over acceptance of such amounts into this Plan; provided, rollovers of any type of property other than cash will not be accepted. In the event a Participant is permitted to contribute a rollover amount, such amount
shall be allocated to a separate, fully vested Rollover Account. 
 A Participant who has not requested distribution of his or her Accounts
under the Plan may request in writing acceptance by the Plan of a direct transfer as a rollover contribution of a lump sum distribution of the Participant’s PensionPlus benefit from the NCR Pension Plan. 
  

	3.4.	Time of Contribution 

  

 15 

 In no event shall Employer contributions for any Plan Year be made later than the time prescribed by law
(i) for the deduction of such contributions for purposes of federal income tax, as determined by the applicable provisions of the Code, or (ii) for making such contributions under a cash or deferred arrangement (within the meaning of
Section 401(k) of the Code). 
  

	3.5.	Profits Not Required 

 The Employer shall make all
contributions to the Plan without regard to current or accumulated earnings and profits for the taxable year ending with or within such Plan Year. Notwithstanding the preceding sentence, the Plan shall continue to be designed to qualify as a profit
sharing plan for purposes of Sections 401(a), 402, 412 and 417 of the Code. 
  

	3.6.	Make-Up Contributions for Participants on Military Leave 

 If a Participant takes a military leave of absence from the Employer for qualified military service, within the meaning of Chapter 43 of Title 38, United States Code, and is reemployed by the Employer as provided in that chapter following
such service, the Participant may “make-up” Employee contributions to the Plan that could have been made during the Plan Years of the qualified military service, as provided in the Uniformed Services Employment and Re-Employment Rights Act
of 1994. The make-up contributions may be made within five years after resuming active employment (or within a period equal to three times the Participant’s qualified military service, if less than five years), and will be subject to all
limitations in effect for the Plan Years to which the make-up contributions relate. The Employer will make Employer Matching Contributions with respect to such make-up Employee Contributions. The make-up contributions will be calculated according to
the compensation the Participant would have earned but for the qualified military service. If such compensation is not readily ascertainable, the average compensation earned by the Participant during the 12 month period immediately prior to the
qualified military service, or, if shorter, the period of the Participant’s employment with the Employer, will be used. For those Participants who were employees of NCR Corporation prior to the Spin-Off and who become Participants in the Plan
as of the Effective Date, or such later date when such Participants become Employees of the Employer following a return to work from an approved leave of absence that commenced prior to the Spin-Off, their compensation received from NCR will also be
taken into account in determining the Participants’ make-up contributions. 
  

 16 

 ARTICLE 4. 
 NONDISCRIMINATION TESTS 
  

	4.1.	Non-Discrimination Test for Deferrals (ADP Test) 

 For each Plan Year, the Plan must meet one of the actual deferral percentage (hereinafter “ADP”) tests described below to satisfy the non-discrimination requirement. For purposes of this ADP test, Eligible Employees who do not
qualify for participation pursuant to Section 2 shall not be considered. 
  

	 	(a)	The ADP for the group of Eligible Employees who are Highly Compensated Employees does not exceed the ADP for all other Eligible Employees multiplied by 1.25; or

  

	 	(b)	The ADP for the group of Eligible Employees who are Highly Compensated Employees (i) is not more than two percentage points higher than the ADP for all other Eligible Employees
and (ii) does not exceed the ADP for all other Eligible Employees multiplied by 2. 

 The ADP for a specified group of
Eligible Employees shall be the average of the ratios (calculated separately for each Employee in the group to the nearest one-hundredth of one percent of the Employee’s Compensation) of (i) Participant Pre-Tax Contributions to
(ii) the Employee’s Compensation earned while a Participant, determined in accordance with Code Section 401(k) and regulations pursuant thereto. 
 For purposes of the ADP tests, the definition of “Compensation” may be modified to mean any definition of compensation that complies with Section 414(s) of the Code. 
 If for any Plan Year a Highly Compensated Employee is also eligible to participate in another cash or deferred arrangement maintained by any Affiliated
Company, then the ADP of such Highly Compensated Employee shall be determined by treating all the cash or deferred arrangements in which he or she is eligible to participate and this Plan as one arrangement. 
  

	4.2.	Non-Discrimination Test for Employer Matching Contributions and After-Tax Contributions (ACP Test) 

 For each Plan Year the Plan must meet one of the average contribution percentage (hereinafter “ACP”) tests described below to satisfy this
non-discrimination requirement. For purposes of this ACP test, Eligible Employees who do not qualify for participation pursuant to Article 2 shall not be considered. 
  

	 	(a)	The ACP for the group of Eligible Employees who are Highly Compensated Employees does not exceed the ACP for all other Eligible Employees multiplied by 1.25; or

  

	 	(b)	 The ACP for the group of Eligible Employees who are Highly Compensated Employees (i) is not more than two percentage points higher than the ACP for all 

  

 17 

	 	 
other Eligible Employees and (ii) does not exceed the ACP for all other Eligible Employees multiplied by 2. 

 The ACP for a specified group of Eligible Employees shall be the average of the ratios (calculated separately for each Employee in the group to the
nearest one-hundredth of one percent of the Employee’s Compensation) of (i) Employer Matching Contributions on behalf of each such Employee and the Employee’s After-Tax Contributions, if any, to (ii) the Employee’s
Compensation earned while a Participant, determined in accordance with Code Section 401(m) and regulations pursuant thereto. 
 For
purposes of the ACP tests, the definition of “Compensation” may be modified to mean any definition of Compensation that complies with Section 414(s) of the Code. 
 If for any Plan Year a Highly Compensated Employee is also eligible to participate in another plan offering employer matching contributions and/or
after-tax contributions maintained by any Affiliated Company, the ACP of such Highly Compensated Employee shall be determined by aggregating all such contributions. 
  

	4.3.	Corrective Procedures to Satisfy Discrimination Tests 

 If at any time during a Plan Year the Administrator determines on a projected basis that it is necessary to reduce the Participant Pre-Tax Contributions, After-Tax Contributions or Employer Matching Contributions to satisfy the dollar limit
on annual deferrals, the ADP non-discrimination test, or the ACP non-discrimination test, it shall have the authority to do so in such amounts and for such periods of time as it deems necessary under the circumstances. 
 The Administrator, in its sole discretion, may elect to aggregate Employer Matching Contributions with Pre-Tax Employee Contributions to the extent
necessary to satisfy the ADP discrimination test provided such aggregation does not itself result in discrimination. Notwithstanding any Plan provisions to the contrary, any Employer contributions so aggregated shall be 100% vested, may not be
withdrawn upon hardship, and the ACP test must be passed without taking such Employer contributions into account. 
  

	4.4.	Return of Contributions 

  

	 	(a)	Mistake of Fact 

 If the amount of contribution made
to the Plan by the Employer for any Plan Year is in excess of the amounts required under Article 3, and such excess payment is due to mistake of fact, the Employer shall have the right to recover such excess contribution within one year after the
date the contribution is made to the Trustee. The return of a contribution shall be permitted hereunder only if the amount so returned (i) is the excess of the amount actually contributed over the amount which would have otherwise been
contributed, (ii) does not include the Compensation attributable to such contribution, and (iii) is reduced by any losses attributable to such contribution. 
  

 18 

	 	(b)	Contributions in Excess of Dollar Limitation 

 An
excess deferral exists for a Participant if Pre-Tax Contributions under this Plan together with any other plans subject to the maximum dollar limitation on elective deferrals under Section 402(g) of the Code for any calendar year exceed such
dollar limitation in effect for such calendar year (as adjusted for increases in the cost of living pursuant to Code Section 402(g) and the regulations thereunder). For 2007, the maximum dollar limitation on elective deferrals under
Section 402(g) of the Code is $15,500. 
 In the event an excess deferral exists in plans maintained by the Employer (and Affiliated
Companies, if applicable) such excess deferral, adjusted for investment gains or losses during the calendar year (using the method described in Section 5.5), less amounts previously returned pursuant to subparagraph (c), shall be distributed no
later than April 15 following the calendar year in which the excess deferral occurred. 
 In the event an excess deferral exists in plans
maintained by the Employer and any unrelated employers, and a Participant submits a written request for a return of excess deferrals by March 1 following the calendar year in which an excess deferral occurs, the Administrator shall distribute
such excess deferral, adjusted for investment gains or losses during the calendar year (using the method described in Section 5.5), less amounts previously returned pursuant to subparagraph (c), no later than April 15 following the
calendar year in which the excess deferral occurred. Such written request shall contain information which the Administrator requires. 
  

	 	(c)	ADP Excess Contribution 

 An ADP excess contribution
exists if contributions under this Plan on behalf of Highly Compensated Employees fail to meet the ADP test described in Section 4.1. Within twelve months after the end of the Plan Year for which there is an excess, the total contributions
which exceed the ADP limitation, adjusted for earnings and losses during the calendar year (using the method described in Section 5.5), less amounts previously returned pursuant to subparagraph (b), shall be determined by reducing each Highly
Compensated Employee’s deferral in the order of deferral percentages beginning with the highest. Then, the total amount will be refunded to the Highly Compensated Employees by reducing the dollar amounts contributed, in increments, beginning
with the highest and then continuing with the next highest as the ceiling declines, until the total amount has been refunded. Pre-Tax Contributions distributed under this provision shall not be eligible for Employer Matching Contributions.

  

	 	(d)	ACP Excess Contributions 

 An ACP excess
contribution exists if contributions under this Plan on behalf of Highly Compensated Employees fail to meet the ACP test described in Section 

  

 19 

 
4.2. Within twelve months after the end of the Plan Year for which there is an excess, the total After-Tax Contributions, and then the total Employer
Matching Contributions of Highly Compensated Employees which exceed the ACP limitation shall be determined by reducing each Highly Compensated Employee’s contributions, beginning with the highest contribution percentage and then continuing with
each next lower percentage as the ceiling declines. Then, the total amount will be refunded to the Highly Compensated Employees by reducing the dollar amounts contributed, in increments, beginning with the highest and then continuing with the next
highest as the ceiling declines, until the total amount has been refunded as follows: 
  

	 	(1)	Any amount reduced from After-Tax Contributions shall be distributed, with related earnings, to the Employee to whom it applies. 

  

	 	(2)	Any amount reduced from Employer Matching Contributions shall be forfeited, with related earnings, to the extent of any unvested balance in the Employer Matching Contribution
Account of the Employee to whom it applies. The unvested balance shall be determined before the reduction. Amounts so forfeited shall be applied to pay Plan expenses or offset future Employer Matching Contributions. 

  

	 	(3)	Any amount reduced from Employer Matching Contributions not forfeited under (2) above shall be adjusted for earnings and losses during the Plan Year (using the method described
in Section 5.5 on a last-in/first-out basis) and distributed to the Employee to whom it applies. 

  

	 	(e)	Vesting Exception 

 Notwithstanding the vesting
provisions of Article 8, a Participant shall not have a nonforfeitable right to excess contributions which are returned, adjusted or forfeited pursuant to this Section 4.5. 
  

 20 

 ARTICLE 5. 
 ACCOUNT ADMINISTRATION 
  

	5.1.	Types of Accounts 

 All contributions shall be made
to the Trust Fund which will have the following types of accounts for each Participant: 
  

	 	(a)	Pre-Tax Contribution Account 

  

	 	(b)	After-Tax Contribution Account 

  

	 	(c)	Employer Matching Contribution Account 

  

	 	(d)	Rollover Account 

  

	5.2.	Investment Options 

 The Trust Fund shall be divided
into one or more investment funds, including an investment fund which shall be invested primarily in Teradata Common Stock (the “Teradata Unitized Stock Fund”). Any fund may hold for investment any assets permitted by the terms of the
Trust Agreement, including without limitation, cash or other types of short-term investments. Investment funds may be established or eliminated by agreement between the Employer and the Trustee. 
  

	5.3.	Participant Direction of Investments 

 Each
Participant shall direct the investment of his or her Accounts among the available investment funds. An investment direction shall remain effective with regard to all subsequent amounts credited to a Participant’s Account, until changed in
accordance with the provisions of this section. An investment direction shall apply proportionately to all of a Participant’s Accounts. A Participant who fails to direct the investment of his or her Accounts, shall be deemed to have directed
the investment of his or her Accounts in the applicable default investment option selected by the Employer. 
  

	 	(a)	When Participation Commences 

 When participation
commences, a Participant shall allocate future contributions to his or her Account among the investment funds in 1% increments by giving direction to the Recordkeeper. 
  

	 	(b)	Changing Investment Allocations 

 A Participant may
change his or her investment election with respect to existing Account balances and/or future contributions as of any Business Day, in 1% increments by giving direction to the Recordkeeper. The Plan Administrator or Recordkeeper may place
restrictions or limitations on the timing or number of 

  

 21 

 
investment changes as reasonably necessary for appropriate fund management. 
  

	5.4.	Allocation of Trust Fund Earnings and Losses to Participant Accounts 

 As of each Business Day, any increase or decrease in the fair market value (including interest, dividends, realized and unrealized gains and losses) of any fund shall be allocated among the Participant Accounts on the
basis of the interests in the particular fund held in the Accounts as of such day. 
 Notwithstanding the foregoing, in the event a
terminated Participant has received a distribution of his or her vested benefit, the nonvested portion of his or her Participant’s Account shall not be credited with Trust Fund earnings and losses pursuant to this section after the date of the
distribution. 
  

	5.5.	Account Statements 

 Each Participant shall be
provided with a statement of his or her Accounts under the Plan showing the Account values as of each calendar quarter. If within thirty (30) days after the statement is mailed (or electronically delivered if so elected by the Participant) the
Participant makes no objection to the statement, it shall become binding and conclusive on the Participant and any Beneficiary. 
  

 22 

 ARTICLE 6. 
 BENEFITS AND FORMS OF PAYMENT 
  

	6.1.	Eligibility for Benefits 

 A Participant shall be
eligible to receive a distribution of his or her Accounts, to the extent vested, upon termination of employment with the Employer and any Affiliated Companies. A Participant’s Beneficiary shall be eligible to receive a distribution of the
Participant’s Accounts upon the death of the Participant. 
 Notwithstanding the foregoing, in the event a Participant again becomes an
Employee before benefits commence, he or she shall no longer be eligible to receive a distribution. 
  

	6.2.	Time of Benefit Commencement 

  

	 	(a)	Benefit Commencement 

 Benefits shall be paid as
soon as practical following a request for benefit commencement. Participants and Beneficiaries may request benefit commencement as described below. 
  

	 	(1)	Participant 

 A Participant who is eligible for
benefits may request benefit commencement by contacting the Recordkeeper. Benefits may commence at any time following termination of employment with the Employer, however, benefits must commence on or before the date the Participant attains or would
have attained age 70-1/2. If a Participant who has terminated employment fails to request benefit commencement, he or she shall be deemed to have requested that benefits commence on the date the Participant attains or would have attained age 70-1/2.

 If a Participant remains employed by the Employer past age 70-1/2 and the Participant is not a 5% owner of the Employer, his or her
benefits shall commence on the first of the month after the date of termination of employment. 
  

	 	(2)	Beneficiary 

 A Beneficiary who is eligible for
benefits shall receive benefits within a reasonable time following the Participant’s death, in the form of a Lump Sum. A Beneficiary who is the surviving Spouse of the Participant may also elect a direct rollover as described in Subsection
6.3(d), Direct Transfer. 
  

 23 

	 	(b)	Amount of Payment 

 The amount distributed shall be
based on the Account balance determined as soon as practical following a request for benefit commencement. 
 Distributions will be made in
cash, except that if a Lump Sum distribution is elected, a Participant may elect to receive the portion of his or her Accounts invested in the Teradata Unitized Stock Fund in whole shares of the applicable common stock, with any fractional shares
distributed in cash. 
  

	 	(c)	Small Benefits 

 Notwithstanding any election to
commence benefits or lack thereof, a benefit which is $1,000 or less (or such other limit as may be set by statute) at the time benefits commence shall be distributed in a lump sum within 90 days following termination of employment, death or
becoming Disabled, without Participant or Beneficiary consent. 
  

	6.3.	Form of Payment 

 The following forms of payment are
available to Participants under this Plan: 
  

	 	(a)	Lump Sum 

 A Lump Sum distribution shall be a single
sum payment which represents the Participant’s vested interest in the Plan. 
  

	 	(b)	Installments 

 Installment payments made quarterly
in accordance with the Participant’s election, for 5, 10, or 15 years or for the life expectancy of the Participant. A Participant may not elect an installment period that exceeds his or her life expectancy. Each installment payment shall be
determined by dividing the total value of the Participant’s Accounts immediately before the installment is paid by the number of such remaining installments (including that installment). The Participant’s Accounts which are not yet
distributed shall continue to be credited with investment earnings and losses pursuant to section 5.5. A Participant who has elected to receive installment payments may at any time request that the remaining installments be accelerated and paid in a
single lump sum. 
  

	 	(c)	Direct Transfer 

 A Participant may elect to have
any portion of an Eligible Rollover Distribution that is equal to at least $500 paid directly to an Eligible Retirement Plan specified by the Participant, in a direct rollover. 
 For purposes of this subsection (d), “Eligible Rollover Distribution” means any distribution to a Participant or surviving Spouse of a
Participant, other than (1)

  

 24 

 
installment payments made for life, the life expectancy of the participant, or over a period of ten years or more; (2) the amount of any distribution
required under Section 401(a)(9) of the Code; and (3) any other distribution that is reasonably expected to total less than $200 during a year. 
 For purposes of this subsection (d), “Eligible Retirement Plan” means an individual retirement account described in Section 408(a) of the Code, an individual retirement annuity described in
Section 408(b) of the Code, an annuity plan described in Section 403(a) of the Code, an annuity plan described in Section 403(b) of the Code, a plan described in Section 457(b) of the Code maintained by a governmental employer or
a qualified plan described in Section 401(a) of the Code, that accepts the Participant’s eligible rollover distribution. In the case of an Eligible Rollover Distribution to the surviving Spouse, an Eligible Retirement Plan is an individual
retirement account or individual retirement annuity. 
  

	 	(d)	Minimum Required Distributions 

 If a Participant is
required to commence benefits due to attaining age 70-1/2 and does not elect a form of distribution, the benefits shall be paid according to the minimum distribution requirements of Section 401(a)(9) of the Code and the regulations thereunder.

  

	6.4.	Benefits for Terminated Participants 

 Benefits
under the Plan shall be determined and paid in accordance with the provisions of the Plan in effect on the Participant’s most recent date of termination of employment. 
  

	6.5.	Commencement of Payment 

 (a) Unless a Participant
elects otherwise, the payment of benefits shall commence no later than 60 days after the end of the Plan Year in which the latest of the following occurs: 
  

	 	(1)	the date the Participant attains age 65, 

  

	 	(2)	the tenth anniversary of the year in which the Participant commenced participation in the Plan, or 

  

	 	(3)	the Participant terminates employment with the Employer; 

 provided, however, that the Administrator shall require such a Participant to file a claim for benefits before such payment of benefits shall commence. If the Participant fails to file a claim for benefits prior to the latest
to occur of the events listed above, the Participant shall be deemed to have elected to defer such distribution until a date no later than the dates required under Subsection (b). 
 (b) Payments shall not commence later than April 1 following the calendar year in which the Participant attains age 70-1/2, if the Participant
(1) has terminated employment with the Employer, or (2) has not terminated employment and is a 5% owner of the Employer. 
  

 25 

 ARTICLE 7. 
 WITHDRAWALS AND LOANS 
  

	7.1.	After-Tax and Rollover Withdrawals 

 A Participant
may withdraw all or a portion of his or her After-Tax Contributions Account and Rollover Account, with earnings, not more than twice in any calendar year, by submitting an application to the Recordkeeper. If a Participant withdraws After-Tax
Contributions that were matched by the Employer, the Participant may not make Employee Contributions to the Plan for twelve months after the withdrawal. Withdrawals will be paid in cash. 
  

	7.2.	Hardship Withdrawal 

  

	 	(a)	Availability 

 Prior to termination of employment, a
Participant may apply for a hardship withdrawal of his or her Employee Contributions. 
 All hardship withdrawals are subject to Administrator
approval, and will be paid in cash. A hardship withdrawal may not be rolled over to another qualified plan or Individual Retirement Account. A hardship withdrawal shall only be approved if it is for a specific type of expense and if it is necessary
to satisfy such expense. 
  

	 	(b)	Hardship Expenses 

 Hardship withdrawals are
available only to pay for the following expenses (including any penalties and taxes incurred as a result of the hardship distribution): 
  

	 	(1)	expenses for medical care described in Code Section 213(d) incurred by the Participant, or his or her Spouse or dependents (as defined in Code Section 152) or amounts
necessary for such persons to obtain such medical care; 

  

	 	(2)	purchase (excluding mortgage payments) of a principal residence for the Participant; 

  

	 	(3)	tuition and related educational fees for the next twelve months of post-secondary education for the Participant, his or her Spouse, children, or dependents;

  

	 	(4)	preventing eviction of the Participant from his or her principal residence or foreclosure on the mortgage of the Participant’s principal residence; 

  

	 	(5)	payment of unreimbursed expenses for maintaining the structural integrity of the Participant’s principal residence; or 

  

 26 

	 	(6)	payment of funeral expenses for a dependent (as defined in Code Section 152) of the Participant. 

  

	 	(c)	Determination of Necessity 

 A distribution shall be
deemed to be necessary to satisfy an expense described in 7.2(b) above if both of the following requirements are satisfied: 
  

	 	(1)	the distribution is not in excess of the amount of such expense (including any excise tax or income tax liability arising from the distribution); and 

  

	 	(2)	the Participant has obtained all distributions (other than hardship distributions), and all nontaxable loans currently available under all plans maintained by the Employer, except
that a Plan loan will not be required for the purchase of a principal residence if the loan may disqualify the Participant from obtaining other necessary financing. 

  

	 	(d)	Order of Withdrawal 

 A hardship distribution shall
be deducted from the Participant’s Accounts in the following order: 
  

	 	(1)	Unmatched After-Tax Contributions, prorated between contributions and earnings. 

  

	 	(2)	Matched After-Tax Contributions, prorated between contributions and earnings. 

  

	 	(3)	Rollover Contributions (other than after-tax contributions), prorated between contributions and earnings. 

  

	 	(4)	After-Tax Rollover Contributions, prorated between contributions and earnings. 

  

	 	(5)	Pre-Tax Contributions (other than catch-up contributions), without earnings. 

  

	 	(6)	Catch-Up Contributions, without earnings. 

 Employer
Matching Contributions are not available for hardship withdrawals. 
  

	 	(e)	Other Requirements 

 A Participant’s Employee
Contributions to this or any other qualified retirement plan maintained by the Employer shall be suspended for six (6) months after a hardship withdrawal. Following the suspension, the Participant may resume contributions. A Participant’s
deferral elections under any nonqualified deferred compensation maintained by the Employer shall be canceled for the remainder of 

  

 27 

 
the calendar year in which the hardship withdrawal occurs. Subject to the rules of Section 409A of the Code, the Participant may make new deferral
elections under any nonqualified deferred compensation maintained by the Employer, but such elections may not be effective with respect to compensation paid during the six (6) months after a hardship withdrawal. 
 In addition, the Participant may not make a Pre-Tax Contribution to the Plan or any other plan maintained by the Employer (other than health or welfare
benefit plans, including cafeteria plans under Code Section 125) for the Participant’s taxable year immediately following the taxable year of the hardship withdrawal, in excess of Pre-Tax Contributions allowable in Section 3.1(b) for
the next taxable year less the amount of such Participant’s Pre-Tax Contributions for the taxable year of the hardship withdrawal. 
 Notwithstanding the foregoing, a Participant whose contributions have been suspended due to a hardship withdrawal shall be deemed to be an Eligible Employee for purposes of the ADP test in Section 4.1, ACP test in Section 4.2, and
multiple use test in Section 4.3. 
  

	7.3.	Loans 

  

	 	(a)	General 

 A Participant who has not terminated
employment with the Employer or an Affiliated Company may borrow from the Plan in accordance with this Section 7.3. Only one loan may be outstanding at any time. 
 To the extent of the loan amount outstanding throughout the term of the loan, a Participant’s Accounts shall not share in investment earnings and losses that would otherwise have been credited or charged to the
Accounts, but it shall be credited with the loan interest payments. A loan may be transacted by contacting the Recordkeeper by telephone. Based upon such a transaction, the Participant will receive a Promissory Note and Security Agreement and
information necessary to complete the processing of the loan. 
  

	 	(b)	Amount 

 No loan shall be in an amount that is less
than $1,000, or greater than the lesser of $50,000 or 50% of the employee’s vested account balance. The $50,000 limit shall be reduced by the Participant’s highest outstanding loan balance in the preceding 12 months. The amount of the loan
shall not exceed an amount that can be repaid by a payroll after-tax deduction which equates to 25% of the employee’s base rate of pay. Loan amounts shall be deducted from a Participant’s Accounts in the following order: 
  

	 	(1)	Pre-Tax Contribution Account and earnings thereon, 

  

	 	(2)	Vested Employer Matching Contribution Account, 

  

 28 

	 	(3)	matched After-Tax Contribution Account and earnings thereon, 

  

	 	(4)	unmatched After-Tax Contribution Account and earnings thereon, and 

  

	 	(5)	Rollover Account and earnings thereon. 

  

	 	(c)	Term 

 An employee may elect a loan term of one,
two, three or four years or the maximum term of five years. However, the term shall end and the outstanding principal amount of the loan shall become due and payable three months following the employee’s retirement, termination of employment
due to disability or other termination of employment. 
  

	 	(d)	Interest 

 The interest rate on any loan shall be
set by the Administrator equivalent to the Prime Rate in effect on the last day of the preceding month, plus 1%. The Prime Rate is the interest rate reported in The Wall Street Journal (Eastern Edition) in its general guide to money rates as
the base rate on corporate loans at large United States money center commercial banks. The interest rate, once established for a loan, shall remain the same throughout the term of the loan. If the Administrator at any time determines that the Prime
Rate is not a reasonable rate of interest, the interest rate shall be another rate which the Administrator determines is reasonable considering the prevailing interest rate charged on similar commercial loans by persons in the business of lending
money, current economic conditions and the facts and circumstances of the loan application. 
  

	 	(e)	Security 

 The amount of the loan, up to 50% of the
employee’s vested account balance, shall be considered as securing the loan. 
  

	 	(f)	Repayment 

 A Participant shall repay a loan with
interest in equal payments over the term of the loan by irrevocably electing after-tax payroll deductions. Loan payments shall be credited to the Participant’s Account on a monthly basis and invested according to the Participant’s current
investment direction. Principal and interest payments shall be allocated prorata among the Accounts described in Subsection 7.3(b) which comprise the unpaid loan principal. The Participant may elect to pre-pay the full outstanding loan balance at
any time during the repayment term. 
 Loan repayments for a Participant who is on an approved leave of absence shall be suspended, provided
the suspension does not exceed one year and does not result in the repayment period exceeding five years. A Participant on an approved leave of absence may continue repaying a loan by personal check each pay period. 
  

 29 

	 	(g)	Default 

 Loan payments will accelerate and come due
upon a Participant’s termination of employment, unless the termination is due to reduction-in-force, long-term disability, or transfer to an Affiliated Company, in which case the Participant will supplied with a coupon book for repaying the
loan by personal check. A Participant who misses loan payments for three consecutive months or whose past due loan amount equals three months of payment, shall be considered in default, unless the loan repayment is suspended due to leave of absence.
Further, if the loan has not been settled at the end of five years from the loan’s inception, the loan shall be considered in default. The defaulted loan balance will be reported as taxable income to the Participant for the year in which the
default occurs. If a loan is in default, the plan shall foreclose upon the Participant’s Account balances to the extent of the unpaid balance of the loan as of the earliest date on which the Participant is eligible for a distribution.

  

	 	(h)	Renegotiation 

 The terms of a loan may be
renegotiated (except that the term may not be extended beyond five years from the original loan date) if the Employee is reclassified to a different job or receives short-term disability benefits and the monthly loan repayment amount then exceeds
25% of the Employee’s monthly pay. 
  

	7.4.	Withdrawals After Age 59-1/2 

 A Participant may
withdraw all or a portion of his or her vested Accounts, with earnings, at any time after attaining age 59-1/2, regardless of whether employment has terminated. 
  

 30 

 ARTICLE 8. 
 VESTING 
  

	8.1.	Vesting 

  

	 	(a)	Fully Vested Accounts 

 Each Participant shall have
a 100% vested, nonforfeitable right to his or her Pre-Tax Contribution Account, After-Tax Contribution Account, and Rollover Account. 
  

	 	(b)	Employer Matching Contribution Accounts 

 Each
Participant shall earn a vested, nonforfeitable right to the Employer Matching Contribution made on his behalf based on his or her service, as follows: 
  

				
	 Years of Service
	  	Percent Vested	 
	 Less than 1
	  	0	%
	 1
	  	20	%
	 2
	  	40	%
	 3
	  	60	%
	 4
	  	80	%
	 5
	  	100	%

 In addition, each Participant shall have a 100% vested, nonforfeitable right to his or her Employer
Matching Contribution Account upon death, becoming Disabled, the attainment of his or her Normal Retirement Date, (provided he or she is an Employee on such date), or if his or her employment with the Employer is terminated due to a Reduction in
Force. “Reduction in Force” means that a Participant’s employment is terminated under circumstances entitling the Participant to benefits under the Teradata Change in Control Severance Plan and any Teradata workforce redeployment or
similar plan of Teradata. 
  

	8.2.	Changes in Vesting Schedule 

 If the vesting
schedule of this Plan is amended, the vested interest of any person who is a Participant on the date such amendment is adopted, or is effective, if later, shall not be less than the vested interest computed under the Plan without regard to such
amendment. 
 If the vesting schedule of this Plan is amended, any Participant who has completed at least three Years of Service may elect to
have his or her vested interest in Employer Matching Contributions determined without regard to such amendment, by giving written notice to the Administrator within sixty days after the date the amendment is adopted, the date the amendment is
effective, or the date written notice of the amendment is issued to the Participant, whichever is later. 
  

 31 

	8.3.	Forfeitures 

 In the event a Participant terminates
prior to becoming 100% vested in his or her Employer Matching Contribution Account, the non-vested portion shall be forfeited upon the earlier of (i) the last day of the Plan Year in which the Participant incurs a five-year Break in Service, or
(if) the date the Participant receives a distribution from the Plan of his or her total vested benefit following termination. The amount forfeited shall equal the non-vested balance as of the Valuation Date coinciding with or next following
termination of employment. Forfeited amounts shall be applied to reduce the Employer Matching Contributions or to pay administrative expenses of the Plan 
 If such Participant returns to service after receiving a distribution but before incurring a five-year Break in Service, the amount forfeited (without adjustment for earnings or losses after the Participant’s
termination) shall be restored as of the last day of the Plan Year in which the Participant returns to service and repays in full the prior distribution, if any, according to Section 8.4(b). 
 If such Participant returns to service before receiving a distribution of his or her vested Accounts and before incurring a five-year Break in Service,
the amount forfeited shall be restored as of the last day of the Plan Year in which the Participant returns to service. 
 Assets to restore
amounts forfeited shall be taken first from current forfeitures. In the event that current year forfeitures are inadequate to fully reinstate the Account, the Employer shall make a contribution in addition to the contributions required under Article
3 equal to the balance necessary to fully reinstate the Account. 
 If a terminated Participant is re-employed after sustaining a five-year
Break in Service, the amount forfeited shall not be restored. 
  

	8.4.	Reemployment 

  

	 	(a)	Service for Vesting 

 If a nonvested Participant
incurs a five-year Break in Service, his or her Years of Service preceding the Break in Service shall be disregarded, and any amounts contributed to the Employer Matching Contribution Account prior to the Break in Service shall be forfeited. If a
vested Participant incurs a Break in Service of any length, all Years of Service before and after the Break in Service shall be aggregated for vesting purposes. 
  

	 	(b)	Repayment 

 If a Participant forfeited all or a
portion of his or her Employer Matching Contribution Account upon termination and he or she returns to service prior to incurring a five-year Break in Service, the Participant may elect to repay the amount previously distributed from his or her
Employer Matching Accounts. Such Participant may elect to repay his or her prior distribution before five years after the date of reemployment. The forfeited amount (without adjustment for 

  

 32 

 
earnings and losses after the Participant’s termination) shall be restored upon such repayment pursuant to Section 8.3. Amounts repaid shall be
100% vested and shall be invested in the same manner as future contributions. 
  

 33 

 ARTICLE 9. 
 LIMITATION ON CONTRIBUTIONS 
  

	9.1.	Maximum Annual Contribution to the Plan 

 For
purposes of this Article 9, the Employer and any Affiliated Companies shall be considered a single employer, to the extent required by the Code. 
  

	 	(a)	Primary Rule 

 Notwithstanding any other Plan
provision to the contrary, the Annual Additions to a Participant’s Accounts in this Plan and any other defined contribution plan maintained by the Employer shall not exceed the lesser of (i) 100% of the Participant’s Compensation, or
(ii) $45,000 (as adjusted for cost of living increases). 
  

	 	(b)	Annual Additions Defined 

 For purposes of this
Article 9, the term “Annual Additions” for any Participant in any Plan Year means the sum of the amount of Employer contributions and Participant Pre-Tax and After- Tax Contributions allocated to a Participant’s Accounts. 

 

	 	(c)	Cost-of-Living Adjustment 

 The $45,000 limit
prescribed above shall be automatically adjusted for cost-of-living increases, to the maximum permissible dollar limitation determined by the Commissioner of Internal Revenue. The dollar amount applicable in computing the maximum contribution for
any Participant shall be the dollar amount in effect for the calendar year in which the contribution is made. 
  

	 	(d)	Remedy 

 If for any Plan Year the Annual Additions
exceed the foregoing limitations because of the allocation of forfeitures or a reasonable error in determining compensation or the amount of a Participant’s Pre-Tax Contribution permitted under Section 415 of the Code, the Employer shall
distribute the amount of the Pre-Tax Contribution in excess of the limits. If the Annual Additions continue to exceed the limitations after such distribution, the Employer shall allocate the excess to a suspense account. The suspense account shall
be credited with investment earnings and losses as of each Business Day in the same manner as Participant Accounts pursuant to Section 5.5. Such suspense account is for accounting purposes only and shall remain in the Trust Fund to be
reallocated as provided below. Contents of the suspense account shall be allocated to the affected Participant’s Account in subsequent years when that can be done without exceeding the limitations of this Section 9.1. So long as any amount
remains in the suspense account, the Employer shall not contribute to the Plan any amount 

  

 34 

 
which would cause an additional allocation to the suspense account. In the event the Participant ceases to be a Participant when any amount remains in a
suspense account, such amount shall be reallocated to active Participants as of the end of the Plan Year following the calendar year in which he or she ceases to be a Participant. In the event the Plan terminates before any amount remaining in the
suspense account has been fully allocated to Participant Accounts, the balance of the suspense account shall be distributed to the Employer. 
  

 35 

 ARTICLE 10. 
 TOP HEAVY PROVISIONS 
  

	10.1. 	Scope 

 Notwithstanding any Plan provision to the
contrary, for any Plan Year in which the Plan is Top Heavy within the meaning of Section 416(g) of the Code, the provisions of this Article 10 shall govern to the extent they conflict with or specify additional requirements to the Plan
provisions governing Plan Years which are not Top Heavy. 
  

	10.2.	 Top Heavy Status 

  

	 	(a)	Top Heavy 

 This Plan shall be “Top Heavy”
if, as of the Determination Date, (1) the Present Value of Accrued Benefits of Key Employees, or (2) the sum of the Aggregate Accounts of Key Employees under this Plan and any plan of an Aggregation Group, exceeds sixty percent
(60%) of the Present Value of Accrued Benefits or the Aggregate Accounts of all Participants under this Plan and any plan of an Aggregation Group, determined in accordance with Code Section 416(g) and regulations thereunder. 
 The Present Value of Accrued Benefits and/or Aggregate Account balance of a Participant who was previously a Key Employee but is no longer a Key Employee
(or his or her Beneficiary), shall not be taken into account for purposes of determining Top Heavy status. Further, a Participant’s Present Value of Accrued Benefits and/or Aggregate Account balance shall not be taken into account if he or she
has not performed services for the Affiliated Companies at any time during the five year period ending on the Determination Date. 
  

	 	(b)	Super Top Heavy 

 This Plan shall be “Super Top
Heavy” if, as of the Determination Date, (1) the Present Value of Accrued Benefits of Key Employees, or (2) the sum of the Aggregate Accounts of Key Employees under this Plan and any plan of an Aggregation Group, exceeds ninety
percent (90%) of the Present Value of Accrued Benefits or the Aggregate Accounts of all Participants under this Plan and any plan of an Aggregation Group. 
  

	 	(c)	Determination Date 

 Whether the Plan is Top Heavy
for any Plan Year shall be determined as of the Determination Date. “Determination Date” means (a) the last day of the preceding Plan Year, or (b) in the case of the first Plan Year, the last day of such Plan Year. 
  

 36 

	 	(d)	Valuation Date 

 “Valuation Date” means,
for purposes of determining Top Heaviness, the Determination Date instead of the meaning set forth in Section 1.37. 
  

	 	(e)	Aggregate Account 

 “Aggregate Account”
means, with respect to a Participant, the sum of: 
  

	 	(1)	his or her account balances as of the Valuation Date; 

  

	 	(2)	contributions after the Valuation Date due as of the Determination Date; 

  

	 	(3)	distributions prior to the Valuation Date, made during the Plan Year that contains the Determination Date and any in-service distributions made during the four preceding Plan Years.

  

	 	(f)	Present Value of Accrued Benefits 

 The
“Present Value of Accrued Benefits” with respect to a defined benefit plan shall be based upon the Participant’s accrued benefits and the actuarial assumptions as determined under the provisions of the applicable defined benefit plan.

  

	 	(g)	Key Employee 

 “Key Employee” means an
Employee or former Employee (and his or her Beneficiaries) who, at any time during the Plan Year containing the Determination Date, is included in one of the following categories as within the meaning of Section 416(i)(l) of the Code:

  

	 	(1)	an officer of the Employer whose annual aggregate Compensation from the Affiliated Companies exceeds $145,000 (or such other amount as may be in effect for such Plan Year under
Section 416(i)(1)(A)(i) of the Code), provided that no more than 50 Employees shall be considered officers, or if less, the greater of 10% of the Employees or 3, 

  

	 	(2)	an Employee who owns more than 5% of the Employer, or 

  

	 	(3)	an Employee who owns more than 1% of the Employer with annual aggregate Compensation from the Affiliated Companies that exceeds $150,000. 

  

	 	(h)	Aggregation Group 

 “Aggregation Group”
means the group of plans that must be considered as a single plan for purposes of determining whether the plans within the group are Top Heavy (Required Aggregation Group), or the group of plans that may be 

  

 37 

 
aggregated for purposes of Top Heavy testing (Permissive Aggregation Group). The Determination Date for each plan must fall within the same calendar year in
order to aggregate the plans. 
  

	 	(1)	The Required Aggregation Group includes each plan of the Affiliated Companies in which a Key Employee is a participant in the Plan Year containing the Determination Date or any of
the four preceding Plan Years, and each other plan of the Affiliated Companies which, during this period, enables any plan in which a Key Employee participates to meet the minimum participation standards or non-discriminatory contribution
requirements of Code Sections 401(a)(4) and 410. 

  

	 	(2)	A Permissive Aggregation Group may include any plan sponsored by an Affiliated Company, provided the group as a whole continues to satisfy the minimum participation standards and
non-discriminatory contribution requirements of Code Sections 401(a)(4) and 410. 

 Each plan belonging to a Required
Aggregation Group shall be deemed Top Heavy, or non-Top Heavy in accordance with the group’s status. In a Permissive Aggregation Group that is determined Top Heavy only those plans that are required to be aggregated shall be Top Heavy. In a
Permissive Aggregation Group that is not Top Heavy, no plan in the group shall be Top Heavy. 
  

	10.3.	 Minimum Contribution 

  

	 	(a)	General Rule 

 For any Plan Year in which the Plan
is Top Heavy, the total Employer contribution under Article 3 allocated to any non-key Participant’s account shall not be less than 3% of such Participant’s Compensation. Participant contributions under Section 3.1(a) are not
considered when determining whether this 3% requirement is satisfied. However, in the event the Employer contributions allocated to each Key Employee’s account do not exceed 3% of his or her Compensation, such Employer contributions and
forfeitures for non-Key Employees are only required to equal the highest percentage of Compensation, including Participant Pre-Tax Contributions under Section 3.1(a), allocated to any Key Employee’s accounts for that Plan Year under any
defined contribution plans sponsored by the Affiliated Companies. The minimum contribution must be made on behalf of all non-Key Participants who are employed on the last day of the Plan Year including non-Key Employees who (1) failed to
complete a Year of Service, or (2) declined to make any mandatory contributions to the Plan or enter an Enrollment Form. 
  

	 	(b)	Special Two Plan Rule 

 Where this Plan and a
defined benefit plan belong to an Aggregation Group that is determined Top Heavy, the minimum contribution required under paragraph (a) above shall be increased to 5%. 
  

 38 

	10.4. 	Limitation to Annual Additions in Top Heavy Plan 

 For any Top Heavy Plan Year in which the Employer does not make the extra minimum allocation provided below, 1.0 shall replace the 1.25 factor found in the denominators of the defined benefit and defined contribution plan fractions for
purposes of calculating the combined limitation on benefits under a defined benefit and defined contribution plan pursuant to Section 415(e) of the Code. 
 If this Plan is Top Heavy, but is not Super Top Heavy, the above referenced fractions set forth in Section 9.2 shall remain unchanged provided the Employer makes an extra minimum allocation for non-Key
Participants. The extra allocation (in addition to the minimum contribution set forth in Section 10.3) shall equal at least 2-1/2% of a non-Key Participant’s Compensation. 
  

	10.5.	Vesting 

 For any Top Heavy Plan Year, a
Participant’s Accounts shall remain subject to the vesting provisions in Section 8.1. 
  

 39 

 ARTICLE 11. 
 ADMINISTRATION OF THE PLAN 
  

	11.1. 	Responsibility for Plan Administration 

 The Employer shall be the “named fiduciary” under ERISA with respect to the operation and administration of the plan, the investment, reinvestment and administration of the assets of the Plan, and shall be the
“Administrator” of the Plan. 
  

	11.2. 	Asset Management Authority of the Employer 

 The Employer shall perform all such duties as are necessary to supervise the investment, reinvestment and administration of the assets of the Plan. The Employer may delegate its authority to administer the investment of the assets of the
Plan (other than trustee responsibilities to the extent that such delegation would be limited by law). The Employer shall have such duties and powers as may be necessary to discharge its duties hereunder, including, but not by way of limitation, the
following: 
  

	 	(a)	to appoint and remove Trustees and Investment Managers; 

  

	 	(b)	to fix the compensation of such Trustees and Investment Managers; 

  

	 	(c)	to enter into and amend trust agreements and other agreements relating to the management and custody of Plan assets; 

  

	 	(d)	to allocate and reallocate Plan assets among Trustees, Investment Managers, insurance companies and others consistent with any governing documents and legal requirements;

  

	 	(e)	to effect transfers of assets from one funding medium or vehicle to another; 

  

	 	(f)	to make investments for each trust, account or other funding vehicle either directly or through Trustees, Investment Managers or others; and 

  

	 	(g)	to issue investment directions and guidelines to Investment Managers, Trustees and others consistent with this Plan and the documents and requirements governing any trust, account
or other funding vehicle and where applicable, any associated asset management agreement. 

  

	11.3. 	Duties and Authority of the Administrator 

 The
Administrator shall perform all such duties as are necessary to supervise the administration of the Plan and to control its operation in accordance with the terms hereof, including, but not limited to, the following: 
  

	 	(a)	Obtain the individual bonding required by law, as described in Section 11.4 below; 

  

 40 

	 	(b)	Retain auditors, accountants, consultants, legal counsel, and other advisors as it may deem necessary to carry out the provisions of the Plan; 

  

	 	(c)	Interpret the provisions of the Plan and resolve any question arising under the Plan, or in connection with the administration or operation of the Plan; 

  

	 	(d)	Make all determinations affecting the eligibility of any Employee to become a Participant in the Plan; 

  

	 	(e)	Determine eligibility for and amount of benefits for any Participant; 

  

	 	(f)	Authorize and direct disbursements of benefits under the Plan; 

  

	 	(g)	Delegate and allocate specific responsibilities, obligations and duties under the Plan to one or more employees, officers or such other persons as the Administrator deems
appropriate; 

  

	 	(h)	Prepare and file, or cause to be prepared and filed, such reports, descriptions, summaries, and financial and other statements with respect to the Plan as may be necessary,
desirable or required by law, within the time prescribed therefore; 

  

	 	(i)	Not later than seven months after the end of each Plan Year, deliver or cause to be delivered to each Participant (or the Beneficiary of a Participant who died) who was such on the
last day of the Plan Year a statement setting forth the Participant’s Account balances as of such date; 

  

	 	(j)	Delegate to any other person, firm or corporation any of the Administrator’s responsibilities; 

  

	 	(k)	Furnish or cause to be furnished such reports, descriptions, summaries and statements to Participants and Beneficiaries as may be necessary, desirable or otherwise required by law,
within the time specified therefore; and 

  

	 	(l)	Appoint a Recordkeeper to maintain records of Participant Accounts, and perform administrative functions related to such recordkeeping. 

  

	11.4. 	Plan Expenses 

 Employees who are acting on behalf
of the Administrator shall not receive additional compensation with respect to their service as such. 
 All reasonable expenses which are
necessary to operate and administer the Plan may be deducted from the Trust Fund, or, at the election of the Employer, paid directly by the Employer; provided, that brokerage commissions and transaction costs with respect to the investment funds
shall be included in the cost of a Participant’s investment in the fund at the time of the investment and in determining net proceeds on sales of investments, and provided, further, that any investment management fees are paid from the
respective investment fund. 
  

 41 

	11.5. 	Bonding and Insurance 

 To the extent required by
law, every Employee acting on behalf of the Administrator, every fiduciary of the Plan and every person handling Plan funds shall be bonded. The Administrator may apply for and obtain fiduciary liability insurance insuring the Plan against damages
by reason of breach of fiduciary responsibility at the Plan’s expense and insuring each fiduciary against liability to the extent permissible by law at the Employer’s expense. 
  

	11.6. 	Maintenance of Written Records 

 The Employer and
subsidiaries of the Employer that are participating in the Plan shall each keep or cause to be kept, such records as shall be proper, necessary or desirable to effectuate the purposes of the Plan, including, but not limited to, records and
information with respect to the compensation of Employees, dates of employment, and Account balances of Participants; and shall give or cause to be given timely notice to the others of such information. Neither the Employer, participating
subsidiaries or the Administrator shall be required to duplicate any records kept by any of the others. To the extent that the Employer or the Administrator prescribes a form for use by Participants and Beneficiaries in submitting a particular
communication to the Employer or the Administrator, and specifies a time period during which such a communication may be submitted, they and the participating subsidiaries shall be protected in disregarding any such communication not made on the
prescribed form or not received during the specified time period. The Employer and the Administrator shall also be protected in acting upon any notice or other communication purporting to be signed by any person and reasonably believed to be genuine
and accurate, and shall not be deemed imprudent by reasons of so doing. 
  

	11.7. 	Scope of Authority 

 The Administrator shall
administer the Plan in a non-discriminatory manner for the exclusive benefit of Participants and their Beneficiaries. 
 The Administrator
shall have all powers necessary or appropriate to carry out its duties, including the discretionary authority to interpret the provisions of the Plan and the facts and circumstances of claims for benefits, including, without limitation, questions of
the eligibility of any person to participate in the Plan and the amounts payable to any person under the Plan. Any interpretation or construction of or action by the Administrator with respect to the administration of the Plan shall be conclusive
and binding upon any and all parties affected thereby, subject to the exclusive appeal procedure set forth in Section 11.8. The actions of the Administrator in administering the Plan shall be overturned only if such actions are arbitrary and
capricious and an abuse of its discretion under the Plan. 
 In addition, the Administrator shall have full authority to interpret, apply and
enforce the provisions of the Plan, including without limitation the authority to correct any defects or omissions or to reconcile any inconsistencies herein, in such manner and to such an extent as deemed necessary or desirable to effectuate the
Plan. The Administrator shall have the authority to make such rules and regulations for the administration of the Plan and the interpretation and application of the provisions hereof, as it deems necessary or desirable. Any determination by 

  

 42 

 
the Administrator within the scope of its authority and any action taken thereon in good faith shall be conclusive and binding on all persons. 
  

	11.8. 	Appeal Procedure 

  

	 	(a)	A claim for benefit payment shall be considered filed when an application for benefits is submitted to the Recordkeeper. 

  

	 	(b)	Notice of Denial 

 Any time a claim for benefits is
wholly or partially denied, the Participant or Beneficiary (hereinafter “Claimant”) shall be given written notice of such action within 90 days after the claim is filed, unless special circumstances require an extension of time for
processing. If there is an extension, the Claimant shall be notified of the extension and the reason for the extension within the initial 90 day period. The extension shall not exceed 180 days after the claim is filed. Such notice will indicate the
reason for denial, the pertinent provisions of the Plan on which the denial is based, an explanation of the claims appeal procedure set forth herein, and a description of any additional material or information necessary to perfect the claim and an
explanation of why such material or information is necessary. 
  

	 	(c)	Right to Request Review 

 Any person who has had a
claim for benefits denied by the Administrator or his or her delegate, or is otherwise adversely affected by action of the Administrator, shall have the right to request review by the Administrator. 
 Such request must be in writing, and must be made within 60 days after such person is advised of the benefit denial. If written request for review is not
made within such 60-day period, the Claimant shall forfeit his or her right to review. The Claimant or a duly authorized representative of the Claimant may review all pertinent documents and submit issues and comments in writing. 
  

	 	(d)	Review of Claim 

 The Administrator shall then
review the claim. He or she may hold a hearing if he or she deems it necessary and shall issue a written decision reaffirming, modifying or setting aside the former action within 60 days after receipt of the written request for review, or 120 days
if special circumstances, such as a hearing, require an extension. The Claimant shall be notified in writing of any such extension within 60 days following the request for review. A copy of the decision shall be furnished to the Claimant. The
decision shall set forth the reasons and pertinent plan provisions on which it is based. The decision shall be final and binding upon the Claimant and the Administrator and all other persons involved. 
  

 43 

 ARTICLE 12. 
 TRUST FUND 
  

	12.1. 	Contributions to the Trust Fund 

 As a part of this
Plan the Employer shall maintain a Trust Fund. From time to time, the Employer shall make contributions to the Trust Fund in accordance with Article 3. 
  

	12.2. 	Trust Fund for Exclusive Benefit of Participants 

 The Trust Fund is for the exclusive benefit of Participants. Except as provided in Sections 4.5 (Return of Contributions), 16.4 (Domestic Relations Orders) and 16.6 (Deductible Contributions), no portion of the Trust Fund shall be diverted
to purposes other than this or revert to or become the property of the Employer at any time prior to the satisfaction of all liabilities with respect to the Participants. 
  

	12.3. 	Trustee 

 As a part of this Plan, the Employer has
entered into an agreement with a Trustee. The Employer has the power to remove the Trustee and appoint successors at any time. As a condition to exercising its power to remove any sole Trustee hereunder, the Employer must first enter into an
agreement with a successor Trustee. The Employer may delegate the authority to direct the investment of all or a portion of the Trust Fund to the Trustee. 
  

	12.4. 	Investment Manager 

 The Employer has the power to
appoint, remove or change from time to time an Investment Manager to direct the investment of all or a portion of the Trust Fund held by the Trustee. For purposes of this section “Investment Manager” shall mean any fiduciary (other than
the Trustee) who: 
  

	 	(a)	has the power to manage, acquire, or dispose of any asset of the Plan; 

  

	 	(b)	is either 

  

	 	(1)	registered as an investment adviser under the Investment Advisers Act of 1940, or 

  

	 	(2)	is a bank, or 

  

	 	(3)	is an insurance company qualified under the laws of more than one state to perform the services described in subparagraph (a); and 

  

	 	(c)	has acknowledged in writing that he, she or it is a fiduciary with respect to the Plan. 

  

 44 

	12.5. 	Voting of Proxies 

 Each Investment Manager shall
vote the proxies for the securities under the Investment Manager’s direction. The Trustee shall vote the proxies for the Teradata Common Stock held in the Teradata Unitized Stock Fund, and any securities in the Trust Fund not subject to the
direction of an Investment Manager. The Trustee shall solicit voting instructions from all Participants with Account balances invested in the Teradata Unitized Stock Fund, and shall follow any such instructions received from Participants.

  

	12.6. 	Voting Shares of Teradata Common Stock: Options and Other Rights 

  

	 	(a)	Voting 

 Notwithstanding any other provision of this
Plan to the contrary, if any, the Trustee shall have no discretion or authority to vote Teradata Common Stock held in the Trust on any matter presented for a vote by the stockholders of the Company except in accordance with timely directions
received by the Trustee from Participants who have Accounts invested in the Teradata Unitized Stock Fund. Such directions shall be given by Participants as Named Fiduciaries under the Plan with respect to their investment in the Teradata Unitized
Stock Fund and, upon timely receipt of such instructions, the Trustee shall vote the Teradata Common Stock held in the Trust pursuant to the directions of Participants giving instructions to the Trustee as set forth below. 
 Each Participant whose Accounts are invested in the Teradata Unitized Stock Fund shall, as Named Fiduciary, direct the Trustee with respect to the vote of
Teradata Common Stock, including fractional shares thereof, represented by his or her unitized shares of the Teradata Unitized Stock Fund and the Trustee shall follow the directions of those Participants who provide timely instructions to the
Trustee. Each such Participant shall, as Named Fiduciary, direct the Trustee with respect to the vote of a portion of the shares of Teradata Common Stock for which no instructions were timely received by the Trustee, whether or not represented by
unitized shares of the Teradata Unitized Stock Fund held in the Account of any Participant. Such direction shall be with respect to such number of votes equal to the total number of votes attributable to Teradata Common Stock not represented by
unitized shares of the Teradata Unitized Stock Fund held in the Accounts of Participants with respect to which no responses were received, multiplied by a fraction, the numerator of which is the number of votes attributable to Teradata Common Stock,
including fractional shares thereof, in the Teradata Unitized Stock Fund and the denominator of which is the total number of votes attributable to Teradata Common Stock, including fractional shares thereof, represented by unitized shares of the
Teradata Unitized Stock Fund held in the Accounts of all Participants who have provided directions to the Trustee under this subsection. All such directions shall be given on a confidential basis to the Trustee. 
 The Trustee shall use its best efforts to communicate or cause to be communicated to all Participants the provisions of this Plan and the Trust 

  

 45 

 
Agreement relating to the right of Participants to direct the Trustee with respect to the voting of Teradata Common Stock represented by shares of the
Teradata Unitized Stock Fund held in their Accounts under the Plan. The Trustee shall use its best efforts to distribute or cause to be distributed to Participants all communications directed generally to the owners of Teradata Common Stock entitled
to vote and the Trustee shall use its best efforts to distribute or cause to be distributed to Participants all communications that the Trustee may receive, if any, from any person soliciting proxies or any other interested party (including the
Employer) relating to the matters being presented for a vote by the stockholders of the Employer. The Employer shall provide the Trustee with such information and assistance as the Trustee may reasonably request in connection with any communications
or distributions to Participants. 
  

	 	(b)	Invalid or Conflicting Provisions Relating to Voting 

 In the event a court of competent jurisdiction shall issue an opinion or order to the Plan, the Employer or the Trustee, which shall, in the opinion of counsel to the Employer or the Trustee, invalidate under ERISA, in all circumstances or
in any particular circumstances, any provision or provisions of this paragraph regarding the manner in which Teradata Common Stock held in the Trust shall be voted or cause any such provision or provisions to conflict with ERISA, then, upon notice
thereof to the Employer or the Trustee, as the case may be, such invalid or conflicting provisions of this section shall be given no further force or effect. In such circumstances the Trustee shall nevertheless have no discretion to vote Teradata
Common Stock held in the Trust unless required under such order or opinion but shall follow instructions received from Participants, to the extent such instructions have not been invalidated. To the extent required to exercise any residual fiduciary
responsibility with respect to voting, the Trustee shall take into account in exercising its fiduciary judgment, unless it is clearly imprudent to do so, directions timely received from Participants, as such directions are most indicative of what is
in the best interests of Participants. Further, the Trustee shall take into consideration any relevant economic factors affecting the interests of current and future Participants. 
  

	 	(c)	Directions Relating to Exercise of Options and Other Rights 

 In the event that any option, right, warrant or similar property derived from or attributable to the ownership of Teradata Common Stock shall be granted, distributed or otherwise issued, which is and shall become exercisable, each
Participant shall be entitled with respect to Teradata Common Stock, including fractional shares thereof, represented by shares of the Teradata Unitized Stock Fund allocated to the Participant’s Accounts, subject to the provisions set forth
below, to direct the Trustee to sell, exercise, distribute, (with the consent of the Administrator), or retain any such option, right, warrant or similar property. For such purpose there shall be furnished to each Participant, on a timely and
confidential basis a form to be returned to the Trustee on which he may set forth his direction whether to sell, exercise, distribute or retain part or all of such 

  

 46 

 
option, right, warrant or similar property. Upon timely receipt of such form or other appropriate written direction, the Trustee shall follow such direction
to sell, exercise, distribute, or retain part or all of any such options, rights, warrants or similar property and, if such direction is to retain the same, the Trustee shall follow any later appropriate written directions to sell, exercise or
distribute such options, rights, warrants or similar property upon receipt thereof. If a Participant shall direct the Trustee to exercise part or all of such options, rights, warrants or similar property, the Trustee shall accumulate the cash equal
to the consideration necessary to exercise, from along the following sources: (i) the transfer and use of the uninvested cash, if any, allocated to the Participant in his Accounts; (ii) if and to the extent necessary, the sale of part of
his options, rights, warrants, or similar property, and use of the proceeds thereof to exercise the remaining options, rights, warrants, or similar property which he has directed to be exercised; (iii) if and to the extent necessary, by
requesting the Participant to remit to the Trustee an amount equal to the consideration necessary to exercise; or (iv) if and to the extent necessary, and to the extent the Trustee is willing and able, by borrowing an amount equal to the
consideration necessary to exercise, provided that any such contribution or borrowing is permitted by applicable law and further provided that such contribution or borrowing will not adversely affect the continued qualified status of the Plan or
continued exempt status of the Trust under the Code. In the event of any such borrowing, the Trustee shall make provisions for repayment thereof. The securities acquired by the Trustee upon such exercise shall be held in a special account or
accounts established in the Trust at that time. If a Participant shall direct the Trustee to distribute to him any such options, rights, warrants or similar property, the Trustee, with the consent of the Administrator, shall distribute such options,
rights, warrants or similar property provided, as certified by the Administrator (i) the Participant is age 65 or more or has five or more Years of Service and (ii) such distribution will not adversely affect the continued qualified status
of the Plan or continued exempt status of the Trust under the Code. 
 If a Participant fails or refuses to file with the Administrator, an
election not to withhold any Federal taxes upon such distribution, the Trustee shall be deemed to be authorized, to the extent necessary, as instructed by the Administrator, to sell part of such options, rights, warrants, or similar property and use
the proceeds from such sales to pay all applicable Federal withholding taxes due in connection with such distribution. Upon any such distribution, the Trustee shall report the same to the Administrator to permit compliance with the applicable
reporting provisions of the Code. For all Plan purposes, all options, rights, warrants or similar property described in this Subsection (c) shall be treated as income added to the appropriate Accounts of Participants. If, within a reasonable
period of time after the form soliciting direction from a Participant has been sent, no written direction shall have been received by the Trustee from him, the Trustee shall, in its sole discretion sell, exercise, or retain and keep unproductive of
income such option, right, warrant, or similar property for which no response has been received from such Participant. 
  

 47 

 In the event of a discretional decision by the Trustee to exercise, the Trustee shall be deemed to be
authorized to accumulate the amount equal to the consideration necessary to exercise from any of the sources specified herein and to hold such acquired securities in the Trust as specified herein. In connection with any discretionary decisions by
the Trustee to sell, exercise or retain and keep unproductive of income any such option, right, warrant, or similar property, the Trustee shall consider relevant economic factors, all as evidenced by the proportion of the directions received from
Participants to either sell, exercise, or retain such options, rights, warrants or similar property, and shall also consider such other factors as the Trustee may deem relevant. 
  

 48 

 ARTICLE 13. 
 AMENDMENT AND TERMINATION 
  

	13.1. 	Amendment - General 

 It is the Employer’s
intention that the plan will continue indefinitely. However, the Employer shall have the right to amend, terminate, or partially terminate this Plan at any time subject to any advance notice or other requirements of ERISA, by a resolution of the
Board. 
 The Board shall also have the authority to authorize officers of the Employer to implement the amendment or termination of the
Plan. The Board of Directors may delegate to other entities, in writing, the authority to amend the Plan with respect to specified topics. 
  

	13.2. 	Amendment - Consolidation or Merger 

 In the event
the Plan’s assets and liabilities are merged into, transferred to or otherwise consolidated with any other retirement plan, then such must be accomplished so as to ensure that each Participant would (if the other retirement plan then
terminated) receive a benefit immediately after the merger, transfer or consolidation, which is equal to or greater than the benefit the Participant would have been entitled to receive immediately before the merger, transfer or consolidation (as if
the Plan had then terminated). This provision shall not be construed as limiting the powers of the Employer to appoint a successor Trustee. 
  

	13.3. 	Termination of the Plan 

 The termination of the
Plan shall not cause or permit any part of the Trust Fund to be diverted to purposes other than for the exclusive benefit of the Participants, or cause or permit any portion of the Trust Fund to revert to or become the property of the Employer at
any time prior to the satisfaction of all liabilities with respect to the Participants. 
 Upon termination of this Plan, the Employer shall
continue to act for the purpose of complying with the preceding paragraph and shall have all power necessary or convenient to the winding up and dissolution of the Plan as herein provided. While so acting, the Administrator shall be in the same
status and position with respect to other persons as if the Plan remained in existence. 
  

	13.4. 	Allocation of the Trust Fund on Termination of Plan 

 In the event of a complete or partial termination of the Plan, or upon complete discontinuance of contributions under the Plan, with respect to all Participants or a specified group or groups of Participants, the Trustee shall allocate and
segregate a proportionate interest in the Trust Fund for the benefit of affected Participants. 
 All Accounts accrued by the affected
Participants shall be 100% vested and non-forfeitable. The Administrator shall direct the Trustee to allocate the assets of the Trust Fund to those affected Participants. 
  

 49 

 ARTICLE 14. 
 FIDUCIARIES 
  

	14.1. 	Limitation of Liability of the Employer and Others 

 To the extent permitted by law, no Participant shall have any claim against the Employer, or against its directors, officers, members, agents or representatives, for any benefits under the Plan, and such benefits shall be payable solely
from the Trust Fund; nor shall the Employer, nor its directors, officers, members, agents or representatives incur any liability to any person for any action taken or suffered or omitted to be taken by them under the Plan in good faith. 

 

	14.2. 	Indemnification of Fiduciaries 

 In order to
facilitate the recruitment of competent fiduciaries, the Employer agrees to provide the indemnification as described herein. This provision shall apply to Employees who are considered Plan fiduciaries including without limitation, Employees acting
on behalf of the Administrator, agents of the Administrator, or any officers, directors or other Employees. Notwithstanding the preceding, this provision shall not apply and indemnification will not be provided for any Trustee or Investment Manager
appointed as provided in this Plan. 
  

	14.3. 	Scope of Indemnification 

 The Employer agrees to
indemnify an Employee fiduciary as described above for all acts taken in good faith in carrying out his or her responsibilities under the terms of this Plan or other responsibilities imposed upon such fiduciary by ERISA. This indemnification for all
acts is intentionally broad but shall not provide indemnification for embezzlement or diversion of Plan assets for the benefit of the Employee fiduciary. The Employer agrees to indemnify Employee fiduciaries described herein for all expenses of
defending an action by a Participant, Beneficiary or government entity, including all legal fees for counsel selected with the consent of the Employer and other costs of such defense. The Employer will also reimburse an Employee fiduciary for any
monetary recovery in any court or arbitration proceeding. In addition, if the claim is settled out of court with the concurrence of the Employer, the Employer will indemnify an Employee fiduciary for any monetary liability under said settlement. The
Employer shall have the right, but not the obligation, to conduct the defense of such persons in any proceeding to which this Section 14.3 applies. The Employer may satisfy its obligations under this Section 14.3 in whole or in part
through the purchase of a policy or policies of insurance providing equivalent protection. 
  

 50 

 ARTICLE 15. 
 ADOPTION BY AFFILIATED COMPANIES 
  

	15.1. 	Adoption by Affiliated Companies 

 Each United
States Affiliated Company listed on Appendix A on the Effective Date shall be considered an “Employer” as of such date for purposes other than Articles 11, 12 and 13. Any other United States Affiliated Company may, pursuant to a resolution
of its board of directors, with the consent of the Board, adopt the Plan for the exclusive benefit of its employees eligible to participate thereunder. Such adoption shall be effective as of such date as shall be specified by such Affiliated Company
and consented to by the Board. Any such Affiliated Company which has so adopted the Plan shall be listed in Appendix A and shall be considered an “Employer” for purposes other than Articles 11, 12 and 13. 
  

	15.2. 	Spin-Off of a Division 

 If any United Stated
division of an Employer shall be established and shall thereafter become an Affiliated Company, then, unless the Board shall otherwise determine, such Affiliated Company shall be deemed to have adopted the Plan effective as of the date such division
becomes an Affiliated Company and shall become an Employer hereunder as of such date without the necessity for any action by its board of directors and without the necessity of the consent of the Board. 
  

	15.3. 	Merger of an Employer 

 Any entity into which an
Employer may be merged, or with which it may be consolidated, or any entity resulting from any merger, reorganization or consolidation to which an Employer may be a party, or any entity to which all or substantially all of the assets of an Employer
may be transferred, shall, so long as it shall continue to be an Affiliated Company, continue as an Employer hereunder without the execution or filing of any instrument or the performance of any further act. 
  

	15.4. 	Termination of Participation by an Employer 

 An
Employer may terminate its participation in the Plan at any time by a resolution of its board of directors. The Board may terminate the participation of an Employer at any time by resolution. 
  

	15.5. 	Adoption by Non-Affiliated Companies 

 An Employer
which is not an Affiliated Company, may adopt the Plan as if it were an Affiliated Company, subject to the terms of this Article 15. 
  

 51 

 ARTICLE 16. 
 MISCELLANEOUS PROVISIONS 
  

	16.1. 	Facility of Payment 

 In the event any benefit under
this Plan shall be payable to a person who is under legal disability or is in any way incapacitated so as to be unable to manage his or her financial affairs, the Administrator may direct payment of such benefit to a duly appointed guardian,
committee or other legal representative of such person or in the absence of a guardian or legal representative, to a custodian for such person under a Uniform Gift to Minors Act or to any relative of such person by blood or marriage, for such
person’s benefit. Any payment made in good faith pursuant to this provision shall fully discharge the Employer and the Plan of any liability to the extent of such payment. 
  

	16.2. 	Correction of Errors 

 Any Employer contribution to
the Trust Fund made under a mistake of fact (or investment proceed of such contribution if a lesser amount) shall be returned to the Employer within one year after payment of the contribution. 
 In the event an incorrect amount is paid to a Participant or Beneficiary, any remaining payments may be adjusted to correct the error. The Administrator
may take such other action it deems necessary and equitable to correct any such error. 
  

	16.3. 	Missing Persons 

 In the event a distribution is
required to commence under Section 6.2 and the Participant or Beneficiary cannot be located, the Participant’s Account shall be forfeited on the last day of the Plan Year following the Plan Year in which distribution was supposed to
commence. Such forfeiture shall be used to reduce Employer Matching Contributions. 
 If the affected Participant or Beneficiary later
contacts the Employer, his or her Account shall be reinstated and distributed as soon as practical. The Employer shall reinstate the amount forfeited by making a special Employer contribution equal to such amount and allocating it to the affected
Participant’s or Beneficiary’s Account. Such reinstatement shall not be considered an annual addition for purposes of the limitations on contributions pursuant to Code Section 415. 
 Prior to forfeiting any Account, the Employer shall attempt to contact the Participant or Beneficiary by return receipt mail at his or her last known
address according to the Employer’s records, and by the letter forwarding services offered through the Internal Revenue Service, or the Social Security Administration, or such other means as the Administrator deems appropriate. 
  

	16.4. 	Domestic Relations Orders 

 Notwithstanding any Plan
provisions to the contrary, benefits under the Plan may be paid to someone other than the Participant or Beneficiary pursuant to a Qualified Domestic Relations Order, in accordance with Section 414(p) of the Code. A Qualified Domestic Relations
Order is 

  

 52 

 
a judgment, decree, or order (“Order”) (including approval of a property settlement agreement) that: 
  

	 	(a)	relates to the provision of child support, alimony payments or marital property rights to a Spouse, former Spouse, child or other dependent of a Participant;

  

	 	(b)	is made pursuant to a state domestic relations law (including a community property law); 

  

	 	(c)	creates or recognizes the existence of an alternate payee’s right to, or assigns to an alternate payee the right to, receive all or a portion of the benefits payable to a
Participant under the Plan; 

  

	 	(d)	specifies the name and last known address of the Participant and each alternate payee; 

  

	 	(e)	specifies the amount or method of determining the amount of benefit payable to an alternate payee; 

  

	 	(f)	names each plan to which the order applies; 

  

	 	(g)	does not require any form, type or amount of benefit not otherwise provided under the Plan, and does not require payment to the alternate payee in a joint and survivor form of
payment; 

  

	 	(h)	does not conflict with a prior Domestic Relations Order that meets the other requirements of this section. 

 Payments to an alternate payee pursuant to a Qualified Domestic Relations Order shall commence as provided in this section, regardless of the
Participant’s age or whether the Participant terminates or continues employment. 
 The Administrator shall determine whether an order
meets the requirements of this section within a reasonable period after receiving an order. The Administrator shall notify the Participant and any alternate payee that an order has been received. Any amounts which are to be paid pursuant to the
order, during the period while its qualified status is being determined, shall be held in a separate account under the Plan for any alternate payee pending determination that an order meets the requirements of this section. If within eighteen months
after such a separate account is established, the order has not been determined to be a qualified Order, the amount in the separate account shall be returned to the Participant’s Account. 
 If an order is determined not be qualified, the separate account shall be maintained for six months after the date the order is returned to the alternate
payee. If a revised order is submitted within the six month period, the separate account will be maintained while the revised order is reviewed. If a revised order is not submitted within the six month period, the separate accounting shall cease
until a revised order is received. 
  

 53 

 If the Administrator receives a court order directing that distribution of a Participant’s Account
be suspended because a Domestic Relations Order is in preparation, the Administrator shall suspend payment of up to 50% of the Participant’s account for not more than 30 days. If no order is received during the 30-day period, distribution of
the Account shall resume. 
 If an order is determined to be qualified, payment to the alternate payee shall be made in a lump sum or a
Direct Transfer as requested by the alternate payee. If the alternate payee does not elect payment within six months after the order is determined to be qualified, a lump sum payment of the alternate payee’s benefit will be made. 
 No portion of an outstanding loan will be distributed to an alternate payee, however, any outstanding loan balance will be included in determining a
Participant’s account balance for purposes of implementing a qualified Order, unless otherwise specified in the Order. 
 Distribution
to an alternate payee shall be made on a pro rata basis from the Participant’s Accounts, and shall be made on a pro rata basis from the investment funds in which the Participant’s Accounts are invested, unless the Order specifies
particular investment funds. 
  

	16.5. 	Plan Qualification 

 Any modification or amendment
of the Plan may be made retroactive, as necessary or appropriate, to establish and maintain a “qualified plan” pursuant to Section 401 of the Code, and ERISA and regulations thereunder and exempt status of the Trust Fund under
Section 501 of the Code. 
  

	16.6. 	Deductible Contribution 

 Notwithstanding anything
herein to the contrary, any contribution by the Employer to the Trust Fund is conditioned upon the deductibility of the contribution by the Employer under the Code and, to the extent any such deduction is disallowed, the Employer may within one year
following a final determination of the disallowance, demand repayment of such disallowed contribution and the Trustee shall return such contribution less any losses attributable thereto to the Employer within one year following the disallowance.

  

	16.7. 	Plan Administration - Miscellaneous 

  

	 	(a)	Limitations on Assignments 

 Benefits under the Plan
may not be assigned, sold, transferred, or encumbered, and any attempt to do so shall be void. The interest of a Participant in benefits under the Plan shall not be subject to debts or liabilities of any kind and shall not be subject to attachment,
garnishment or other legal process, except as provided in Section 16.4 relating to Domestic Relations Orders, or otherwise permitted by law. 
  

 54 

	 	(b)	Masculine and Feminine, Singular and Plural 

 Whenever used herein, pronouns shall include the opposite gender, and the singular shall include the plural, and the plural shall include the singular, whenever the context shall plainly so require. 
  

	 	(c)	No Additional Rights 

 No person shall have any
rights in or to the Trust Fund, or any part thereof, or under the Plan, except as, and only to the extent, expressly provided for in the Plan. Neither the establishment of the Plan, the establishment of Participant Accounts nor any action of the
Employer shall be held or construed to confer upon any person any right to be continued as an Employee, or, upon dismissal, any right or interest in the Trust Fund other than as herein provided. The Employer expressly reserves the right to discharge
any Employee at any time. 
  

	 	(d)	Governing Law 

 This Plan shall be construed in
accordance with applicable federal law and the laws of the State of Ohio. 
  

	 	(e)	Disclosure to Participants 

 Each Participant shall
be advised of the general provisions of the Plan and, upon written request addressed to the Administrator, shall be furnished any information requested regarding the Participant’s status, rights and privileges under the Plan as may be required
by law. 
  

	 	(f)	Income Tax Withholding Requirements 

 Any retirement
benefit payment made under the Plan will be subject to any applicable income tax withholding requirements. For this purpose, the Administrator shall provide the Trustee with any information the Trustee needs to satisfy such withholding obligations
and with any other information that may be required by regulations promulgated under the Code. 
  

	 	(g)	Severability 

 If any provision of this Plan shall
be held illegal or invalid for any reason, such determination shall not affect the remaining provisions of this Plan which shall be construed as if said illegal or invalid provision had never been included. 
  

 55 

 The Teradata Savings Plan is hereby amended and restated. 
 IN WITNESS WHEREOF, the Employer has caused this Plan to be duly executed on this 1st day of October, 2007. 
  

			
	FOR TERADATA CORPORATION
		
	By:	 	/s/ Saundra Davis
		 	Saundra Davis
		 	Vice President, Human Resources

  

 56 

 APPENDIX A 
 Participating Affiliated Companies 
  

	
	Legal Entity Name (English)
	
	 DecisionPoint Applications, Inc.

	
	 DecisionPoint Applications Europe, Inc.

	
	 Teradata US, Inc.

	
	 Teradata Operations, Inc.

	
	 Teradata International, Inc.

	
	 Teradata Government Systems LLC

	
	 Teradata Australia Pty Ltd.

	
	 Teradata Information Systems (China) Limited

	
	 Teradata (Hong Kong) Limited

	
	 Teradata Japan KK

	
	 TeraWarehouse Korea Co. Ltd.

	
	 TData Corporation (Malaysia) Sdn. Bhd.

	
	 Teradata (NZ) Corporation

	
	 Teradata (Singapore) Pte. Ltd.

	
	 Teradata Taiwan LLC, Taiwan Branch

	
	 Teradata (Thailand) Co. Ltd.

	
	 Teradata de Argentina S.R.L.

	
	 TRDT Brasil Tecnologia Ltda.

	
	 Teradata Canada ULC

	
	 DecisionPoint Applications Canada, Inc.

	
	 Teradata Chile Technologias de Informacion Limitada

	
	 TDC Colombia Ltda.

	
	 Teradata Solutions México, S. de R.L. de C.V.

	
	 Teradata de México, S. de R.L. de C.V.

	
	 Teradata GmbH

	
	 Teradata Belgium SNC

	
	 Teradata Czeska Republika spol. Sro.

	
	 Teradata Danmark ApS

	
	 Teradata Egypt WLL

	
	 Teradata Finland Oy

	
	 Teradata France SAS

	
	 Teradata GmbH

	
	 Teradata Magyarosrzag Kft.

	
	 Teradata India Private Limited

	
	 Teradata Ireland Limited

  

 57 

	
	Legal Entity Name (English)
	
	 Teradata Italia Srl

	
	 Teradata Netherlands BV

	
	 Teradata Norge AS

	
	 Teradata Global Consulting Pakistan (Private) Limited

	
	 Teradata Pakistan (Private) Limited

	
	 Teradata Polska Sp. z o.o.

	
	 “Teradata” LLC

	
	 Teradata Iberia SL

	
	 Teradata Sweden AB

	
	 Teradata (Schweiz) GmbH

	
	 Teradata Bilisim Sistemleri Ltd. Sti.

	
	 Teradata (UK) Limited

  

 58Assignment and Purchase Agreement

 Exhibit 10.17 
 EXHIBIT 10.17 TO FORM 10-Q 
 ASSIGNMENT AND PURCHASE AGREEMENT 
 THIS ASSIGNMENT AND PURCHASE AGREEMENT (the “Agreement”) is entered into this 25th day of April, 2007 (the “Effective
Date”) by and among Resistys, Inc., a Delaware corporation having its principal place of business at 2121 Avenue of the Stars, Suite 2550, Los Angeles, California 90067 (“Resistys”), Avantogen Limited (formerly, Australian
Cancer Technology Limited), an Australian corporation having its principal place of business at 2121 Avenue of the Stars, Suite 2550, Los Angeles, California 90067 (“Avantogen”), Avantogen Oncology, Inc. (formerly, Innovate
Oncology, Inc.), a Nevada corporation having its principal place of business at 2121 Avenue of the Stars, Suite 2550, Los Angeles, California 90067 (“AOI”), and SciClone Pharmaceuticals, Inc. a Delaware corporation, having its
principal place of business at 901 Mariners Island Blvd., San Mateo, California 94404 (“Buyer”) (Resistys, Avantogen and AOI also referred to herein individually and collectively as, “Seller”). 
 RECITALS 
 A. Avantogen formed Resistys in
August 2004 as a wholly-owned subsidiary. 
 B. Resistys, Avantogen and RESprotect GmbH, a German corporation having an office at Fiedlerstr.
34, D-01307 Dresden, Germany (“Licensor”), entered into that certain License Agreement dated August 30, 2004 (the “License Agreement”), pursuant to which, among other things, (1) RESprotect granted
Resistys an exclusive license to develop and commercialize certain pharmaceutical products in the United States and Canada under certain intellectual property rights of RESprotect related to RP101 ((E)-5-(2-
bromovinyl-)2’-deoxyuridine—also known as BVDU) (“RP101”), and (2) Avantogen guaranteed the payment of Resistys’ royalty and other financial obligations to RESprotect under the License Agreement. 
 C. In connection with the License Agreement, Resistys and RESprotect entered into that certain Supply Agreement for Clinical Trial Material dated
September 13, 2004 (the “Supply Agreement”), pursuant to which, among other things, RESprotect agreed to supply Resistys with tablets containing RP101 for use by Resistys in conducting certain clinical trials related to RP101.

 D. In October 2004, Bioaccelerate Holdings, Inc. (now known as Gardant Pharmaceuticals, Inc.) (“Gardant”), AOI’s then
parent, entered into an agreement with Avantogen pursuant to which Gardant acquired a 50% shareholder interest in Resistys and agreed to provide 50% of the funding for the development of RP101. 

 E. In March 2006, AOI became the holder of Gardant’s 50% shareholder interest in Resistys.

 F. In May 2006, Avantogen and Gardant entered into an agreement pursuant to which Avantogen transferred its 50% shareholder interest in
Resistys to AOI in exchange for a majority shareholder interest in AOI (54.2%) and Resistys became the wholly-owned subsidiary of AOI. In connection with these transactions, AOI changed its name from Innovate Oncology, Inc. to Avantogen
Oncology, Inc. 
 G. Buyer desires to purchase, and Seller desires to sell to Buyer, certain assets owned or controlled by Seller related to
Seller’s program to develop and commercialize RP101 under the License Agreement (the “RP101 Program”), on the terms and subject to conditions of this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing recitals, the agreements of the parties hereinafter set forth, and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows: 
 ARTICLE 1 
 DEFINITIONS AND INTERPRETATIONS 
 1.1 Definitions. When used in this Agreement, the following capitalized terms shall have the meanings set forth below, and any other capitalized
term used herein shall have the meaning set forth in the particular provision of this Agreement in which it is first defined. 
 (a)
“Additional Payment Term” means the period commencing on the Effective Date and ending on the earlier to occur of (i) August 30, 2029, or (ii) the termination of the License Agreement. 
 (b) “Affiliate” shall mean any entity that controls, is controlled by, or is under common control with a party. An entity shall be
regarded as in “control” of another entity if it owns, or directly or indirectly controls, more than fifty percent (50%) of the voting stock or other ownership interest of the other entity, or if it possesses, directly or indirectly,
the power to direct or cause the direction of the management and policies of the entity or the power to elect or appoint fifty percent (50%) or more of the members of the governing body of the entity. 

 (c) “Agreement” shall have the meaning given in the opening paragraph of this Agreement.

 (d) “AOI” shall have the meaning given in the opening paragraph of this Agreement. 
 (e) “Asset Transfer and Assumption Agreements” shall have the meaning given in the first paragraph of Article 2. 
 (f) “Assumed Agreements” shall have the meaning given in Section 2.1(a). 
 (g) “Assumed Liabilities” shall have the meaning given in Section 3.1. 
 (h) “Avantogen” shall have the meaning given in the opening paragraph of this Agreement. 
 (i) “Books and Records” shall have the meaning given in Section 2.1(f). 
 (j) “Buyer” shall have the meaning given in the opening paragraph of this Agreement. 
 (k) “Buyer Indemnitee(s)” shall have the meaning given in Section 8.4. 
 (l) “Buyout Consideration” shall have the meaning given in Section 7.8. 
 (m) “Buyout Date” shall have the meaning given in Section 7.8. 
 (n) “Buyout Notice” shall have the meaning given in Section 7.8. 
 (o) “Buyout Period” shall have the meaning given in Section 7.8. 
 (p) “Buyout Right” shall have the meaning given in Section 7.8. 
 (q) “Claim” shall have the meaning given in Section 8.5. 
 (r) “Closing” shall have the meaning given in Section 7.1. 
 (s) “Collateral” shall have the meaning given in Section 4.5. 
 (t) “Common Stock” shall mean Buyer’s common stock, par value $0.001 per share. 
 (u) “Confidential Information” shall mean all confidential and proprietary information provided by one party to the other party pursuant
to this Agreement, or generated pursuant to this Agreement, except any portion thereof which: (i) the recipient can demonstrate by its written records was rightfully known by the recipient prior to the disclosure thereof by the disclosing
party; (ii) is disclosed to the recipient without restriction, after disclosure thereof by the disclosing party, by a third party who has the right to make such disclosure; or (iii) is or becomes part of the public domain through no breach
of this Agreement by the recipient. 

 (v) “Creditors” shall have the meaning given in Section 5.3. 
 (w) “Disclosure Schedule” shall mean the Disclosure Schedule of Seller attached hereto as Schedule 5. 
 (x) “Effective Date” shall have the meaning given in the opening paragraph of this Agreement. 
 (y) “Escrow Agent” shall have the meaning given in Section 4.1. 
 (z) “Escrow Agreement” shall have the meaning given in Section 4.1. 
 (aa) “Escrow Period” shall have the meaning given in Section 4.1. 
 (bb) “Excluded Liabilities” shall have the meaning given in Section 3.2. 
 (cc) “FDA” shall mean the United States Food and Drug Administration or any successor agency thereof. 
 (dd) “First Commercial Sale” shall mean the first sale of RP101 Product by Buyer, an Affiliate thereof, and/or its Sublicensees.

 (ee) “Liabilities” shall mean any debt, obligation, duty or liability of any nature whatsoever (including any unknown,
undisclosed, unmatured, unaccrued, unasserted, contingent, indirect, conditional, implied, vicarious, derivative, joint, several or secondary liability), regardless of whether such debt, obligation, duty or liability would be required to be
disclosed on a balance sheet prepared in accordance with generally accepted accounting principles and regardless of whether such debt, obligation, duty or liability is immediately due and payable. 
 (ff) “License Agreement” shall have the meaning given in Recital B. 
 (gg) “Licensor” shall have the meaning given in Recital B. 
 (hh) “Manufacturing Information” shall mean all documents, materials, data, know-how and other information owned by Seller, or in which
Seller has rights, related to producing, manufacturing, labeling, packaging, storing, handling, testing (including stability and quality control testing) and release of RP101, existing as of the date hereof, including specifications and
manufacturing and quality control instructions or requirements under any quality control agreements, and any and all other written or electronic information related thereto. 
 (ii) “Market Sales” means the gross amount invoiced for the sale of RP101 Product in the Territory by Buyer, its Affiliates and
Sublicensees, less any amounts invoiced to customers for customs duties or sales taxes directly related to the sale of the RP101 Product, or for transportation, shipping and insurance costs. 

 (jj) “NDA” means a means a New Drug Application filed with the FDA. 
 (kk) “Net Sales” means the gross invoiced sales price of RP101 Product in the Territory by Buyer, its Affiliates and Sublicensees, less
all customs, duties or sales taxes directly related to the sale of the RP101 Product, transportation, shipping and insurance costs, customary industry discounts or rebates actually granted and amounts repaid or credited for the rejection or return
of RP101 Product consistent with normal business practices for similar products. 
 (ll) “Patent Rights” shall mean the
rights under any patent applications, issued patents and any and all substitutions, divisions, continuations, continuations-in-part, reissues, renewals, reexaminations. 
 (mm) “Phase II Clinical Trial” shall mean a phase II clinical trial as defined in 21 C.F.R. 312.21(b), as amended from time to time. 
 (nn) “Phase III Clinical Trial” shall mean a phase III clinical trial as defined in 21 C.F.R. 312.21(c), as amended from time to time.

 (oo) “PRA” shall mean Pharmaceutical Research Associates, Inc. 
 (pp) “PRA Agreement” shall mean that certain Agreement for Clinical Trials Management Services dated as of August 31, 2006 by and
between AOI and PRA (PRA Project ID: INV101II-101IIX). 
 (qq) “Purchase Price” shall have the meaning given in
Section 4.1. 
 (rr) “Regulatory Filings” shall mean (i) all notices, submissions, applications and other
regulatory filings filed or otherwise submitted to the FDA or any other U.S. or foreign regulatory agency with similar responsibilities to the FDA (individually and collectively, a “Regulatory Authority”), (ii) all permits,
licenses, registrations and other approvals or authorizations issued or otherwise granted by a Regulatory Authority, and (iii) all correspondence related thereto, with respect to RP 101 or the RP101 Program, including investigational new drug
applications and approvals to conduct clinical trials. 
 (ss) “Research and Development Materials” shall mean all research
and development information owned by Seller, or in which Seller has rights, related to the RP101 Program or the RP101 Assets, including clinical and non-clinical data, lab notebooks and reports, existing as of the date hereof, and any and all other
written or electronic information related thereto. 

 (tt) “RESprotect Invoices” shall have the meaning given in Section 3.1. 

(uu) “RESprotect Know-How Rights” means any of Licensor’s confidential proprietary information and materials relating to the
research, development, manufacture, approval, marketing, use or sale of RP101 which during the term of the License Agreement are or prior to the License Agreement were developed by Licensor and which Licensor is permitted to disclose to Resistys
without violating any third party agreements . 
 (vv) “RESprotect Patent Rights” means any Patent Rights under U.S. Patent
No. 6,589,941, a patent or patents issuing on U.S. patent application published as 20040127454 only to the extent they relate to RP 101 and any U.S. and/ or Canadian patents or patent applications claiming priority to, or directly related to,
the foregoing patents or patent applications filed by Licensor only to the extent they relate to RP 101. 
 (ww) “Returns”
shall have the meaning given in Section 5.11. 
 (xx) “RP101 Assets” shall have the meaning given in Section 2.1.

 (yy) 
 (zz) “RP101
IND” means Investigational New Drug Application (IND) 70,841 (Serial No. 0001) of AOI, approved by the FDA on October 30, 2006. 
 (aaa) 
 (bbb) “RP101 Product” means RP101 ((E)-5-(2- bromovinyl-)2’-deoxyuridine—also known as BVDU), a
salt of BVDU or a prodrug of BDVU (if developed by Licensor) for use under the RESprotect Patent Rights, (a) which incorporates, embodies, utilizes or is based on RESprotect Know-How Rights, or (b) the manufacture, use, importation or sale
of which would, but for the rights granted hereunder, constitute infringement of a Valid Claim under the RESprotect Patent Rights. 
 (ccc)
“RP101 Program” shall have the meaning given in Recital G. 
 (ddd) “Securities Act” shall mean the
Securities Act of 1933, as amended. 
 (eee) “Security Agreement” shall have the meaning given in Section 4.5.

 (fff) “Seller” shall have the meaning given in the opening paragraph of this Agreement. 
 (ggg) “Seller Indemnities” shall have the meaning given in Section 8.3. 

 (hhh) “Seller IP Rights” shall mean all intellectual property made, developed, reduced
to practice or licensed or otherwise acquired and controlled by Seller in the course of or in connection with the RP101 Program or relating to the RP101 Assets (other than the RESprotect Patent Rights and RESprotect Know-How Rights themselves, but
including any improvements or enhancements thereto), including all tangible and intangible information, know-how, methods, procedures, processes, formulations, technical information, trade secrets, inventions, specifications, instructions, formulae,
expertise, and biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical and analytical, safety, quality control, manufacturing, preclinical, clinical, and other data and information, improvements and enhancements,
the Manufacturing Information and the Research and Development Materials, whether or not patentable, and any patent, patent applications, or other intellectual property rights based on the foregoing. 
 (iii) “Sublicensee” shall mean any party who receives a sublicense from Buyer relating to the License Agreement upon entering into any
of the following agreements with Buyer: (i) a sublicense agreement, (ii) research and development agreement, or (iii) alternative form of collaboration or commercialization agreement, such as, but not limited to, a co-promotion or
co-marketing arrangement to research, develop, import, make, use, offer for sale, and/or sell RP101 Product in the Territory. 
 (jjj)
“Supply Agreement” shall have the meaning given in Recital C. 
 (kkk) “Tax” and “Taxes”
shall mean all present or future taxes, charges, fees, levies, or other assessments including, without limitation, income, excise, property, value added, real estate, sales, payroll, transfer, social security and franchise taxes imposed by any
federal, state, county, or local government, or a subdivision or agency thereof. Such term shall include any interest, penalties, or additions payable in connection with such taxes, charges, fees, levies, duties, or other assessments. 
 (lll) “Territory” means the United States of America and Canada. 
 (mmm) “Valid Claim” shall mean a claim of an issued and unexpired patent within the RESprotect Patent Rights, which has not been held
permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or
unenforceable through reissue or disclaimer or otherwise. 

 1.2 Interpretation. In this Agreement, words importing the singular number only shall include the
plural and vice versa, words importing a specific gender shall include the other genders and references to persons shall include their heirs, executors, administrators or assigns, as the case may be. As used in this Agreement, “including”
means “including, without limitation,”, and “herein”, “hereof”, and “hereunder” refer to this Agreement as a whole. Unless otherwise expressly provided herein, any reference to a number of “days”
hereunder shall refer to calendar days. All references to “Dollars” stated in this Agreement are to U.S. dollars. 
 ARTICLE 2

 TRANSFER OF RP101 ASSETS 
 Subject to the terms and conditions of this Agreement, at Closing Seller shall sell, transfer, assign, convey and deliver to Buyer all of their respective right, title and interest in and to the RP101 Assets, and Buyer shall assume all of
the rights, obligations and responsibilities associated therewith, including all claims, causes of action, rights of recovery and rights of set off of any kind, as stated in this Agreement. The sale, transfer, assignment, conveyance and delivery of
the RP101 Assets to Buyer will be effected by Seller pursuant to such good and sufficient instruments of conveyance, transfer and assignment, as determined by Buyer in its reasonable discretion (the “Asset Transfer and Assumption
Agreements”), as shall be necessary or advisable to transfer to Buyer good and valid title to the RP101 Assets. Seller shall execute on or prior to the Effective Date, the Asset Transfer and Assumption Agreements and such bills of sale and
other instruments, documents and agreements as may be necessary to effect the transactions contemplated by this Agreement. 
 2.1 RP101
Assets. The following assets related to the RP101 Program shall constitute the RP101 Assets: 
 (a) the agreements listed on Schedule
2.1(a) hereto (the “Assumed Agreements”); 
 (b) all Seller IP Rights, including the Seller IP Rights set forth on
Schedule 2.1(b); 
 (c) all Regulatory Filings set forth on Schedule 2.1(c); 
 (d) all Manufacturing Information, including the Manufacturing Information set forth on Schedule 2.1(d); 

 (e) all Research and Development Materials, including the Research and Development Materials set forth on
Schedule 2.1(e); 
 (f) all books, files, papers, correspondence, databases, software, documents and records relating to the RP101
Assets or the Assumed Liabilities, on whatever medium (“Books and Records”). 
 2.2 Third Party Consents. At Closing,
Seller shall obtain and deliver to Buyer, at Seller’s sole cost and expense, any and all required consents to the sale, transfer, assignment, conveyance and delivery of the RP101 Assets, in form and substance reasonably acceptable to Buyer.

 2.3 Transfer Taxes. All applicable sales, transfer, documentary, use, filing, recording and other taxes and fees that may be levied
on the sale, assignment, transfer or delivery of the RP101 Assets to be sold and transferred as provided herein based on the Purchase Price, if any, shall be borne equally by Seller and Buyer, and all other applicable sales, transfer, documentary,
use, filing, recording and other taxes and fees shall be borne solely by Seller. 
 ARTICLE 3 
 ASSUMED LIABILITIES 
 3.1 Assumed
Liabilities. Subject to the terms and conditions of this Agreement, at Closing Seller shall assign, and Buyer shall assume, the Liabilities of Seller under the Assumed Agreements arising after the Effective Date (the “Assumed
Liabilities”). The parties acknowledge that the Assumed Liabilities include Three Hundred Sixty-Five Thousand Four Hundred Seventy-Four United States Dollars (US$365,474) owed by Resistys to Licensor under the Supply Agreement (Invoice Nos.
07/2006 and 08/2006) for certain RP101 product ordered, but not delivered to Seller (the “RESprotect Invoices”), which invoices shall be paid by Buyer at Closing. 
 3.2 Excluded Liabilities. Except for the Assumed Liabilities, Buyer shall not assume and shall not be liable or responsible for, and Seller shall
retain, and as between (a) Buyer and (b) Seller, remain solely liable for and obligated to discharge, all other Liabilities of Seller, including Liabilities related or attributable to the RP101 Assets or the RP101 Program arising prior to
the Effective Date (the “Excluded Liabilities”). 

 ARTICLE 4 
 CONSIDERATION 
 4.1 Purchase Price; Escrow. As full consideration for the sale, purchase,
assignment, transfer and delivery of the RP101 Assets as contemplated hereby, at Closing Buyer shall pay to Resistys cash in the aggregate amount of One Million Six Hundred Eighty Thousand Dollars ($1,680,000) (the “Purchase
Price”). The Buyer and Seller agree that, at Closing, Buyer shall pay the Purchase Price as follows: (a) (i) Forty Nine Thousand Seven Hundred Sixty One Dollars and Forty Eight Cents ($49,761.48) shall be paid to Licensor on
behalf of Seller in payment of the amount owed to RESprotect as indicated on Schedule 5.3, and (i) One Hundred Thirteen Thousand Five Hundred Eighty Nine Dollars and Sixty Three Cents ($113,589.63) shall be paid to PRA on behalf of Seller in
payment of the amount owed to PRA as indicated on Schedule 5.3, (the “Direct Payments”), and (b) One Million Five Hundred Sixteen Thousand Six Hundred Forty Eight Dollars and Eighty Nine Cents ($1,516,648.89) (the
“Purchase Price Balance”) shall be paid to Katten Muchin Rosenman LLP (the “Escrow Agent”), who shall hold the Purchase Price Balance in escrow pursuant to the Escrow Agreement attached hereto as Exhibit 4.1
(the “Escrow Agreement”). As provided in the Escrow Agreement, at Closing the Escrow Agent shall use the Purchase Price Balance to pay the amounts owed to the Creditors as set forth in Schedule 5.3 of the Disclosure Schedule
(except the Direct Payments, which shall be paid by Buyer as set forth above in this paragraph), and shall hold the balance remaining after making such payments in escrow for a period of thirty (30) days (the “Escrow Period”).
During the Escrow Period, if Buyer, Seller or Escrow Agent becomes aware of the existence of any other creditors of Seller or additional claims of existing Creditors, they shall promptly inform the other parties. If after consultation among Buyer
and Seller, the parties agree as to the validity of any such claims, Buyer and Seller shall instruct the Escrow Agent to pay such claims out of the remaining balance of the Purchase Price Balance. Upon the expiration of the Escrow Period, any
remaining balance less any amounts equal to any pending unresolved claims shall be distributed to Resistys. 
 4.2 Milestone Payments.
During the Additional Payment Term, Buyer shall also make the following one-time milestone payments to Resistys in accordance with Section 4.4, as and only to the extent that they become due and payable hereunder (the “Milestone
Payments”): 
 (a) Three Hundred Sixty Thousand United States Dollars (US$360,000) upon the filing by Buyer or its sublicensees with,
and acceptance by, the FDA of the first NDA or abbreviated NDA for registration of a RP101 Product for any indication; 

 (b) Three Million Four Hundred Thousand United States Dollars (US$3,400,000) upon FDA approval of a RP101
Product for any indication. For purposes of this Agreement, “FDA approval” shall mean the receipt of approval from the FDA under the Prescription Drug User Fee Act (PDUFA) for the RP101 Product in the United States; 
 (c) One Million United States Dollars (US$1,000,000) upon FDA approval of a RP101 Product for a second (2nd) indication; 
 (d) One Million United States Dollars (US$1,000,000) upon FDA approval of a RP101 Product for a third (3rd) indication; 
 (e) Forty Thousand United States Dollars (US$40,000) when cumulative Market Sales reach US$100 million; and 
 (f) Three Million United States Dollars (US$3,000,000) when cumulative Market Sales reach US$200 million. 
 4.3 Net Sales Payments. During the Additional Payment Term and subject to Section 7.8, Buyer shall also make the following payments to
Resistys in accordance with Section 4.4, as and only to the extent that they become due and payable hereunder (the “Net Sales Payments”): 
 (a) 4.5% of annual Net Sales for annual Market Sales in that year between US$0 and US$100 million, and 
 (b)
5.5% of annual Net Sales for annual Market Sales in that year above US$100 million. 
 Example: If annual Market Sales are US$150
million, of which (1) US$95 million in Net Sales are attributable to the first US$100 million in Market Sales and (2) US$45 million in Net Sales are attributable to Market Sales above $100 million, then the Net Sales Payments during that
year shall be as follows: 
  

			
		  	4.5% x US$95 million = US$4,275,000
		
	 PLUS
	  	5.5% x US$45 million = US$2,475,000
		
	 TOTAL
	  	US$6,750,000

 4.4 Payment of Milestone and Net Sales Payment. 
 (a) Method of Payment. The payments to be made pursuant to Sections 4.2 and 4.3 shall be made when due and payable in U.S. dollars by wire
transfer in immediately available funds to such account as Resistys shall have designated to Buyer in writing, and any such payment shall be deemed to have been paid when recorded in the proper account. 
 (b) Payment of Milestone Payments. Buyer shall pay Resistys the Milestone Payment in the amount, and within thirty (30) days of the
occurrence, of the applicable Milestone Event. 
 (c) Reports and Payments of Net Sale Payments. Within sixty (60) days after the
close of each calendar quarter after the First Commercial Sale of RP101 Product by Buyer, its Affiliates or its Sublicensees to third parties in the Territory, Buyer shall deliver to Resistys a report showing (i) the Net Sales of the RP101
Product during the reporting period, (ii) the payment due thereon pursuant to Section 4.3; and (iii) withholding and other taxes, if any, required by law to be deducted in respect of such payments. If no payment is due under
Section 4.3 for any quarterly period, Buyer shall so report. Buyer shall keep complete and accurate records in sufficient detail to properly reflect all Net Sales and to enable the amounts payable pursuant to Section 4.3 to be determined.

 (d) Exchange Rates. For purposes of calculating the amounts payable Resistys pursuant to Section 4.2 or 4.3, Net Sales in
Canadian dollars shall be converted into U.S. dollars using the arithmetic average of the spot rates on the last business day of each month of the calendar quarter in which the Net Sales were made. The “closing mid-point rates” found in
the “dollar spot forward against the dollar” table published by The Wall Street Journal or any other publication as agreed to by the parties shall be used as the source of spot rates to calculate the average as defined in the preceding
sentence. 
 (e) Prohibitions on Remittances. If at any time legal restrictions in any country in the Territory prevent the prompt
remittance of any payments due with respect to Net Sales in that country, Buyer shall have the right and option to make such payments by depositing the amount thereof in local currency to a Resistys account in a bank or depository in such country
designated by Resistys. 
 (f) Tax Matters. Any withholding or other taxes which Buyer is required by law to pay or withhold on behalf
of Resistys with respect to any payments required to be made hereunder shall be deducted from the amount of such payments due, and promptly paid or 

 
remitted as appropriate, by Buyer on behalf of Resistys. Any such tax required by law to be paid or withheld shall be an expense of, and borne solely by,
Resistys. Buyer shall furnish Resistys with evidence of such payment or amount withheld as soon as practicable after such payment is made or such amount is withheld. Buyer and Resistys shall use commercially reasonable efforts to minimize any such
taxes required to be paid or withheld by Buyer on behalf of Resistys. Without limitation of the foregoing, the parties will reasonably co-operate in completing and filing documents required under the provisions of any applicable tax laws or any
other applicable law in connection with the making of any required tax payment or withholding payment, in connection with a claim of exemption from, or entitlement to, a reduced rate of withholding or in connection with any claim to a refund of or
credit for any such payment. 
 (g) Audits. Upon written request and advance notice of not less than thirty (30) days, Buyer
shall permit an internal auditor or independent public accountant selected by Resistys and acceptable to Buyer, which acceptance shall not be unreasonably withheld or delayed, to have access during normal business hours to such records of Buyer as
may be reasonably necessary to verify the accuracy of the reports described in Section 4.4(c), in respect of any calendar year ending not more than three (3) calendar years prior to the date of such request. All such verifications shall be
conducted at Resistys’ expense and not more than once in any calendar year. If, after consultation with Buyer, such Resistys representative concludes, providing sufficient evidence, that additional amounts were owed to Resistys during such
period pursuant to Section 4.3, the additional amount shall be paid by Buyer within thirty (30) days of the date Resistys delivers to Buyer such representative’s written report so concluding. The fees and expenses charged by such
representative shall be paid by Resistys unless the audit discloses that the amounts payable by Buyer for the audited period are underpaid by more than five percent (5%), in which case Buyer shall pay the reasonable fees and expenses charged by such
representative as well as the amount of such underpayment. Any overpayment will be refundable or credited against future payments hereunder. Buyer shall include in each sublicense of the RESprotect Patent Rights a provision requiring the sublicensee
to make reports to Buyer, to keep and maintain records of sales made pursuant to such sublicense and to grant access to such records by Resistys’ representatives to the same extent required of Buyer under this Agreement. Resistys agrees that
all information subject to review under this Section 4.5(g) or under any sublicense agreement will be Confidential Information and that Resistys will cause its representatives to retain all such information in confidence. 

 (h) Late Payments. If any payments owed by Buyer to Resistys under Sections 4.2 or 4.3 are not
paid when due and payable, Resistys will have the right to charge interest on the past due amounts at a rate equal to two (2) percentage points over the one (1) year LIBOR rate applicable at the time the payment is due. 
 (i) Termination. For the avoidance of doubt, Buyer’s obligation to make the Milestone Payments and the Net Sales Payments shall terminate
upon the expiration of the Additional Payment Term, provided that if Buyer earlier exercises its Buyout Right pursuant to Section 7.8, its obligation to make Net Sales Payments (but not Milestone Payments) shall terminate as provided in
Section 7.8. 
 4.5 Grant of Security Interest. The Buyer’s obligations to make the Milestone Payments and the Net Sales
Payments shall be secured by a security interest in the RP101 Assets as of the Effective Date, which shall include, for the avoidance of doubt, the License Agreement as amended from time to time on and after the Effective Date (the
“Collateral”), as set forth in the form of Security Agreement attached hereto as Exhibit 4.5 hereto (the “Security Agreement”). For the avoidance of doubt, the Collateral shall not be deemed to include any
other property, assets or rights of Buyer or any third parties. 
 ARTICLE 5 
 REPRESENTATIONS AND WARRANTIES OF SELLER 
 Except as set forth in the Disclosure
Schedule attached hereto, each of Resistys, AOI and Avantogen represent and warrant to Buyer with respect to itself as follows: 
 5.1
Organization and Authority. Resistys is a corporation duly organized, validly existing and in good standing under the laws of the state of Delaware with full corporate power and authority to execute and consummate this Agreement and such
other instruments, agreements and transactions as may be contemplated hereunder. AOI is a corporation duly organized, validly existing and in good standing under the laws of the state of Nevada with full corporate power and authority to execute and
consummate this Agreement and such other instruments, agreements and transactions as may be contemplated hereunder. Avantogen is a corporation duly organized, validly existing and in good standing under the laws of Australia with full corporate
power and authority to execute and consummate this Agreement and such 

 
other instruments, agreements and transactions as may be contemplated hereunder. All corporate acts and other proceedings required to be taken by or on the
part of Seller to authorize it to execute, deliver and perform this Agreement and such other instruments, agreements and transactions as may be contemplated hereunder, have been duly and properly taken. This Agreement has been duly executed and
delivered by Seller and constitutes the legal, valid and binding obligations of such party enforceable in accordance with its terms. 
 5.2
Subsidiaries. Resistys represents and warrants that it does not own directly or indirectly any interest or investment (whether equity or debt) in any corporation, partnership, joint venture, business, trust or other entity. AOI represents and
warrants that Seller is a wholly-owned subsidiary of AOI. 
 5.3 Indebtedness. Schedule 5.3 of the Disclosure Schedules
contains a complete, true, and correct description of (a) the amount of all Liabilities of Resistys and AOI and (b) the basis and holders thereof (individually and collectively, the “Creditors”). Resistys and AOI have not
entered into this Agreement with the intent to hinder, delay or defraud any Creditor or any other person to which Resistys or AOI was, is or may become indebted. Resistys or AOI have engaged in the transactions contemplated by this Agreement on an
arm’s-length basis with Buyer. For its own part, each of Resistys or AOI has conducted such transactions in a manner intended to obtain the highest and best price for the RP101 Assets and to ensure that the amount of the Purchase Price
represents at least the fair value of, and fair consideration in exchange for, the RP101 Assets. 
 5.4 No Violation or Conflict. The
execution and delivery by Seller of this Agreement and such other instruments, agreements and transactions as may be contemplated hereunder, and the consummation by Seller of the transactions contemplated hereby and thereunder will not (a) to
Seller’s knowledge, violate any law, statute, rule or regulation or judgment, order, writ, injunction or decree of any court, administrative agency or governmental body, or (b) conflict with, result in any breach of, or constitute a
default (or an event which with notice or lapse of time or both would become a default) under the Certificate of Incorporation or By-Laws (or equivalent governing documents) of Seller or, to Seller’s knowledge, any agreement to which Seller is
a party. 
 5.5 Consents and Approvals. Except as set forth on Schedule 5.5 of the Disclosure Schedule, no notice to,
declaration, filing or registration with, or authorization, consent or 

 
approval of, or permit from, any domestic or foreign governmental or regulatory body or authority, or any other person or entity, is required to be made or
obtained by Seller in connection with the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby. All approvals of the Board of Directors (or equivalent) and shareholders of each Seller
necessary to authorize the execution and performance of this Agreement have been obtained by Seller. 
 5.6 Title to RP101 Assets.
Seller has good and marketable title to all the RP101 Assets, and Seller shall convey good and marketable title to the RP101 Assets at Closing, free and clear of any and all liens, encumbrances, charges, claims, restrictions, pledges, security
interests, or impositions of any kind, including those of secured parties. Except as set forth on Schedule 5.6 of the Disclosure Schedule, (a) Seller beneficially owns all of the right, title or other interests to be transferred to Buyer
hereunder with respect to all the RP101 Assets, and (b) none of the RP101 Assets is leased, rented, licensed, or otherwise not owned by Seller. 
 5.7 Rights with Respect to Intellectual Property. 
 (a) Seller IP Rights. Schedule
2.1(b) hereto sets forth all of the Seller IP Rights. Seller has the right to convey to Buyer the Seller IP Rights as contemplated hereby. Except as set forth on Schedule 5.7(a) of the Disclosure Schedule, (a) the Seller IP
Rights do not, to the knowledge of Seller, infringe any patent or other intellectual property right of any third party; (b) there are no claims, demands, or proceedings instituted pending or, to the knowledge of Seller, threatened by any party
pertaining to or challenging any of Seller’s rights in the Seller IP Rights; and (c) Seller is not aware of any facts which would render any of the Seller IP Rights invalid or unenforceable. The Seller IP Rights were invented, reduced to
practice, produced, developed and/or prepared, as applicable, solely by employees or independent contractors of Seller, as applicable, in the course of their employment or engagement, and no other party invented or contributed to such intellectual
property in any way. Seller has taken all steps reasonably necessary to maintain its rights in the Seller IP Rights, including normal and customary protections of confidential information. 
 (b) RESprotect IP. Without having made any independent investigation, Seller is not aware of any facts that would make Licensor’s
representations in the second, third, seventh and ninth sentences of Section 6.2.1 of the License Agreement untrue. Seller has taken all steps reasonably necessary to maintain its rights in the RESprotect Patents or the RESprotect Know-How,
including normal and customary protections of confidential information. 

 5.8 Assumed Agreements. Each of the Assumed Agreements to which Seller is a party is valid,
binding and in full force and effect. Seller is not in default under any of the Assumed Agreements, nor to Seller’s knowledge is any other party in default under such agreements, nor is any such default pending or threatened. Other than the
Assumed Agreements, Seller is not a party to any agreements of any kind whatsoever, whether written or oral, concerning or in any way related to the RP101 Program or the RP101 Assets. 
 5.9 Violations of Law. The utilization of the RP101 Assets and the conduct of the RP101 Program by Resistys and AOI (a) does not, to the
knowledge of Resistys and AOI, violate any law, governmental specification, authorization, requirement or any decree, judgment, order or similar restriction in any material respect; and (b) to the knowledge of Resistys and AOI, has not, in any
material respect, been the subject of any investigation or inquiry by any governmental agency or authority regarding violations or alleged violations or, in any material respect been found by any such agency or authority to be in violation of any
law. 
 5.10 Litigation. Neither the RP101 Assets nor the RP101 Program is the subject of (a) any outstanding judgment, order,
writ, injunction or decree of any court, arbitrator or administrative or governmental authority or agency limiting, restricting or affecting the RP101 Assets or the RP101 Program in any material aspect; (b) any pending, or to the knowledge of
Seller, threatened, lawsuit, claim, proceeding, written charge, inquiry, investigation or action of any kind. There are no written claims, actions, suits, proceedings, or investigations pending or, to the knowledge of Seller, threatened, against
Seller with respect to the transactions contemplated in this Agreement. 
 5.11 Taxes. There are no liens for Taxes accrued upon the
RP101 Assets prior to the Closing except for current Taxes not yet due and payable. Resistys has prepared and timely filed all returns, estimates, information statements and reports required to be filed by Resistys with any taxing authority
(“Returns”) that Resistys was required to file prior to the date hereof and such Returns were true and correct in all material respects and were completed in accordance with applicable law. Resistys has paid all Taxes shown to be
payable on all Returns required to have been filed and has withheld all taxes required to have been withheld and, to the extent required, has properly paid such Taxes to the appropriate taxing authority. 

 5.12 Disclosure. No representation or warranty by Seller in this Agreement or any schedule or
exhibit hereto, or any statement, list or certificate furnished by Seller pursuant hereto, contains or will contain any untrue statement of a material fact, or omits or will omit to state a material fact required to be stated therein or necessary to
make the statements contained therein not misleading or necessary in order to provide a prospective purchaser of the RP101 Assets with proper information related to such assets and RP101 Program. Resistys and AOI have disclosed all material adverse
facts of which they have knowledge relating to the RP101 Assets, the RP101 Program and the consummation of the transactions contemplated by this Agreement. 
 ARTICLE 6 
 REPRESENTATIONS AND WARRANTIES OF BUYER 
 Buyer hereby represents and warrants to Seller as follows: 
 6.1 Organization and Authority. Buyer is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. Buyer has full corporate power and authority to execute and
deliver this Agreement and such other instruments, agreements and transactions as may be contemplated hereunder, and to perform its obligations hereunder and thereunder. All corporate acts and other proceedings required to be taken by or on the part
of Buyer to authorize Buyer to execute, deliver and perform this Agreement and such other instruments, agreements and transactions as may be contemplated hereunder, have been duly and properly taken. This Agreement has been duly executed and
delivered by Buyer and constitutes the legal, valid and binding obligation of Buyer enforceable in accordance with its terms. 
 6.2 No
Conflict or Violation. The execution and delivery by Buyer of this Agreement and such other instruments, agreements and transactions as may be contemplated hereunder and the consummation by Buyer of the transactions contemplated hereby and
thereunder will not (a) to Buyer’s knowledge, violate any law, statute, rule or regulation or judgment, order, writ, injunction or decree of any court, administrative agency or governmental body, or (b) conflict with, result in any
breach of, or constitute a default (or an event which with notice or lapse of time or both would become a default) under the Certificate of Incorporation or By-Laws of Buyer or, to Buyer’s knowledge, any agreement to which Buyer is a party.

 6.3 Consents and Approvals. No notice to, declaration, filing or registration with, or
authorization, consent or approval of, or permit from, any domestic or foreign governmental or regulatory body or authority, or any other person or entity, is required to be made or obtained by Buyer in connection with the execution, delivery and
performance of this Agreement and the consummation of the transactions contemplated hereby. 
 ARTICLE 7 
 CLOSING; FURTHER ASSURANCES; 
 POST
CLOSING COVENANTS; BUYOUT 
 7.1 Closing. Subject to the terms and conditions of this Agreement, the purchase and sale of the
RP101 Assets pursuant to the terms and conditions hereof (the “Closing”) shall take place on the Effective Date at the offices of DLA Piper US LLP, 153 Townsend, Suite 800, San Francisco, CA 94107, counsel to Buyer, or at such other
time, date and place as mutually agreed upon by the parties. 
 7.2 Escrow Agreement and Purchase Price. At the Closing: 

(a) Buyer, Seller and Escrow Agent shall enter into the Escrow Agreement as provided in Section 4.1; 
 (b) Buyer and Seller shall deliver the list of Creditors set forth on Schedule 5.3 of the Disclosure Schedule to Escrow Agent; and 
 (c) Buyer shall deliver to the Escrow Agent the Purchase Price as set forth in Section 4.1. 
 7.3 Asset Transfer and Assumption Agreements. At the Closing, Seller shall deliver to Buyer such Asset Transfer and Assumption Agreements in form
and substance reasonably satisfactory to Buyer, as shall be effective to vest in Buyer all right, title and interest of Seller in and to the RP101 Assets. 
 7.4 Other Closing Deliverables. At the Closing, the parties shall deliver the following: 
 (a) Seller
shall deliver to Buyer documentation acceptable to Buyer demonstrating that their respective signatories to this Agreement are duly authorized to execute the Agreement on their behalf. 

 (b) Seller shall deliver to Buyer an Assignment and Amendment No. 1 to the PRA Agreement dated as of
the Effective Date among PRA, AOI and Buyer (the “PRA Assignment”), in form and substance satisfactory to Buyer, duly executed by AOI and PRA. 
 (c) Seller shall deliver to Buyer an Assignment of that certain Services Agreement dated October 18, 2004 between Resistys and Hesperion Ltd., as amended by COS#1 dated December 6, 2005 and COS#2 dated
April 12, 2007 (the “Hesperion Assignment”), in form and substance satisfactory to Buyer. 
 (d) Seller shall deliver
to Buyer the Licensor’s consent in writing to the assignment of the License Agreement and the Supply Agreement contemplated hereby, in form and substance satisfactory to Buyer. 
 (e) Seller shall deliver to Buyer all other consents and approvals required of third parties with respect to the transactions contemplated in this
Agreement, in form and substance satisfactory to Buyer, including copies of the approvals of the Boards of Directors of each Seller and of the approval of the shareholders of Resistys and AOI certified by the Secretary of each Seller. 
 (f) AOI shall deliver to Buyer such documents and instruments as are necessary or desirable to transfer the sponsorship of the RP101 IND to Buyer, in
form and substance satisfactory to Buyer. 
 (g) Seller shall deliver to Buyer physical copies of the Assumed Agreements, Seller IP Rights,
Regulatory Filings, Manufacturing Information and Research and Development Materials and all Books and Records related thereto. 
 (h) AOI
shall deliver to Buyer evidence of the conversion of at least 75% of the debt owed by AOI to Chopin Opus One, L.P. into equity of AOI, in form and substance reasonably satisfactory to Buyer. For the avoidance of doubt, the balance of said debt shall
be included in the list of Creditors set forth in Schedule 5.3 of the Disclosure Schedule and shall be paid by the Escrow Agent within thirty (30) days after Closing pursuant to Section 4.1 unless theretofore converted. 

(i) Buyer shall pay the Licensor the RESprotect Invoices in the amount of Three Hundred Sixty-Five Thousand Four Hundred Seventy-Four United States
Dollars (US$365,474). 

 (j) Buyer shall deliver to Seller appropriate documentation (in form and substance reasonably
satisfactory to Seller) demonstrating that the signatory to this Agreement is duly authorized to execute the Agreement on behalf of Buyer. 
 (k) Buyer shall deliver to Seller copies of the approval of its Board of Directors certified by the Secretary of Buyer. 
 (l) Buyer
shall deliver to Seller an executed Security Agreement as set forth in Section 4.5. 
 (m) Buyer shall deliver to Seller the PRA
Assignment and the Hesperion Assignment, duly executed by Buyer. 
 7.5 Further Assurances; Power of Attorney. From time to time after
the Closing, at the request of Buyer and for no further consideration, Seller shall execute, acknowledge and deliver such assignments, transfers, consents and other documents and instruments and take such other actions as may be reasonably necessary
or desirable to consummate the transactions contemplated hereby, or to effectuate any action contemplated under this Agreement (individually and collectively, the “Further Assurances”). Each of Resistys, AOI and Avantogen hereby
irrevocably makes, constitutes and appoints Buyer, and any officers, employees or agents of Buyer designated by Buyer, with full power of substitution, as its agent and attorney-in-fact with full power and authority in its place, name and stead, or
in Buyer’s name, to execute, acknowledge and deliver such assignments, transfers, consents and other documents and instruments and take such other actions as may be reasonably necessary or desirable to consummate the transactions contemplated
hereby, or to effectuate any action contemplated under this Agreement, with the same legal force and effect as if executed by it (the “Power of Attorney”), provided that Buyer may only exercise the Power of Attorney if
Resistys, AOI and/or Avantogen, as applicable, fail for any reason (including due to its dissolution or liquidation) to perform the Further Assurances within thirty (30) days of Buyer’s written request describing the Further Assurances
requested to be performed. The Power of Attorney is coupled with an interest and shall be irrevocable. Each of Resistys, AOI and Avantogen hereby ratify and confirm all actions Buyer lawfully does or causes to be done pursuant to the Power of
Attorney. Each of Resistys, AOI and Avantogen hereby agree that third parties may rely upon the representations of Buyer, and any officers, employees or agents of Buyer designated by Buyer, as to any and all matters with respect to any power granted
by the 

 
Power of Attorney, and no person or entity who shall act in reliance upon such representations or the authority granted by the Power of Attorney shall incur
any liability to Resistys, AOI or Avantogen as a result of such reliance. The powers conferred on Buyer by the Power of Attorney are solely to protect Buyer’s interests herein and do not impose any duty upon it to exercise any such powers.

 7.6 Access to Books and Records After Closing. Seller will permit Buyer and its duly authorized representatives access during
normal business hours (upon 24 hours written notice to Seller) to all Books and Records in the possession or control of Seller to the extent that such books and records were not delivered to Buyer. 
 7.7 Buyout of Net Sales Payments. During the Buyout Period (as defined below), Buyer shall have the right (the “Buyout Right”) to
buy out its obligation to pay Resistys the Net Sales Payments pursuant to Section 4.3, on the terms and conditions set forth in this Section 7.8. For the avoidance of doubt, if Buyer exercises the Buyout Right in accordance with this
Section 7.8, its obligation to make any Net Sales Payments to Resistys that would otherwise have been due and payable under Section 4.2 after the date of the Buyout Notice shall terminate upon the payment to Resistys of the applicable
Buyout Consideration (as defined below). For the avoidance of doubt, the exercise of the Buyout Right by Buyer shall not relieve Buyer of its obligation to pay the Milestone Payments to Resistys pursuant to Section 4.2. 
 (a) Buyout Period. The Buyout Right shall be exercisable by Buyer during the following periods (each, a “Buyout Period”):

 (i) During the period commencing on the date of the completion of the Phase II Clinical Trial for the first RP101 Product and ending ten
(10) days prior to the commencement of the Phase III Clinical Trial for the first RP101 Product (the “First Buyout Period”). For purposes of this paragraph, (a) “completion of the Phase II Clinical Trial” shall
be deemed to have occurred thirty (30) days after Buyer receives the final statistical analysis of the data generated from the Phase II Clinical Trial, and (b) “commencement of the Phase III Clinical Trial” shall be deemed to
have occurred upon the dosing of the first patient enrolled in such clinical trial; or 
 (ii) During the period commencing on the date of
the completion of the Phase III Clinical Trial for the first RP101 Product and ending ten (10) days prior to the filing of an NDA for the first RP101 Product (the “Second Buyout Period”). For purposes of this 

 
paragraph, “completion of the Phase III Clinical Trial” shall be deemed to have occurred thirty (30) days after Buyer receives the final
statistical analysis of the data generated from the Phase III Clinical Trial. 
 (b) Buyout Consideration. The consideration payable
to Resistys for the Buyout Right shall be: 
 (i) during the First Buyout Period, Twelve Million United States Dollars (US$12,000,000),
payable at Buyer’s option in cash or Common Stock (the “Buyout Consideration”); or, 
 (ii) during the Second Buyout
Period, Twenty Million United States Dollars (US$20,000,000), payable at Buyer’s option in cash or Common Stock (also, “Buyout Consideration”). 
 (c) Exercise of Buyout Right. The Buyer may exercise the Buyout Right during the applicable Buyout Period by delivering to Resistys a notice (the “Buyout Notice”) specifying a date (the
“Buyout Date”) not less than thirty (30) days after the date of the Buyout Notice on which the closing of the Buyout Right will occur and whether the Buyout Consideration will be in the form of cash or Common Stock. 

(d) Calculation of Buyout Consideration in the Form of Common Stock. If Buyer elects to pay the Buyout Consideration in Common Stock, the
number of shares of Common Stock comprising the Buyout Consideration shall be determined by dividing the dollar value of the applicable Buyout Consideration by the average closing sales price of the Common Stock as traded on The Nasdaq Stock Market
(or such other securities exchange on which the Common Stock is traded) and reported in The Wall Street Journal for the forty (40) consecutive market trading days on which the Common Stock is traded ending on the date of the Buyout Notice, or
the last market trading day prior to the date of the Buyout Notice, if the date of the Buyout Notice is not itself a market trading day, and rounding to the nearest whole share. 
 (e) Procedure for Payment of Buyout Consideration; Registered Stock. On the Buyout Date, Buyer shall deliver the Buyout Consideration to Resistys.
If Buyer elects to pay the Buyout Consideration in cash, Buyer shall pay the Buyout Consideration by wire transfer in immediately available funds to such account as Resistys shall have designated to Buyer in writing. If Buyer elects to issue Common
Stock in payment of the Buyout Consideration, Buyer shall issue or cause to be issued the number of shares of Common Stock comprising the Buyout 

 
Consideration in the name of Resistys, which stock shall be registered at the time of issuance under the Securities Act. If Buyer issues Common Stock, each
of Buyer and Seller shall cooperate in a reasonable manner to provide all information required in connection with the registration of such Common Stock. 
 7.8 Confidentiality. On and after the Effective Date, Seller shall keep secret and retain in strictest confidence, shall not use for the benefit of themselves or others and shall not disclose to any third
party, except with Buyer’s prior written consent, any Confidential Information related to the RP101 Assets or the RP101 Program or any Confidential Information provided by Buyer after the Effective Date, including any information provided in
connection with Section 4.4. 
 7.9 Publicity. The parties agree that each party may make a public announcement of the execution
of this Agreement, provided that the text of any such announcement shall be subject to the approval of the other parties, such approval not to be unreasonably withheld. Any other publication, news release or other public announcement relating to
this Agreement shall first be reviewed and approved by Buyer, AOI and Avantogen, such approval not to be unreasonably withheld unless such publication, news release or other public announcement contains information previously approved for release
hereunder. Notwithstanding the foregoing, any disclosure that is required by applicable law, or by the rules of a nationally recognized securities exchange, as advised by the disclosing party’s counsel, may be made without the consent of the
other parties, although the other parties shall be given prompt written notice of such legally required disclosure and to the extent practicable shall have a reasonable opportunity to comment on the proposed disclosure. 
 7.10 Operation of Resistys following Closing. Resistys and AOI agree that Resistys shall have no business or operations following the Closing
other than the ownership of its rights under this Agreement, and shall not acquire assets or incur obligations or liabilities of any kind, other than directly pursuant to this Agreement and the transactions contemplated hereby. 
 ARTICLE 8 
 LIABILITY AND
INDEMNIFICATION 
 8.1 Buyer Liabilities. Buyer, and not Seller, shall be liable for any and all Assumed Liabilities and all
Liabilities that arise in connection with the RP101 Assets and/or Buyer’s conduct of the RP101 Program after the date hereof, but only to the extent such Liabilities are 

 
caused or are alleged to have been caused by an act or omission occurring after the date hereof (the “Buyer Liabilities”). Buyer’s
Liabilities shall be understood to include all Assumed Liabilities and all Liabilities which accrue after the date hereof under the Assumed Agreements. 
 8.2 Seller Liabilities. Seller, and not Buyer, shall be liable for any and all Liabilities that arise in connection with the RP101 Assets and/or the conduct of the RP101 Program on or prior to the date hereof
(the “Seller Liabilities”). The Seller Liabilities shall be understood to include all Liabilities which accrued on or prior to the date hereof under the Assumed Agreements. 
 8.3 Indemnification by Buyer. Buyer indemnifies and holds harmless Seller and their respective Affiliates and their respective directors,
officers, employees, controlling persons, agents and representatives (the “Seller Indemnitees”) from and against (a) the Buyer Liabilities, including any and all claims by third parties arising out of the conduct after the
Closing of the RP101 Program or use or ownership of the RP101 Assets after the Closing; and (b) any and all Liabilities which Seller may incur or suffer which arise out of (i) Buyer’s breach of any representation, warranty, covenant
or agreement made by Buyer in this Agreement; or (ii) any and all actions, suits, proceedings, demands, assessments, judgments, reasonable costs and expenses incident to any of the foregoing. Notwithstanding that a claim with respect to
indemnified Liabilities falls into multiple categories of this Section 8.3, Buyer shall only be required to indemnify a Seller Indemnitee up to the amount of the Liability incurred or suffered. 
 8.4 Indemnification by Seller. Seller jointly and severally indemnify and hold harmless Buyer, its Affiliates and their respective directors,
officers, employees, controlling persons, agents and representatives (the “Buyer Indemnitees”) from and against (a) the Seller Liabilities, including any and all claims by third parties arising out of the conduct, on or prior
to the Closing, of the RP101 Program or use or ownership of any of the RP101 Assets on or prior to the Closing; and (b) any and all Liabilities which Buyer may incur or suffer which arise out of (i) Seller’s breach of any
representation, warranty, covenant or agreement made by Seller in this Agreement; or (ii) any and all actions, suits, proceedings, demands, assessments, judgments, reasonable costs and expenses incident to any of the foregoing. Notwithstanding
that a claim with respect to indemnified Liabilities falls into multiple categories of this Section 8.4, Seller shall only be required to indemnify up to the amount of the Liability incurred or suffered. 

 8.5 Claims. Any Buyer Indemnitee or Seller Indemnitee claiming it may be entitled to
indemnification under this Article 8 (the “Indemnified Party”) shall give prompt notice to the other Party (the “Indemnifying Party”) of each matter, action, cause of action, claim, demand, fact or other
circumstances upon which a claim for indemnification (a “Claim”) under this Article 8 may be based. Such notice shall contain, with respect to each Claim, such facts and information as are then reasonably available, and the
specific basis for indemnification hereunder. Failure to give prompt notice of a claim hereunder shall not affect the Indemnifying Party’s obligations under this Section, except to the extent the Indemnifying Party is prejudiced by such
failure. 
 8.6 Defense of Actions. The Indemnified Party shall permit the Indemnifying Party, at the Indemnifying Party’s option
and expense, to assume the complete defense of any Claim based on any action, suit, proceeding, claim, demand or assessment by any third party with full authority to conduct such defense and to settle or otherwise dispose of the same and the
Indemnified Party will fully cooperate in such defense; provided the Indemnifying Party will not, in defense of any such action, suit, proceeding, claim, demand or assessment, except with the consent of the Indemnified Party (which consent will not
be unreasonably withheld), consent to the entry of any judgment or enter into any settlement which provides for any relief other than the payment by the Indemnifying Party of monetary damages and which does not include as an unconditional term
thereof the giving by the claimant or plaintiff to the Indemnified Party of a release from all liability in respect thereof. After notice to the Indemnified Party of the Indemnifying Party’s election to assume the defense of such action, suit,
proceeding, claim, demand or assessment, the Indemnifying Party shall be liable to the Indemnified Party for such legal or other expenses subsequently incurred by the Indemnified Party in connection with the defense thereof at the request of the
Indemnifying Party. As to those actions, suits, proceedings, claims, demands or assessments with respect to which the Indemnifying Party does not elect to assume control of the defense, the Indemnified Party will afford the Indemnifying Party an
opportunity to participate in such defense, at its cost and expense, and will consult with the Indemnifying Party prior to settling or otherwise disposing of any of the same. Notwithstanding anything to the contrary herein, with respect to any Claim
asserted by a governmental entity relating to Taxes, the Indemnifying Party shall be entitled to participate in the defense, but the Indemnified Party shall control such defense. The Indemnified Party will not settle any such Claim without the prior
consent of the Indemnifying Party, such consent not to be unreasonably withheld. 

 8.7 Remedies Cumulative. The remedies provided in this Agreement shall be cumulative and shall not
preclude any party from asserting any other right, or seeking any other remedies, against the other party. 
 8.8 Survival of
Representations and Warranties. The representations and warranties of the parties set forth in this Agreement shall survive the Closing. All Claims under this Article 8 shall expire on the third anniversary of the Effective Date. Notwithstanding
the foregoing, termination of such Claims and of the parties’ obligations hereunder shall not terminate or affect obligations in respect of claims for indemnity or otherwise for which written notice shall have been given by the Identified Party
prior to expiration date. 
 8.9 Limitations. The indemnification obligations hereunder shall be limited to the amount of the Purchase
Price and the Milestone Payments. In no event shall either party be entitled to indirect, special, consequential or punitive damages. 
 ARTICLE 9 
 MISCELLANEOUS 
 9.1 Governing Law. This Agreement shall be deemed to have been made in the State of California and its form, execution, validity, construction and effect shall be governed and construed in accordance with the
laws of the State of California, without giving effect to the principles of conflicts of law thereof. 
 9.2 Jurisdiction. The parties
consent to the exclusive jurisdiction of the state and federal courts within the state of California with respect to any dispute arising out of this Agreement. 
 9.3 Headings. All section headings contained in this Agreement are for convenience of reference only and shall not affect the meaning or interpretation of this Agreement. 
 9.4 Entire Agreement. This Agreement and the schedules and exhibits hereto are intended to define the full extent of the legally enforceable
undertakings and representations of the parties hereto, and no promise or representation, written or oral, which is not set forth explicitly in such Agreement is intended by either party to be legally binding. Each of the parties acknowledge that in
deciding to enter into this Agreement and to consummate the transaction contemplated hereby none of them has relied upon any statements or representations, written or oral, other than those explicitly set forth herein. 

 9.5 Amendment. This Agreement may not be amended, supplemented or otherwise modified except by an
instrument in writing signed by the parties hereto that specifically refers to this Agreement. 
 9.6 Notices. All notices and other
communications required to be given under this Agreement shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) five (5) days after having been sent by registered or
certified mail, return receipt requested, postage prepaid, or (c) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be
sent to the following respective addresses (or to such other address as may be specified by notice from time to time by the relevant party): 
  

					
	If to Resistys:	 		  	 2121 Avenue of the Stars
 Suite 2550
 Los Angeles, California 90067
 Attn: Christopher Nowers

			
		 	with a copy to:	  	 Michael Hirschberg, Esq.
 Katten Muchin Rosenman
LLP
 575 Madison Avenue
 New York, New York
10022-2585

			
	If to AOI:	 		  	 2121 Avenue of the Stars
 Suite 2550
 Los Angeles, California 90067
 Attn: Christopher Nowers

			
		 	with a copy to:	  	 Michael Hirschberg, Esq.
 Katten Muchin Rosenman
LLP
 575 Madison Avenue
 New York, New York
10022-2585

					
			
	If to Avantogen:	 		  	 2121 Avenue of the Stars
 Suite 2550
 Los Angeles, California 90067
 Attn: William Ardrey

			
	If to Buyer:	 		  	 901 Mariners Island Blvd.
 San Mateo, California 94404

 Attn: Friedhelm Blobel, Chief Executive Officer

			
		 	with a copy to:	  	 J. Howard Clowes, Esq.
 DLA Piper US LLP
 153 Townsend Street, Suite 800
 San Francisco, CA 94107

 9.7 Assignment. This Agreement and the rights and obligations hereunder shall be binding
upon and inure to the benefit of the parties hereto, their respective successors and permitted assigns. Unless consent in writing is first obtained from the other parties hereto, this Agreement and the rights granted hereunder shall not be
assignable by any party hereto, and any attempted assignment without such consent shall be void. Notwithstanding the foregoing, Buyer may transfer or assign its rights and obligations under this Agreement to (a) an Affiliate, or (b) a
successor to all or substantially all of its business or assets relating to this Agreement whether by sale, merger, consolidation, acquisition, transfer, operation of law or otherwise, provided that such Affiliate or successor agrees to be
bound by the terms of this Agreement. 
 9.8 No Agency. It is understood and agreed that each party shall have the status of an
independent contractor under this Agreement and that nothing in this Agreement shall be construed as authorization for either party to act as agent for the other. No party shall incur any liability for any act or failure to act by employees of
another party. 
 9.9 No Strict Construction. This Agreement has been prepared jointly and shall not be strictly construed against
either party. 
 9.10 Counterparts. This Agreement may be executed in two counterparts, each of which shall be an original as against
any party whose signature appears thereon but both of which together shall constitute one and the same instrument. A facsimile transmission of the signed Agreement shall be legal and binding on both parties. 

 9.11 Payment of Expenses. All costs and expenses associated with this Agreement and the
transactions contemplated thereby, including the fees of counsel and accountants, shall be borne by the party incurring such expenses. 
 9.12 No Brokers. No broker, finder, agent or similar intermediary has acted for or on behalf of any party hereto or in connection with this Agreement or the transactions contemplated hereby and no broker, finder, agent or
intermediary is entitled to any fee from any party hereto in connection with this Agreement or the transactions contemplated hereby. 
 [Signature Page Follows] 

 IN WITNESS WHEREOF, the parties, through their authorized officers, have duly executed this
Agreement as of the Effective Date. 
  

									
	RESISTYS:	 		 	BUYER:
			
	RESISTYS, INC.	 		 	SCICLONE PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Chris Nowers
	 		 	By:	 	 /s/ Friedhelm Blobel

	Name:	 	Chris Nowers	 		 	Name:	 	Friedhelm Blobel
	Title:	 	President	 		 	Title:	 	CEO and President
			
	AVANTOGEN:	 		 	AOI:
			
	AVANTOGEN LIMITED	 		 	AVANTOGEN ONCOLOGY, INC.
					
	By:	 	 /s/ William Ardrey
	 		 	By:	 	 /s/ Angela Bronow Davanzo

	Name:	 	William Ardrey	 		 	Name:	 	Angela Bronow Davanzo
	Title:	 	Chairman of the Board	 		 	Title:	 	Chief Financial Officer

 [Signature Page to Assignment and Purchase Agreement] 

 SCHEDULE 2.1(A) 
 Assumed Agreements 
 1. License Agreement dated August 30, 2004 among Resistys, Inc., Avantogen Limited (formerly,
Australian Cancer Technology Limited) and RESprotect GmbH. 
 2. Supply Agreement for Clinical Trial Material dated September 13, 2004 between Resistys,
Inc. and RESprotect GmbH. 
 3. Agreement for Clinical Trials Management Services (PRA Project ID: INV101II-101IIX) dated August 31, 2006 by and between
Avantogen Oncology, Inc. and Pharmaceutical Research Associates, Inc., as amended by the PRA Assignment. 
 4. Services Agreement dated October 18, 2004
between Resistys, Inc. and Hesperion Ltd., as amended by COS#1 dated December 6, 2005 and COS#2 dated April 12, 2007. 

 SCHEDULE 2.1(B) 
 Seller IP Rights 
 1. Phase I/II Study of RP101 in Combination with Gemcitabine in Patients with Pancreas Carcinoma dated
July 2, 2004 (Protocol Number: BVDU-II-01). 
 2. Randomized, Double Blind, Placebo Controlled, Phase II Study Evaluating the Efficacy and Safety of
RP101 in Combination with Gemcitabine Administered as First-Line Treatment to Subjects with Metastatic Pancreatic Adenocarcinoma dated August 3, 2006 (Protocol Number RP101-II). 
 3. See Schedules 2.1(D) and (E). 

 SCHEDULE 2.1(C) 
 Regulatory Filings 
 1. Investigational New Drug Application (IND) 70,841 (Serial No. 0001) of AOI, approved by the FDA
on October 30, 2006. 
 2. Letter dated October 26, 2004 from Australian Cancer Technology to the FDA. 
 3. Telecon Minutes dated December 7, 2004. 
 4. Australian Cancer
Technology Pre IND Toxicology Consultations for RP 101. 
 5. Email dated 11-8-05 from the FDA to Theresa Gerrard, Ph.D. 
 6. Letter dated October 24, 2005 and attachments from Resistys, Inc. to the FDA. 
 7. Letter dated November 30, 2006 from Avantogen Oncology, Inc. to the FDA. 
 8. Email dated November 16, 2006
from the FDA to Avantogen Oncology, Inc. 
 9. Email dated December 5, 2006 from the FDA to Avantogen Oncology, Inc. 
 10. Email dated October 30, 2006 from the FDA to Avantogen Oncology, Inc. 
 11. Letter dated October 10, 2006 from the FDA to Avantogen Oncology, Inc. 
 12. Letter dated October 2, 2006 from Avantogen Oncology,
Inc. to the Office of Oncology Drug Products. 
 13. Phase I/II Study of RP101 in Combination with Gemcitabine in Patients with Pancreas Carcinoma dated
July 2, 2004 (Protocol Number: BVDU-II-01). 
 14. Randomized, Double Blind, Placebo Controlled, Phase II Study Evaluating the Efficacy and Safety of
RP101 in Combination with Gemcitabine Administered as First-Line Treatment to Subjects with Metastatic Pancreatic Adenocarcinoma dated August 3, 2006 (Protocol Number RP101-II). 

 SCHEDULE 2.1(D) 
 Manufacturing Information 
 1. Stability and other data on RP101 190 mg tablets and placebos, described in invoice
No. 27858 (Stability Brivudin) dated February 22, 2007 and invoice No. 27491 dated December 19, 2006 of allphamed PHARBIL Arzneimittel GmbH (AOI Customer No. 1344511). 

 SCHEDULE 2.1(E) 
 Research and Development Materials 
 1. Phase I Dose Ranging Study Data produced by Hesperion Ltd. pursuant to that certain
Services Agreement dated October 8, 2004 between Resistys and Hesperion Ltd., as amended by COS#1 dated December 6, 2005 and COS#2 dated April 12, 2007 (“Phase I Dose Ranging Study Data”). 

 EXHIBIT 4.1 
 Form of Escrow Agreement 
 ESCROW AGREEMENT, dated this 25th day of April, 2007 (this
“Agreement”), by and among SCICLONE PHARMACEUTICALS, INC. (“SciClone”), RESISTYS, INC. (“Resistys”), AVANTOGEN LIMITED, (“Avantogen”), AVANTOGEN ONCOLOGY, INC. (“AOI”) and KATTEN MUCHIN ROSENMAN LLP
(the “Escrow Agent”). 
 WHEREAS, Resistys, Avantogen and AOI are selling certain assets to SciClone pursuant to that certain
Assignment and Purchase Agreement of even date herewith by and among Resistys, Avantogen, AOI and SciClone (the “Purchase Agreement”) in consideration for which SciClone will pay Resistys, among other things, the cash amount of
$1,516,648.89 (the “Initial Cash Payment”) at the closing of the transactions contemplated by the Purchase Agreement (the “Closing”). 
 WHEREAS, the parties have agreed that the Initial Cash Payment will be deposited in escrow at the Closing for direct payment to certain creditors of Resistys and AOI; and 
 WHEREAS, the parties propose to establish an escrow account with the Escrow Agent pursuant to the terms and conditions of this Agreement. 
 NOW THEREFORE, it is agreed as follows: 
 1.
Establishment of Escrow. The Escrow Agent hereby agrees to receive and disburse the Initial Cash Payment in accordance herewith. 
 2.
Deposit of Escrowed Property. Upon the Closing, SciClone shall deliver the Initial Cash Payment to the Escrow Agent by wire transfer to the Escrow Agent in immediately available funds. Upon receipt of the Initial Cash Payment from SciClone,
the Escrow Agent shall credit such funds (the “Escrow Funds”) to an interest-bearing account (the “Escrow Account”) held by the Escrow Agent. 
 3. List of Creditors. At the Closing, Resistys, AOI and SciClone shall furnish to the Escrow Agent the list of creditors of Resistys and AOI attached to the Purchase Agreement, which list shall be attached
hereto as Schedule A. 
 4. Disbursements from the Escrow Account. Promptly after the Closing, but in no event later than five
(5) days after the Closing, the Escrow Agent shall disburse from the Escrow Account the amounts listed on Schedule A to the creditors listed on such schedule, other than RESprotect GmbH and Pharmaceutical Research Associates, Inc., who shall be
paid $49,761.48 and $113,589.63, respectively, by Buyer on behalf of Seller pursuant to Section 4.1 of the Purchase Agreement. The Escrow Agent shall hold the balance of the Escrow Funds for a period of thirty (30) days after the Closing
(the “Escrow Period”). During the Escrow Period, upon receipt of joint written instructions from the other parties to this Agreement, the Escrow Agent 

 
shall disburse additional amounts from the Escrow Account to discharge claims of other creditors of Resistys and AOI or additional claims of the creditors
listed on Schedule A. During the Escrow Period, Escrow Agent shall notify Resistys, AOI, Avantogen and SciClone if it receives any claims from creditors of Resistys and AOI not listed on Schedule A or additional claims from the creditors listed on
Schedule A. Upon the expiration of the Escrow Period, the Escrow Agent shall disburse to Resistys the remaining balance of the Escrow Funds, less any amounts equal to any pending unresolved creditor claims. The Escrow Agent shall continue to hold
the Escrow Funds with respect to pending unresolved creditor claims in the Escrow Account after the expiration of the Escrow Period and disburse such funds only upon receipt of joint written instructions from the other parties to this Agreement.

 5. Concerning the Escrow Agent. To induce the Escrow Agent to act hereunder, it is further agreed by SciClone, Resistys, Avantogen
and AOI that: 
 (a) The Escrow Agent shall not be under any duty to give the Escrow Funds held by it hereunder any greater degree of care
than it gives its own similar property and shall not be required to invest any funds held hereunder except as may be otherwise directed in this Agreement. Uninvested funds held hereunder shall not earn or accrue interest. 
 (b) This Agreement expressly sets forth all the duties of the Escrow Agent with respect to any and all matters pertinent hereto. No implied duties or
obligations shall be read into this Agreement against the Escrow Agent. The Escrow Agent shall not be bound by the provisions of any agreement among the other parties hereto except this Agreement. 
 (c) The Escrow Agent shall not be liable for any action taken or omitted by it in good faith unless a court of competent jurisdiction determines that the
Escrow Agent’s willful misconduct was the primary cause of any loss to the other parties to this Agreement. The Escrow Agent may consult with counsel of its own choice and shall have full and complete authorization and protection for any action
taken or omitted by it hereunder in good faith and in accordance with the opinion of such counsel. 
 (d) The Escrow Agent shall be entitled
to rely upon any order, judgment, certification, demand, notice, instrument or other writing delivered to it hereunder without being required to determine the authenticity or the correctness of any fact stated therein or the propriety or validity of
the service thereof. The Escrow Agent may act in reliance upon any instrument or signature believed by it in good faith to be genuine and may assume, if in good faith, that any person purporting to give notice or receipt or advice or make any
statement or execute and document in connection with the provisions hereof has been duly authorized to do so. 
 (e) SciClone, on the one
hand, and Resistys, Avantogen and AOI, on the other hand, jointly agree to indemnify the Escrow Agent for, and to hold it harmless against, any loss, liability or expense arising out of or in connection with this Agreement and carrying out its
duties hereunder, including the costs and expenses of defending itself against any claim of liability, except in those cases where the Escrow Agent has been guilty of gross negligence or willful misconduct. Anything in this Agreement to the contrary
notwithstanding, in no event shall the Escrow Agent be liable for special, indirect or consequential loss or damage of any kind 

 
whatsoever (including but not limited to lost profits), even if the Escrow Agent has been advised of the likelihood of such loss or damage and regardless of
the form of action. This paragraph (e) and paragraph (c) of this Section 6 shall survive notwithstanding any termination of this Agreement or the resignation of the Escrow Agent. 
 (f) The Escrow Agent does not have any interest in the Escrow Funds deposited hereunder but is serving as escrow holder only. 
 (g) The Escrow Agent makes no representation as to the validity, value, genuineness or the collectibility of any security or other documents or
instruments held by or delivered to it. 
 (h) The Escrow Agent shall not be called upon to advise any party as to the wisdom in selling or
retaining or taking or refraining from any action with respect to any securities or other property deposited hereunder. 
 (i) The Escrow
Agent (and any successor escrow agent) at any time may be discharged from its duties and obligations hereunder by the delivery to it of notice of termination signed jointly by SciClone, Resistys, Avantogen and AOI or at any time may resign by giving
written notice to such effect to SciClone, Resistys, Avantogen and AOI, and, upon any such termination or resignation, the Escrow Agent shall deliver the Escrow Funds to any successor escrow agent designated jointly by SciClone, Resistys, Avantogen
and AOI in writing, or to any court of competent jurisdiction if no such successor escrow agent is designated, whereupon the Escrow Agent shall be discharged of and from any and all further obligations arising in connection with this Agreement. The
termination or resignation of the Escrow Agent shall take effect on the earlier of (i) the appointment of a successor (including a court of competent jurisdiction) or (ii) the day that is thirty (30) days after the date of delivery:
(A) to the Escrow Agent of the joint notice of termination or (B) to SciClone, Resistys, Avantogen and AOI of the Escrow Agent’s written notice of resignation. If at that time the Escrow Agent has not received a designation of a
successor escrow agent, the Escrow Agent’s sole responsibility after that time shall be to keep the Escrow Funds safe until receipt of a designation of successor escrow agent or any enforceable order of a court of competent jurisdiction.

 (j) The Escrow Agent shall have no responsibility for the contents of any writing of any third party contemplated herein as a means to
resolve disputes and may rely without any liability upon the contents thereof. 
 (k) The Escrow Agent shall not incur any liability for
following the instructions herein contained or expressly provided for or written instructions given by the parties hereto. 
 (l) In the
event that the Escrow Agent shall be uncertain as to its duties or rights hereunder or shall receive instructions, claims or demands from any party hereto which, in its opinion, conflict with any of the provisions of this Agreement, it shall be
entitled to refrain from taking any action and its sole obligation shall be to keep safely all property held in escrow until it shall be directed otherwise in writing by all of the other parties hereto or by a final order 

 
or judgment of a court of competent jurisdiction. Additionally, in the event of any disagreement between the parties hereto resulting in adverse claims or
demands being made in connection with the Escrow Funds, the Escrow Agent shall be entitled to retain the Escrow Funds until the Escrow Agent shall have received a final and non-appealable order of a court of competent jurisdiction directing delivery
of the Escrow Funds. Any court order referred to in the preceding sentence shall have been accompanied by a legal opinion of counsel for the presenting party satisfactory to the Escrow Agent to the effect that said court order is final and
non-appealable. The Escrow Agent shall act on such court order and legal opinion without further question. 
 (m) SciClone, on the one hand,
and Resistys, Avantogen and AOI, on the other hand, jointly agree to pay or reimburse the Escrow Agent upon request for all reasonable expenses, disbursements and advances, including reasonable attorney’s fees, incurred or made by it in
connection with the performance of this Agreement. 
 (n) The parties hereto irrevocably (i) submit to the jurisdiction of any New York
State or federal court sitting in New York City in any action or proceeding arising out of or relating to this Agreement, (ii) agree that all claims with respect to such action or proceeding shall be heard and determined in such New York State
or federal court and (iii) waive, to the fullest extent possible, the defense of an inconvenient forum. The parties hereby consent to and grant any such court jurisdiction over the persons of such parties and over the subject matter of any such
dispute and agree that delivery or mailing of process or other papers in connection with any such action or proceeding in the manner provided hereinabove, or in such other manner as may be permitted by law, shall be valid and sufficient service
hereof. 
 (o) The duties and responsibilities of the Escrow Agent hereunder shall be determined solely by the express provisions of this
Agreement, and no other or further duties or responsibilities shall be implied. The Escrow Agent shall not have any liability under, nor duty to inquire into, the terms and provisions of any agreement or instructions, other than as outlined in this
Agreement. 
 (p) The parties acknowledge that the Escrow Agent is acting as counsel to Resistys, Avantogen and AOI in connection with the
Purchase Agreement and the transactions contemplated thereby and shall have the right to continue to act in such capacity notwithstanding its appointment as Escrow Agent hereunder. 
 6. Notices. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be (i) delivered by
hand, (ii) sent by mail with proper postage prepaid, (iii) sent by reputable overnight express courier, (iv) telecopied or (v) sent by email and addressed as follows: 
  

	
	 If to SciClone:

	 901 Mariners Island Blvd.

	 San Mateo, California 94404

	 Attention: Richard Waldron, Chief Financial Officer

	 Fax No.: (650) 358-3469

	 Email: rwaldron@SCICLONE.com

	
	
	 If to Resistys, Avantogen and AOI:

	
	 2121 Avenue of the Stars, Suite 2550

	 Los Angeles, California 90067

	 Attention: William Ardrey

	 Fax No.:

	 Email: qmgardrey@aol.com

	
	 If to the Escrow Agent:

	
	 Katten Muchin Rosenman LLP

	 575 Madison Avenue

	 New York, New York 10022

	 Attention: Michael Hirschberg, Esq.

	 Fax No.: (212) 894-5646

	 Email: michael.hirschberg@kattenlaw.com

 or to such other address as the person to whom notice is to be given may have previously furnished to the other in
the above-referenced manner. All such notices and communications, if mailed, shall be effective when deposited in the mails, except that notices and communications to the Escrow Agent and notices of changes of address shall not be effective until
received. In the event that the Escrow Agent, in its sole discretion, shall determine that an emergency exists, the Escrow Agent may use such other means of communications as the Escrow Agent deems advisable. 
 7. Miscellaneous. 
 (a) This Agreement
shall be binding upon and inure solely to the benefit of the parties hereto and their respective successors and assigns, heirs, administrators and representatives and shall not be enforceable by or inure to the benefit of any other third party
except as provided in paragraph (i) of Section 5 with respect to the termination of, or resignation by, the Escrow Agent. No party may assign any of its rights or obligations under this Agreement without the written consent of the other
party. 
 (b) This Agreement shall be construed in accordance with and governed by the internal laws of the State of New York (without
reference to its rules as to conflicts of law). 
 (c) This Agreement may only be modified by a writing signed by all of the parties hereto.
No waiver hereunder shall be effective unless in a writing signed by the party to be charged. 
 (d) This Agreement shall terminate upon the
disbursement pursuant to Section 4 of all amounts held in the Escrow Account. 
 (e) The section headings herein are for convenience
only and shall not affect the construction thereof. Unless otherwise indicated, references to Sections are to Sections contained herein. 

 (f) This Agreement may be executed in one or more counterparts but all such separate counterparts shall
constitute but one and the same instrument; provided that, although executed in counterparts, the executed signature pages of each such counterpart may be affixed to a single copy of this Agreement which shall constitute an original. 
 (g) For purposes of this Agreement, “business day” shall be defined as any day which is not a Saturday, a Sunday or a day on which banks or
trust companies in the City and State of New York are authorized or obligated by law, regulation or executive order to remain closed. 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the day and year
first above written. 
  

			
	SCICLONE PHARMACEUTICALS, INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	RESISTYS, INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	AVANTOGEN LIMITED
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	AVANTOGEN ONCOLOGY, INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	KATTEN MUCHIN ROSENMAN LLP
		
	By:	 	  

	Name:	 	Michael Hirschberg
	Title:	 	Partner

 SCHEDULE A 

 EXHIBIT 4.5 
 Form of Security Agreement 
 THIS SECURITY AGREEMENT (the “Agreement”) is entered into as
of April 25, 2007 (the “Effective Date”) by and between SciClone Pharmaceuticals, Inc., a Delaware corporation having a principal place of business at 901 Mariners Island Boulevard, Suite 205, San Mateo, California 94404
(“Buyer”), and Resistys, Inc., a Delaware corporation having a principal place of business at having its principal place of business at 2121 Avenue of the Stars, Suite 2550, Los Angeles, California 90067 (“Seller”).

 RECITALS 
 WHEREAS, Buyer and
Seller are parties to that certain Assignment and Purchase Agreement of even date herewith (the “Assignment Agreement”) by and among Buyer, Seller, Avantogen Limited (formerly, Australian Cancer Technology Limited), an Australian
corporation (“Avantogen”), and Avantogen Oncology, Inc., a Nevada corporation (“AOI”), pursuant to which Buyer will purchase from Seller, Avantogen and AOI the RP101 Assets (as that term is defined in the Assignment
Agreement). 
 WHEREAS, pursuant to Section 4.5 of the Assignment Agreement, Buyer has agreed to secure its obligation to make certain
payments to Seller by granting a security interest in the RP101 Assets to Seller, on the terms and conditions of this Agreement. 
 NOW,
THEREFORE, in consideration of the foregoing recitals, the agreements of the parties hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Buyer and Seller hereby agree as
follows: 
 1. Defined Terms. The following capitalized terms shall have the meanings ascribed to them below: 
 a. “Chattel Paper” shall have the meaning ascribed thereto in the Code. 
 b. “Code” shall mean the Uniform Commercial Code as from time to time in effect in the State of Delaware. 
 c. “Collateral” shall have the meaning set forth in section 2 hereof. 
 d. “Contract” shall have the meaning ascribed thereto in the Code. 
 e. “Event of Default” shall mean the failure by Buyer to make (a) a Milestone Payment within thirty (30) days of such payment
becoming due and payable as required by Section 4.4(b) of the Assignment Agreement, or (b) a Net Sales Payment within sixty (60) days of after the close of the applicable quarter as required by Section 4.4(c) of the Assignment
Agreement. 

 f. “Instrument” shall have the meaning ascribed thereto in the Code. 
 g. “Obligations” shall mean the Buyer’s obligations to make (a) the Milestone Payments pursuant to Sections 4.2 and 4.4 of the
Assignment Agreement, and (b) the Net Sales Payments pursuant to Sections 4.3 and 4.4 of the Assignment Agreement, subject to Section 4 below. 
 Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Assignment Agreement. 
 2. Grant of Security Interest. To secure Buyer’s prompt, punctual, and faithful performance in making Milestone Payments and Net Sales Payments pursuant to the Assignment Agreement, Buyer hereby grants to
Seller a security interest in the RP101 Assets as received from Seller on the Effective Date, which shall include, for the avoidance of doubt, that certain License Agreement dated August 30, 2004 among Seller, Avantogen Limited and RESprotect
GmbH, as such agreement may be amended from time to time on and after the Effective Date (the “Collateral”), which Collateral shall not be deemed to include any other property, assets or rights of Buyer or any third parties;
provided, however, that the grant of the foregoing security interest shall not extend to, and the term “Collateral” shall not include, any Contract, Instrument or Chattel Paper in which Buyer has any right, title or interest
if and to the extent such Contract, Instrument or Chattel Paper includes a provision containing a restriction on assignment such that the creation of a security interest in the right, title or interest of Buyer therein would be prohibited and would,
in and of itself, cause or result in a default thereunder enabling another person party to such Contract, Instrument or Chattel Paper to enforce any remedy with respect thereto; provided further that the foregoing exclusion shall not apply if
(a) such prohibition has been waived or such other person has otherwise consented to the creation hereunder of a security interest in such Contract, Instrument or Chattel Paper or (b) such prohibition would be rendered ineffective pursuant
to Sections 9-407(a) or 9-408(a) of the UCC, as applicable and as then in effect in any relevant jurisdiction, or any other applicable law (including the Bankruptcy Code) or principles of equity; provided further that immediately upon the
ineffectiveness, lapse or termination of any such provision, the Collateral shall include, and Buyer shall be deemed to have granted a security interest in, all its rights, title and interests in and to such Contract, Instrument or Chattel Paper as
if such provision had never been in effect; and provided further that the foregoing exclusion shall in no way be construed so as to limit, impair or otherwise affect Seller’s security interest in and to all rights, title and interests of
the Collateral in or to any payment obligations or other rights to receive monies due or to become due under any such Contract, Instrument or Chattel Paper and in any such monies and other proceeds of such Contract, Instrument or Chattel Paper.

 3. Remedies. If an Event of Default shall occur and be continuing, Seller may exercise, in addition to all other rights and
remedies granted to it this Agreement and in any other instrument or agreement securing, evidencing or relating to the Obligations, all rights and remedies of a secured party under the Code. Without limiting the generality of the foregoing, Seller,
without demand of performance or other demand, presentment, protest, advertisement or notice of any kind (except any notice required by law referred to below) to or upon Buyer or any 

 
other person (all and each of which demands, defenses, advertisements and notices are hereby waived), may in such circumstances forthwith sell, lease,
assign, give option or options to purchase, or otherwise dispose of and deliver the Collateral or any part thereof (or contract to do any of the foregoing), in one or more parcels at public or private sale or sales, at any exchange, broker’s
board or office of Seller or elsewhere upon such terms and conditions as they may deem advisable and at such prices as they may deem best, for cash or on credit or for future delivery without assumption of any credit risk. Seller shall have the
right upon any such public sale or sales, and, to the extent permitted by law, upon any such private sale or sales, to purchase the whole or any part of the Collateral so sold, free of any right or equity of redemption in Buyer, which right or
equity is hereby waived or released. Buyer further agrees, at Seller’s request, to assemble the Collateral and make it available to Seller at places that Seller shall reasonably select, whether at Buyer’s premises or elsewhere. Seller
shall apply the net proceeds of any such collection, recovery, receipt, appropriation, realization or sale, after deducting all reasonable costs and expenses of every kind incurred therein or incidental to the care or safekeeping of any of the
Collateral or in any way relating to the Collateral or the rights of Seller hereunder, including, without limitation, reasonable attorney’s fees and disbursements, to the payment in whole or in part of the Obligations, in such order as Seller
may elect, and only after such application and after the payment by Seller of any other amount required by any provision of law, need Seller account for the surplus, if any, to Buyer. To the extent permitted by applicable law, Buyer waives all
claims, damages and demands it may acquire against Seller arising out of the exercise by Seller of any of their rights hereunder. If any notice of a proposed sale or other disposition of Collateral shall be required by law, such notice shall be
deemed reasonable and proper if given at least ten (10) days before such sale or other disposition. Buyer shall remain liable for any deficiency if the proceeds of any sale or other disposition of the Collateral are insufficient to pay the
Obligations and the reasonable fees and disbursements of any attorneys employed by Seller to collect such deficiency. 
 4. Term of
Agreement. This Agreement and the security interest in the Collateral granted by Buyer to Seller hereunder shall terminate upon the expiration of the Additional Payment Term as provided in Section 4.4(i) of the Assignment Agreement,
provided that if Buyer earlier exercises its Buyout Right with respect to the Net Sales Payments pursuant to Section 7.8 of the Assignment Agreement, the Net Sales Payments shall no longer be included as an Obligation hereunder. Promptly
following any such termination, the Seller on their behalf will join in executing any termination statements and other filings with respect to any financing statement executed and filed pursuant to this Agreement or required for evidencing
termination of this Agreement or Seller’s security interest in the Collateral and file any such termination statements or other filings with the appropriate agencies. 
 5. Notices. All notices, requests, demands and other communications provided for hereunder shall be as provided under Section 9.6 of the
Assignment Agreement. 
 6. Governing Law. This Agreement shall be deemed to have been made in the State of California and its form,
execution, validity, construction and effect shall be governed and construed in accordance with the laws of the State of California, without giving effect to the principles of conflicts of law thereof. 

 7. Jurisdiction. The parties consent to the exclusive jurisdiction of the state and federal courts
within the state of California with respect to any dispute arising out of this Agreement. 
 8. Headings. All section headings
contained in this Agreement are for convenience of reference only and shall not affect the meaning or interpretation of this Agreement. 
 9.
Entire Agreement. This Agreement and the Assignment Agreement are intended to define the full extent of the legally enforceable undertakings and representations of the parties hereto, and no promise or representation, written or oral, which
is not set forth explicitly in such agreements is intended by either party to be legally binding. Each of the parties acknowledge that in deciding to enter into this Agreement and to consummate the transaction contemplated hereby none of them has
relied upon any statements or representations, written or oral, other than those explicitly set forth herein. 
 10. Amendment. This
Agreement may not be amended, supplemented or otherwise modified except by an instrument in writing signed by the parties hereto that specifically refers to this Agreement. 
 11. Assignment. This Agreement and the rights and obligations hereunder shall be binding upon and inure to the benefit of the parties hereto,
their respective successors and permitted assigns. Unless consent in writing is first obtained from the other parties hereto, this Agreement and the rights granted hereunder shall not be assignable by any party hereto, and any attempted assignment
without such consent shall be void. Notwithstanding the foregoing, Buyer may transfer or assign its rights and obligations under this Agreement to (a) an Affiliate, or (b) a successor to all or substantially all of its business or assets
relating to this Agreement whether by sale, merger, consolidation, acquisition, transfer, operation of law or otherwise, provided that such Affiliate or successor agrees to be bound by the terms of this Agreement. 
 12. Counterparts. This Agreement may be executed in two counterparts, each of which shall be an original as against any party whose signature
appears thereon but both of which together shall constitute one and the same instrument. A facsimile transmission of the signed Agreement shall be legal and binding on both parties. 
 [Remainder of Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, the parties, through their authorized officers, have duly executed this Agreement as
of the date first written above. 
  

									
	SELLER:	 		 	BUYER:
			
	RESISTYS, INC.	 		 	SCICLONE PHARMACEUTICALS, INC.
					
	By:	 	  
	 		 	By:	 	  

	Name:	 	  
	 		 	Name:	 	  

	Title:	 	  
	 		 	Title:	 	  

 SCHEDULE 5 
 Disclosure Schedules 
 This Disclosure Schedule is made and given by Seller pursuant to Article 5 of the Agreement. All
capitalized terms used but not defined herein shall have the meanings assigned to those terms in the Agreement, unless otherwise provided. The section numbers below correspond to the section numbers of the representations and warranties in the
Agreement which are modified by this Disclosure Schedule. 

 SCHEDULE 5.3 
 Creditors 
  

							
	 Payment
Method
	  	 Creditor
	  	Payment
Amount	  	 Reference

	 Check
	  	 AFCO Financing
	  		  	
		  	 Dept LA 21315
	  	18,366.36	  	 April & May D & O payments

		  		  	 	  	
		  	 Pasadena, CA 91185-1315
	  	18,366.36	  	 Reference Account #55-20-051566-2

				
	 Check
	  	 AL Holdings, Inc.
	  		  	
		  	 c/o Arbios Systems, Inc.
	  	18,400.00	  	 Bridge Loan

		  	 Attn: Scott Hayashi
	  	13,104.66	  	 Dec Shared Services & Jan Rent

		  	 8797 Beverly Blvd., Suite 304
	  	12,060.00	  	 Jan & Feb Shared Services & Feb Rent

		  		  	 	  	
		  	 Los Angeles, CA 90048
	  	43,564.66	  	
				
		  	 Angela Bronow Davanzo
	  		  	
	 ADP
	  	 2765 Allyson Court
	  	108,335.50	  	 Retention Bonus - ABD

	 Check
	  	 Westlake Village, CA 91362
	  	4,000.00	  	 Retainer

	 Check
	  		  	7,470.00	  	 Jan - May COBRA Reimbursement

		  		  	 	  	
		  		  	119,805.50	  	
				
	 Check
	  	 BioPharma Consulting Services, Inc.
	  		  	
		  	 ATTN: Rick Stead
	  	2,000.00	  	 Nov Services

		  	 691 96 Avenue SE
	  	1,000.00	  	 Dec Services

		  	 Bellevue, WA 98004
	  	600.00	  	 Jan Services

		  		  	 	  	
		  		  	3,600.00	  	
				
	 Check
	  	 Cheryl Agris, PhD., P.C.
	  		  	
		  	 P.O. Box 806
	  	9,775.70	  	 Inv #926

		  		  	 	  	
		  	 Pelham Manor, NY 10803
	  	9,775.70	  	
				
	 Pending
	  	 Chopin Capital Partners
	  		  	
		  	 2121 Avenue of the Stars, Ste. 2550
	  	100,000.00	  	 Settlement to be negotiated post transaction

		  		  	 	  	
		  	 Los Angeles, CA 90067
	  	100,000.00	  	

							
				
	 Pending
	  	 Chopin Opus One, LLC.
	  		  	
		  	 Bank of New York, New York
	  	250,000.00	  	 To be paid within 30 days by Escrow Agent

		  		  	 	  	
		  	 Chips Uid 382526
	  	250,000.00	  	 or converted to AOI stock persuant to

		  	 FW021000018
	  		  	 Conversion Agreement dated April     , 2007

		  	 Swift: IRVTUS3N
	  		  	
		  	 For the account of:
	  		  	
		  	 Credit Suisse, Singaport Branch
	  		  	
		  	 Swift: CSPBSGSG
	  		  	
		  	 Account No. 890-0360-925
	  		  	
		  	 For Further reference of:
	  		  	
		  	 Account Name: Chopin Opus One L.P.
	  		  	
		  	 Account No: 122244
	  		  	
		  	 Attn: Mr. Reto Marx
	  		  	
				
		  	 Chris Nowers
	  		  	
	 ADP
	  		  	162,500.00	  	 Retention Bonus - CJN

		  		  	 	  	
		  		  	162,500.00	  	
	 Check
	  	 Cunyet M. Serdar
	  		  	
		  	 P.O. Box 230576
	  	660.00	  	 Nov & Dec services

		  	 Encinitas, CA 92023-0576
	  	360.00	  	 Jan/Feb Services

		  		  	 	  	
		  		  	1,020.00	  	
	 Check
	  	 Good Swartz Brown & Berns
	  		  	
		  	 11755 Wilshire Blvd., Suite 1700
	  	1,050.00	  	 Inv# LAO75142

		  		  	 	  	
		  	 Los Angeles, CA 90025
	  	1,050.00	  	
				
	 Check
	  	 Info 2 Extreme, Inc.
	  		  	
		  	 5777 W. Century Blvd., Suite 1680
	  	95.00	  	 Inv #7374

		  	 Los Anageles, CA 90045
	  	99.90	  	 Jan/Feb Network

		  		  	 	  	
		  		  	194.90	  	
				
	 Check
	  	 James A Rice
	  		  	
		  	 P.O. Box 2577
	  	5,242.25	  	 Nov Services

		  	 Carmel, CA 93921
	  	2,940.00	  	 Dec Services

		  		  	4,899.00	  	 Jan Services

		  		  	2,548.00	  	 Feb Services

		  		  	3,429.50	  	 March Services

		  		  	 	  	
		  		  	19,058.75	  	

							
				
	 Pending
	  	 Joe Boystak
	  		  	
		  	 Information to follow
	  	10,000.00	  	 BOD Fees - Pending Release

		  		  	 	  	
		  		  	10,000.00	  	
				
	 Check
	  	 Katten Muchin Rosenmann LLP
	  		  	
		  	 575 Madison Avenue
	  	18,209.95	  	 Inv #1300374597

		  	 New York, NY 10022-2585
	  	19,741.88	  	 Inv #1300383343

		  		  	18,499.76	  	 Inv #1300386738

		  		  	8,695.24	  	 Inv #1300397809

		  		  	8,033.25	  	 Inv# 1300410709

		  		  	1,548.82	  	 Inv #1300412418

		  		  	34,524.29	  	 March Services

		  		  	 	  	
		  		  	109,253.19	  	
				
	 Wire
	  	 Lee Cole
	  		  	
		  	 Beneficiary: Silverberg Stonehill Goldsmith & Haber, P.C. Operating Account
	  	10,000.00	  	 BOD Fees

		  		  	 	  	
		  	 Acct #: 53493355
	  	10,000.00	  	
		  	 Citibank, N.A.
	  		  	
		  	 120 Broadway 2nd Floor, Sort 2413
	  		  	
		  	 New York, New York 10271
	  		  	
		  	 ABA #: 021000089
	  		  	
				
	 Check
	  	 Liberty Transfer Co.
	  		  	
		  	 274B New York Avenue
	  	250.00	  	 Inv 9193

		  		  	 	  	
		  	 Huntington, NY 11743
	  	250.00	  	
				
	 Check
	  	 Michael Hillmeyer
	  		  	
		  	 305 West Broadway, Suite 216
	  	10,000.00	  	 BOD Fees

		  		  	 	  	
		  	 New York, New York 10013
	  	10,000.00	  	
				
	 Check
	  	 NDA, LLC
	  		  	
		  	 Daniel Von Hoff
	  	1,500.00	  	 Nov Services

		  		  	 	  	
		  	 9830 E. Thompson Peak Parkway #906
	  	1,500.00	  	
		  	 Scottsdale, AZ 85255
	  		  	

							
				
	 Wire
 EUROs
	 	 Next Pharma
	  		  	
		 	 Dresdner Bank Frankfurt
	  	5,380.00	  	 Inv# 27491: 4,096 Euro

		 	 Account #942 285 00
	  	6,120.00	  	 Inv #27858: 4,636 Euro

		 		  	 	  	
		 	 BLZ 500 800 00
	  	11,500.00	  	 Total: 8,732 Euro

		 	 SWIFT-BIC: DRES DE FF
	  		  	
		 	 IBAN: DE89 5008 0000 0094 2285 00
	  		  	
				
	 Pending
	 	 Nigel Ruwleski
	  		  	
		 	 Information to follow
	  	10,000.00	  	 BOD Fees - Pending Release

		 		  	 	  	
		 		  	10,000.00	  	
				
		 	 Richard Opara
	  		  	
	 Wire
	 	 Account # 0747542153
	  	1,636.78	  	 T & E

	 Pending
	 	 Bank of America
	  	10,000.00	  	 BOD Fees - Pending Release

		 		  	 	  	
		 	 Century City Main, Los Angeles
	  	11,636.78	  	
		 	 ABA #122000661
	  		  	
		 	 Alfred Villalobos - VP Senior Client Manager
	  		  	
		 	 (310) 247-2080
	  		  	
				
	 Check
	 	 RR Donnelley Receivables, Inc.
	  		  	
		 	 P.O. Box 100112
	  	7,149.00	  	 Inv #1202297200

		 	 Pasadena, CA 91189-0001
	  	1,493.00	  	 Inv #1206038000

		 		  	2,565.00	  	 Inv #1208865900

		 		  	707.00	  	 Inv #1207946300

		 		  	 	  	
		 		  	11,914.00	  	
				
	 Check
	 	 Scott Cruickshank & Associates
	  		  	
		 	 3118 Calles Rosales
	  	2,812.50	  	 Inv#AV-11302006

		 	 Santa Barbara, CA 93105
	  	975.00	  	 Inv #AV-12312006

		 		  	300.00	  	 Inv #AV-01312007

		 		  	 	  	
		 	 Total Scott Cruickshank & Associates
	  	4,087.50	  	
				
	 Check
	 	 Singer Lewak Greenbaum & Goldstein LLP
	  		  	
		 	 10960 Wilshire Blvd., Suite 1100
	  	46,247.06	  	 Inv# LA67573

		 	 Los Angeles, CA 90024
	  	4,523.75	  	 Inv# LA68092

		 		  	9,865.00	  	 Inv #LA68599

		 		  	996.25	  	 Inv #LA69613

		 		  	5,757.30	  	 Inv #LA70004

		 		  	 	  	
		 		  	67,389.36	  	

							
				
	 Check
	  	 Think Equity Partners LLC
	  		  	
		  	 31 W. 52nd Street, 17th Floor
	  	41,866.09	  	 Inv #AVTO-01182007

		  		  	 	  	
		  	 New York, NY 10019
	  	41,866.09	  	
				
	 Check
	  	 TLG Consulting, Inc.
	  		  	
		  	 Theresa Gerrard
	  	1,725.00	  	 Inv #122906R

		  	 14521 West Salisbury Road
	  	525.00	  	 Inv #2012007R

		  	 Midlothian, VA 23113-6455
	  	1,275.00	  	
		  		  	 	  	
		  		  	3,525.00	  	
				
	 Check
	  	 Vintage Filings
	  		  	
		  	 150 W. 46th Street, 6th Floor
	  	139.00	  	 Inv #1-58832

		  		  	 	  	
		  	 New York, New York 10036
	  	139.00	  	
				
	 Wire
	  	 William Ardrey
	  		  	
		  	 Account 136 68 8122
	  	10,000.00	  	 BOD Fees

		  		  	 	  	
		  	 Mellon Bank Pittsburgh PA
	  	10,000.00	  	
		  	 ABA 04300261
	  		  	
		  	 For Credit to
	  		  	
		  	 Merrill Lynch
	  		  	
		  	 Account 1011 730
	  		  	
		  	 For further Credit to
	  		  	
		  	 850 19M 39
	  		  	
		  	 Swift Code MELNUS 3P
	  		  	
				
	 Check
	  	 Wilson Sonsini Goodrich & Rosati
	  		  	
		  	 Accounts Receivable
	  	3,063.00	  	 Inv #1028363

		  		  	 	  	
		  	 650 Page Mill Road
	  	3,063.00	  	
		  		  	 	  	
		  	 Palo Alto, CA 94304-1050
	  		  	
		  		  	1,045,059.79	  	
		  		  	 	  	

 SCHEDULE 5.5 
 Consents and Approvals 
 1. Consent of RESprotect GmbH to the assignment to SciClone of that certain (a) License
Agreement dated August 30, 2004 among Resistys, Inc., Avantogen Limited (formerly, Australian Cancer Technology Limited) and RESprotect GmbH, and (b) Supply Agreement for Clinical Trial Material dated September 13, 2004 between
Resistys, Inc. and RESprotect GmbH. 
 2. Consent of Pharmaceutical Research Associates, Inc. to the assignment to SciClone of that certain Agreement for
Clinical Trials Management Services (PRA Project ID: INV101II-101IIX) dated August 31, 2006 by and between Avantogen Oncology, Inc. and Pharmaceutical Research Associates, Inc. 
 3. Consent of Hesperion Ltd. to the assignment to SciClone of that certain of Services Agreement dated October 18, 2004 between Resistys, Inc. and Hesperion Ltd., as amended by COS#1 dated December 6, 2005
and COS#2 dated April 12, 2007. 
 4. Notice to FDA regarding transfer of RP101 IND sponsorship to SciClone. 
 5. Approvals of the Boards of Directors of Seller and the Shareholders of Resistys, Inc. and Avantogen Oncology, Inc. 

 SCHEDULE 5.6 
 Title Exceptions 
 None 

 SCHEDULE 5.7(a) 
 Seller IP Rights Exceptions 
 None

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}]]